Document:

Exhibit
10.64

 

SECURITIES
PURCHASE AGREEMENT

 

SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of February 7, 2020, by and among Sonnet BioTherapeutics,
Inc., a New Jersey corporation, with headquarters located at 100 Overlook Center, Second Floor, Princeton, NJ 08540 (“Sonnet”),
Chanticleer Holdings, Inc., a Delaware corporation, with headquarters located at 7621 Little Avenue, Suite 414, Charlotte, NC
28226 (“Chanticleer”), and the investors listed on the Schedule of Buyers attached hereto (each, a “Buyer”
and collectively, the “Buyers”).

 

WHEREAS:

 

A.
Sonnet, Chanticleer and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506(b) of
Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the 1933 Act.

 

B.
Each Buyer wishes to purchase, and Sonnet wishes to sell, upon the terms and conditions stated in this Agreement, (i) that aggregate
number of shares of Sonnet’s common stock, no par value per share (the “Sonnet Common Stock”), set forth
opposite such Buyer’s name in column (3) on the Schedule of Buyers (which aggregate amount of Sonnet Common Stock for all
Buyers together (the “Buyers’ Allocation Number”) shall equal a number of shares, to be determined on
the Closing Date, that is exchangeable on the terms described in the Merger Agreement for an aggregate of 12.75% of the estimated
“fully-diluted” post-Merger outstanding shares of Chanticleer Common Stock, assuming solely for this purpose that
all of the Exchange Shares estimated to be issued in exchange for Additional Common Shares were not then outstanding, and shall
collectively be referred to herein as the “Initial Common Shares”), and (ii) up to that aggregate number of
shares of Sonnet Common Stock set forth opposite such Buyer’s name in column (4) of the Schedule of Buyers attached hereto
(which aggregate amount for all Buyers shall equal the Buyers’ Allocation Number) (the “Additional Common Shares”
and together with the Initial Common Shares, the “Common Shares”), which shall be issued in escrow to The Bank
of New York Mellon acting as escrow agent (the “Escrow Agent”) in accordance with those certain escrow agreements
by and among each Buyer, on the one hand, and Sonnet, Chanticleer and the Escrow Agent on the other hand, in the form attached
hereto as Exhibit A (collectively, the “Securities Escrow Agreement”) and which shall be delivered from
time to time to the Buyers pursuant to the terms and conditions set forth in this Agreement.

 

C.
In addition, Chanticleer hereby agrees to issue to each Buyer, upon the terms and conditions stated in this Agreement (i) warrants,
in the form attached hereto as Exhibit B-1 (the “Series A Warrants”), representing the right to acquire
an initial amount of shares of Chanticleer’s common stock, par value $0.0001 per share (the “Chanticleer Common
Stock”) equal to seventy-five (75%) percent of the quotient determined by dividing the Purchase Price (as defined below)
paid by such Buyer on the Closing Date (as defined below), by the Final Per Share Price (as defined below) (such shares of Chanticleer
Common Stock issuable upon exercise of the Series A Warrants, collectively, the “Series A Warrant Shares”),
and (ii) warrants, in the form attached hereto as Exhibit B-2 (the “Series B Warrants” and, together
with the Series A Warrants, the “Warrants”), representing the right to acquire that number of shares Chanticleer
Common Stock in accordance with its terms and conditions (such shares of Chanticleer Common Stock issuable upon exercise of the
Series B Warrants, collectively, the “Series B Warrant Shares” and, together with the Series A Warrant Shares,
the “Warrant Shares”).

 

    	 

    	 

    

 

D.
Contemporaneously with the execution and delivery of this Agreement, the Buyers and Chanticleer are executing and delivering a
Registration Rights Agreement, in the form attached hereto as Exhibit C (the “Registration Rights Agreement”),
pursuant to which Chanticleer has agreed to provide certain registration rights with respect to the Registrable Securities (as
defined in the Registration Rights Agreement) under the 1933 Act and the rules and regulations promulgated thereunder, and applicable
state securities laws.

 

E.
The Common Shares (and, as applicable, the Exchange Shares issued in exchange therefor), the Warrants and the Warrant Shares collectively
are referred to herein as the “Securities.”

 

NOW,
THEREFORE, Sonnet, Chanticleer and each Buyer hereby agree as follows:

 

1.
PURCHASE AND SALE OF COMMON SHARES AND WARRANTS.

 

(a)
Purchase of Initial Common Shares. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 7 and
8 below, (x) Sonnet shall issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from Sonnet
on the Closing Date (as defined below), the number of Initial Common Shares as is set forth opposite such Buyer’s name in
column (3) on the Schedule of Buyers and (y) Sonnet shall issue in escrow in the name of the Escrow Agent a number of shares of
Sonnet Common Stock equal to the Buyers’ Allocation Number (as adjusted for any stock dividend, stock split, stock combination,
reclassification or similar transaction occurring after the date hereof) issuable as Additional Common Shares, in accordance with
the terms hereof and the Securities Escrow Agreement (the “Closing”).

 

(b)
Closing. The date and time of the Closing (the “Closing Date”) shall be 10:00 a.m., New York City time,
on a date mutually agreed to by Sonnet, Chanticleer and each Buyer after notification of satisfaction (or waiver) of the conditions
to the Closing set forth in Sections 7 and 8 below, at the offices of Schulte Roth & Zabel LLP, 919 Third Avenue, New York,
New York 10022. The Closing may also be undertaken remotely by electronic transfer of Closing documentation.

 

(c)
Issuance of Warrants and Delivery of Additional Common Shares.

 

(i)
Obligation to Issue Warrants. On the Warrant Closing Date (as defined below), and for no additional consideration, Chanticleer
shall issue to each Buyer (x) Series A Warrants to acquire an initial amount of shares of Chanticleer Common Stock equal to seventy-five
(75%) percent of the quotient determined by dividing the Purchase Price paid by such Buyer on the Closing Date, by the Final Per
Share Price and (y) Series B Warrants to acquire Series B Warrant Shares in accordance with its terms and conditions (the “Warrant
Closing”).

 

    	2

    	 

    

 

(ii)
Obligation to Deliver Additional Common Shares. Promptly but in any event by no later than (x) the tenth (10th)
Trading Day (as defined in the Warrants) immediately following the Closing Date and/or (y) if Section 1(c)(iv) prevents the delivery
on the tenth (10th) Trading Day immediately following the Closing Date of all or any portion of the Exchange Shares
(as defined in Section 5(d)) issued in exchange of Additional Common Shares to a Buyer, the second (2nd) Trading Day
immediately after the delivery to Chanticleer of a notice by such Buyer in the form attached hereto as Exhibit D setting
forth such Buyer’s election to receive all or any portion of the Exchange Shares issued in exchange of the Additional Common
Shares such Buyer is entitled to pursuant to this Section 1(c)(ii) and the delivery of which is no longer prevented by Section
1(c)(iv) (a “Capacity Notice”) (the Warrant Closing Date and each second (2nd) Trading Day immediately
following the delivery to Chanticleer of a Capacity Notice, an “Additional Exchange Shares Delivery Date”),
subject to Section 1(c)(iv), Chanticleer shall, in each case, without any additional consideration, cause the Escrow Agent to
transfer from the escrow account governed by the Securities Escrow Agreement and deliver by crediting to such Buyer’s or
its designee’s balance account with The Depository Trust Company (“DTC”) through its Deposit / Withdrawal
At Custodian system, the Additional Common Shares (once exchanged for the Exchange Shares as set forth herein) (as adjusted for
stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other
similar events occurring after the date hereof and including any securities, cash, rights or other property distributed with respect
to such Additional Common Shares or in exchange for such Additional Common Shares), which such Exchange Shares issued in exchange
of Additional Common Shares shall be equal to the lesser of (A) the number of Exchange Shares issued in exchange for the Additional
Common Shares deposited in such Buyer’s escrow account (as adjusted for stock splits, stock dividends, recapitalizations,
reorganizations, reclassification, combinations, reverse stock splits or other similar events occurring after the date hereof)
and (B) the number (if positive) obtained by subtracting (I) the number of Exchange Shares issued in exchange for the Initial
Common Shares purchased by such Buyer on the Closing Date (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations,
reclassification, combinations, reverse stock splits or other similar events occurring after the date hereof), from (II) the quotient
determined by dividing (x) the aggregate Purchase Price paid by such Buyer on the Closing Date, by (y) the greater of (a) the
Reset Floor Price (as defined in the Warrants) and (b) eighty-five percent (85%) of the sum of the three (3) lowest Weighted Average
Prices (as defined in the Warrants) of the Chanticleer Common Stock during the period beginning on the first (1st)
Trading Day immediately following the Closing Date and ending on the Warrant Closing Date, inclusive (as adjusted for stock splits,
stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other similar events
during such period), divided by three (3) (such price, the “Final Per Share Price”). On the Warrant Closing
Date, each Investor Representative (as defined in the applicable Escrow Agreement), Sonnet and Chanticleer shall instruct the
Escrow Agent to release to Chanticleer from the applicable escrow account governed by the Securities Escrow Agreement any Exchange
Shares issued in exchange for Additional Common Shares to the extent that the Buyer(s) affiliated with such Investor Representative
is not entitled to receive such Exchange Shares pursuant to this Section 1(c)(ii) without giving effect to the limitations under
Section 1(c)(iv).

 

    	3

    	 

    

 

(iii)
Mechanics of Delivery.

 

(1)
General. Chanticleer shall be responsible for all fees and expenses of its transfer agent (the “Transfer Agent”)
and all fees and expenses with respect to the delivery of Exchange Shares issued in exchange of Additional Common Shares and transfer
of such shares to each Buyer’s or its designee’s balance account with DTC, if any, including, without limitation,
for same day processing. Chanticleer’s obligations to cause the Transfer Agent to deliver and transfer Exchange Shares issued
in exchange of Additional Common Shares to the Buyers in accordance with the terms and subject to the conditions hereof and the
Securities Escrow Agreement are absolute and unconditional, irrespective of any action or inaction by such Buyer to enforce the
same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action
to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination. Notwithstanding anything to the contrary
contained herein, in no event will any Exchange Shares issued in exchange of Additional Common Shares be delivered with any restrictive
legends or any restrictions or limitations on resale by the Buyers. If Chanticleer and/or the Transfer Agent requires any legal
opinions with respect to the delivery of any Exchange Shares issued in exchange of Additional Common Shares without restrictive
legends or the removal of any such restrictive legends, Chanticleer agrees to cause at its expense its legal counsel to issue
any such legal opinions. Chanticleer hereby acknowledges and agrees that the holding period of any Exchange Shares issued in exchange
of Additional Common Shares delivered hereunder for purposes of Rule 144 shall be deemed to have commenced on the Closing Date.
For purposes of this Agreement, “Person” means an individual, a limited liability company, a partnership, a
joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof.

 

(2)
Chanticleer’s Failure to Timely Deliver Securities. If Chanticleer shall fail for any reason or for no reason to
credit such Buyer’s or its designee’s balance account with DTC on the applicable Additional Exchange Shares Delivery
Date for such number of Exchange Shares issued in exchange of shares of Chanticleer Common Stock to which such Buyer is entitled
under Section 1(c)(ii) (a “Delivery Failure”), then, in addition to all other remedies available to such Buyer,
Chanticleer shall pay in cash to such Buyer on each day after such Additional Exchange Shares Delivery Date that Chanticleer shall
fail to credit such Buyer’s or its designee’s balance account with DTC for the number of shares of Chanticleer Common
Stock to which such Buyer is entitled pursuant to Chanticleer’s obligation pursuant to clause (ii) below, an amount equal
to 1.5 % of the product of (A) the number of Exchange Shares not issued to such Buyer on or prior to the applicable Additional
Exchange Shares Delivery Date and to which the Buyer is entitled, and (B) any trading price of the Chanticleer Common Stock selected
by the Buyer in writing as in effect at any time during the period beginning on the applicable Additional Exchange Shares Delivery
Date and ending on the date Chanticleer makes the applicable cash payment, and if on or after such Trading Day such Buyer (or
any Person in respect of, or on behalf, of such Buyer) purchases (in an open market transaction or otherwise) shares of Chanticleer
Common Stock related to the applicable Delivery Failure, then, in addition to all other remedies available to such Buyer, Chanticleer
shall, within two (2) Trading Days after such Buyer’s request and in such Buyer’s discretion, either (i) pay cash
to such Buyer in an amount equal to such Buyer’s total purchase price (including brokerage commissions and other out-of-pocket
expenses, if any) for the shares of Chanticleer Common Stock so purchased (the “Buy-In Price”), at which point
Chanticleer’s obligation to credit such Buyer’s or its designee’s balance account with DTC for such shares of
Chanticleer Common Stock shall terminate, or (ii) promptly honor its obligation to credit such Buyer’s or its designee’s
balance account with DTC and pay cash to such Buyer in an amount equal to the excess (if any) of the Buy-In Price over the product
of (A) such number of shares of Chanticleer Common Stock, multiplied by (B) any trading price of the Chanticleer Common Stock
selected by such Buyer in writing as in effect at any time during the period beginning on the applicable Additional Exchange Shares
Delivery Date and ending on the date of such delivery and payment under this Section 1(c)(iii)(2). Nothing shall limit any Buyer’s
right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of
specific performance and/or injunctive relief with respect to Chanticleer’s failure to timely electronically deliver shares
of Chanticleer Common Stock as required pursuant to the terms hereof.

 

    	4

    	 

    

 

(3)
Charges, Taxes and Expenses. Issuance of the Additional Common Shares to the Escrow Agent and subsequent delivery of the
Exchange Shares issued in exchange thereof to the Buyers shall be made without charge to the Buyers for any issue or transfer
tax or other incidental expense in respect of such issuance and transfer, all of which taxes (other than the Buyers’ income
taxes) and expenses shall be paid by Chanticleer, and the Exchange Shares issued in exchange of such Additional Common Shares
shall be delivered in the name of the respective Buyer or in such name or names as may be directed by the respective Buyer.

 

(4)
Closing of Books. Neither Sonnet nor Chanticleer will close its stockholder books or records in any manner which prevents
the timely exercise of such Buyer’s rights with respect to the Exchange Shares issued in exchange of the Additional Common
Shares.

 

(iv)
Blocker. Notwithstanding anything to the contrary contained herein, Chanticleer shall not deliver Exchange Shares issued
in exchange of Additional Common Shares, and no Buyer shall have the right to receive Exchange Shares issued in exchange of Additional
Common Shares, and any such delivery shall be null and void and treated as if never made, to the extent that after giving effect
to such delivery, such Buyer together with its other Attribution Parties (as defined in the Warrants) would beneficially own in
excess of such percentage corresponding to the checked box on such Buyer’s signature page attached hereto (the “Maximum
Percentage”) of the number of shares of Chanticleer Common Stock outstanding immediately after giving effect to such
delivery. For purposes of the foregoing sentence, the aggregate number of shares of Chanticleer Common Stock beneficially owned
by such Buyer and the other Attribution Parties shall include the number of shares of Chanticleer Common Stock held by such Buyer
and all other Attribution Parties plus the number of Exchange Shares issued in exchange of Additional Common Shares delivered
to such Buyer pursuant to Section 1(c) hereof with respect to which the determination of such sentence is being made, but shall
exclude the number of shares of Chanticleer Common Stock which would be issuable upon (i) exercise of the remaining, unexercised
portion of the Warrants beneficially owned by such Buyer or any of the other Attribution Parties and (ii) exercise or conversion
of the unexercised or unconverted portion of any other securities of Chanticleer beneficially owned by such Buyer or any of the
other Attribution Parties (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject
to a limitation on conversion or exercise analogous to the limitation contained herein. For purposes of this Section 1(c)(iv),
beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the
“1934 Act”). For purposes of determining the number of outstanding shares of Chanticleer Common Stock that
the Buyers may receive without exceeding the Maximum Percentage, the Buyers may rely on the number of outstanding shares of Chanticleer
Common Stock as reflected in (1) Chanticleer’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current
Report on Form 8-K or other public filing with the SEC, as the case may be, (2) a more recent public announcement by Chanticleer
or (3) any other written notice by Chanticleer or the Transfer Agent setting forth the number of shares of Chanticleer Common
Stock outstanding (the “Reported Outstanding Share Number”). If Chanticleer receives a Capacity Notice from
such Buyer at a time when the actual number of outstanding shares of Chanticleer Common Stock is less than the Reported Outstanding
Share Number, Chanticleer shall promptly notify the Buyers in writing of the number of shares of Chanticleer Common Stock then
outstanding and, to the extent that such Capacity Notice would otherwise cause a Buyer’s beneficial ownership, as determined
pursuant to this Section 1(c)(iv), to exceed the Maximum Percentage, such Buyer must notify Chanticleer of a reduced number of
Exchange Shares issued in exchange of Additional Common Shares to be delivered pursuant to such Capacity Notice. For any reason
at any time, upon the written or oral request of a Buyer, Chanticleer shall within one (1) Business Day confirm in writing or
by electronic mail to such Buyer the number of shares of Chanticleer Common Stock then outstanding. In any case, the number of
outstanding shares of Chanticleer Common Stock shall be determined after giving effect to the conversion or exercise of securities
of Chanticleer, including the Warrants held by each Buyer and the other Attribution Parties since the date as of which the Reported
Outstanding Share Number was reported. In the event that the delivery of Exchange Shares issued in exchange of Additional Common
Shares to such Buyer results in such Buyer and the other Attribution Parties being deemed to beneficially own, in the aggregate,
more than the Maximum Percentage of the number of outstanding shares of Chanticleer Common Stock (as determined under Section
13(d) of the 1934 Act), the number of shares so delivered by which such Buyer’s and the other Attribution Parties’
aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and
void and shall be cancelled ab initio, and such Buyer shall not have the power to vote or to transfer the Excess Shares. If a
Buyer’s right to receive Exchange Shares issued in exchange of Additional Common Shares is limited, in whole or in part,
by this Section 1(c)(iv), all such Exchange Shares issued in exchange of Additional Common Shares that are so limited shall be
held in abeyance for the benefit of such Buyer by the Escrow Agent until the earlier to occur of the fifth (5th) anniversary
of the Closing Date and such time as such Buyer notifies Chanticleer that its right thereto would not result in such Buyer exceeding
the Maximum Percentage and Chanticleer shall promptly but in any event within two (2) Trading Days after the delivery of such
Capacity Notice deliver to such Buyer the Exchange Shares issued in exchange of such Additional Common Shares. Upon delivery of
a written notice to Chanticleer, each Buyer may from time to time increase or decrease the Maximum Percentage to any other percentage
not in excess of 9.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage will
not be effective until the sixty-first (61st) day after such notice is delivered to Chanticleer and (ii) any such increase
or decrease will apply only to such Buyer and the other Attribution Parties and not to any of the other Buyers that is not an
Attribution Party of such Buyer. For purposes of clarity, the Exchange Shares issued in exchange of the Additional Common Shares
deliverable pursuant to the terms hereof in excess of the Maximum Percentage shall not be deemed to be beneficially owned by such
Buyer for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(c)(iv) to
the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the
intended beneficial ownership limitation contained in this Section 1(c)(iv) or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a
successor of such Buyer. As used herein, “Business Day” means any day other than Saturday, Sunday or other
day on which commercial banks in The City of New York are authorized or required by law to remain closed.

 

    	5

    	 

    

 

(d)
Warrant Closing. The time of the Warrant Closing shall be 10:00 a.m., New York City time on the tenth (10th)
Trading Day immediately following the Closing Date (the “Warrant Closing Date”), at the offices of Schulte
Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022. The Warrant Closing may also be undertaken remotely by electronic
transfer of Warrant Closing documentation.

 

(e)
Purchase Price. The purchase price for the Common Shares and the related Warrants to be purchased by each Buyer pursuant
to this Agreement shall be the amount set forth opposite such Buyer’s name in column (5) of the Schedule of Buyers (the
“Purchase Price”).

 

(f)
Form of Payment. On the Closing Date, (i) each Buyer shall pay its respective Purchase Price (less, in the case of [  ]
(the “Lead Investor”), any amounts withheld pursuant to Section 5(h)) to Sonnet for the Common Shares and the
Warrants to be issued and sold to such Buyer pursuant to this Agreement by wire transfer of immediately available funds in accordance
with Sonnet’s written wire instructions; provided, however, that with respect to Chardan Capital Markets,
LLC (“Chardan”), its Purchase Price shall be deemed paid by virtue of the services provided by Chardan to Sonnet
and Chanticleer as contemplated by that certain Omnibus Amendment to Letter Agreements dated as of February 7, 2020, and
the Agreements referenced therein, and (ii) Sonnet shall deliver to each Buyer the number of Initial Common Shares such Buyer
is purchasing as is set forth opposite such Buyer’s name in column (3) of the Schedule of Buyers. On the Warrant Closing
Date, Chanticleer shall deliver to each Buyer (x) a Series A Warrant pursuant to which such Buyer shall have the right to acquire
an initial amount of shares of Chanticleer Common Stock equal to seventy-five (75%) percent of the quotient determined by dividing
the Purchase Price paid by such Buyer on the Closing Date, by the Final Per Share Price, and (y) a Series B Warrant pursuant to
which such Buyer shall have the right to acquire Series B Warrant Shares in accordance with its terms and conditions, in each
case duly executed on behalf of Chanticleer and registered in the name of such Buyer or its designee.

 

2.
BUYER’S REPRESENTATIONS AND WARRANTIES. Each Buyer, severally and not jointly, represents and warrants with respect
to only itself to each of Sonnet and Chanticleer that, as of the date hereof and as of the Closing Date:

 

(a)
No Public Sale or Distribution. Such Buyer is (i) acquiring the Common Shares and the Warrants and (ii) upon exercise of
the Warrants (other than pursuant to a Cashless Exercise (as defined in the Warrants)) will acquire the Warrant Shares issuable
upon exercise of the Warrants, for its own account and not with a view towards, or for resale in connection with, the public sale
or distribution thereof, except pursuant to sales registered or exempted under the 1933 Act; provided, however,
that by making the representations herein, such Buyer does not agree to hold any of the Securities for any minimum or other specific
term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement
or an exemption under the 1933 Act. Such Buyer is acquiring the Securities hereunder in the ordinary course of its business. Such
Buyer does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any of the
Securities.

 

    	6

    	 

    

 

(b)
Accredited Investor Status; No Disqualification Events. Such Buyer is an “accredited investor” as that term
is defined in Rule 501(a) of Regulation D. To the extent such Buyer is a beneficial owner of 10% or more of Chanticleer Common
Stock as of the date hereof or as of the Closing Date, none of (i) such Buyer, (ii) any of such Buyer’s directors, executive
officers, other officers that may serve as a director or officer of any company in which it invests, general partners or managing
members, or (iii) any beneficial owner of Sonnet’s or Chanticleer’s voting equity securities (in accordance with Rule
506(d) of the Securities Act) held by such Buyer is subject to any Disqualification Event, except for Disqualification Events
covered by Rule 506(d)(2) or (d)(3) under the Securities Act and disclosed reasonably in advance of the Closing in writing in
reasonable detail to Sonnet and Chanticleer.

 

(c)
Reliance on Exemptions. Such Buyer understands that the Securities are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that Sonnet and Chanticleer
are relying in part upon the truth and accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of such Buyer set forth herein in order to determine the availability of such exemptions and
the eligibility of such Buyer to acquire the Securities.

 

(d)
Information. Such Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances
and operations of Sonnet and Chanticleer and materials relating to the offer and sale of the Securities that have been requested
by such Buyer. Such Buyer and its advisors, if any, have been afforded the opportunity to ask questions of Sonnet and Chanticleer.
Neither such inquiries nor any other due diligence investigations conducted by such Buyer or its advisors, if any, or its representatives
shall modify, amend or affect such Buyer’s right to rely on Sonnet’s and Chanticleer’s representations and warranties
contained herein. Such Buyer understands that its investment in the Securities involves a high degree of risk. Such Buyer has
sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect
to its acquisition of the Securities. Such Buyer acknowledges and agrees that neither the Placement Agent (as defined in Section
3(g)) nor any Affiliate (as defined in Rule 144) of the Placement Agent has provided such Buyer with any information or advice
with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate
has made or makes any representation as to Sonnet and Chanticleer or the quality of the Securities and the Placement Agent and
any Affiliate may have acquired non-public information with respect to Sonnet and Chanticleer which such Buyer agrees need not
be provided to it. In connection with the issuance of the Securities to such Buyer, neither the Placement Agent nor any of its
Affiliates has acted as a financial advisor or fiduciary to such Buyer.

 

    	7

    	 

    

 

(e)
No Governmental Review. Such Buyer understands that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of
the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(f)
Transfer or Resale. Such Buyer understands that except as provided in the Registration Rights Agreement: (i) the Securities
have not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold,
assigned or transferred unless (A) subsequently registered thereunder, (B) subject to Section 1(c)(iii)(1), such Buyer shall have
delivered to Chanticleer an opinion of counsel, in a form reasonably satisfactory to Chanticleer, to the effect that such Securities
to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C)
such Buyer provides Chanticleer with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to
Rule 144 or Rule 144A promulgated under the 1933 Act, as amended, (or a successor rule thereto) (collectively, “Rule
144”); (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of
Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or
the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require
compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither
Chanticleer nor any other Person is under any obligation to register the Securities under the 1933 Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder; provided, however, that the Common
Shares will be exchanged on the Closing Date, or pursuant to Section 5(d) will be exchangeable, for shares of Chanticleer Common
Stock registered under the 1933 Act pursuant to the registration statement on Form S-4 filed by Chanticleer (File No. 333-235301)
(as amended from time to time, the “Form S-4”). Notwithstanding the foregoing, the Securities may be pledged
in connection with a bona fide margin account or other loan or financing arrangement secured by the Securities and such pledge
of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Buyer effecting a pledge
of Securities shall be required to provide Chanticleer with any notice thereof or otherwise make any delivery to Chanticleer pursuant
to this Agreement or any other Transaction Document (as defined in Section 4(b)), including, without limitation, this Section
2(f).

 

(g)
Legends. Such Buyer understands that the certificates or other instruments representing the Common Shares and the Warrants
and, until such time as the resale or exchange of the Common Shares and the Warrant Shares have been registered under the 1933
Act as contemplated by the Registration Rights Agreement or the Form S-4, as applicable, the stock certificates representing the
Securities, except as set forth below, shall bear a restrictive legend in the following form (and a stop-transfer order may be
placed against transfer of such stock certificates):

 

[NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED
(I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR (B) AN OPINION OF COUNSEL SELECTED BY THE HOLDER, IN A FORM REASONABLY SATISFACTORY TO THE COMPANY, THAT REGISTRATION IS NOT
REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES.

 

    	8

    	 

    

 

The
legend set forth above shall be removed and Chanticleer shall issue a certificate without such legend to the holder of the Securities
upon which it is stamped or issue to such holder by electronic delivery at the applicable balance account at DTC, if (i) such
Securities are registered for resale under the 1933 Act or exchanged for other securities in a transaction registered under the
1933 Act, (ii) in connection with a sale, assignment or other transfer, except as provided in Section 1(c)(iii)(1), such holder
provides Chanticleer with an opinion of counsel, in a form reasonably satisfactory to Chanticleer, to the effect that such sale,
assignment or transfer of the Securities may be made without registration under the applicable requirements of the 1933 Act, or
(iii) the Securities can be sold, assigned or transferred pursuant to Rule 144. Chanticleer shall be responsible for the fees
of its Transfer Agent and all DTC fees associated with such issuance. If Chanticleer shall fail for any reason or for no reason
to issue to the holder of the Securities within two (2) Trading Days after the occurrence of any of (i) through (iii) above (the
initial date of such occurrence, the “Legend Removal Date” and such failure, a “Legend Removal Failure”),
a certificate without such legend to such holder or to issue such Securities to such holder by electronic delivery at the applicable
balance account at DTC, then, in addition to all other remedies available to such holder, Chanticleer shall pay in cash to such
holder on each day after the second (2nd) Trading Day after the Legend Removal Date and during such Legend Removal
Failure an amount equal to 2.0% of the product of (i) the number of shares represented by such certificate, and (ii) any trading
price of the Chanticleer Common Stock selected by the holder in writing as in effect at any time during the period beginning on
the applicable Legend Removal Date and ending on the date Chanticleer makes the applicable cash payment, and if on or after such
Trading Day the holder purchases (in an open market transaction or otherwise) Chanticleer Common Stock relating to the applicable
Legend Removal Failure, then Chanticleer shall, within two (2) Trading Days after the holder’s request and in the holder’s
discretion, either (i) pay cash to the holder in an amount equal to the holder’s total purchase price (including brokerage
commissions, if any) for the Chanticleer Common Stock so purchased (the “Legend Buy-In Price”), at which point
the obligation of Chanticleer to deliver such unlegended Securities shall terminate, or (ii) promptly honor its obligation to
deliver to the holder such unlegended Securities as provided above and pay cash to the holder in an amount equal to the excess
(if any) of the Legend Buy-In Price over the product of (A) such number of shares of Chanticleer Common Stock, times (B) any trading
price of the Chanticleer Common Stock selected by the holder in writing as in effect at any time during the period beginning on
the applicable Legend Removal Date and ending on the date Chanticleer makes the applicable cash payment. Chanticleer shall be
responsible for the fees of its Transfer Agent and all DTC fees associated with such issuance.

 

    	9

    	 

    

 

(h)
Validity; Enforcement. This Agreement and the other Transaction Documents to which such Buyer is a party have been duly
and validly authorized, executed and delivered on behalf of such Buyer and shall constitute the legal, valid and binding obligations
of such Buyer enforceable against such Buyer in accordance with their respective terms, except as such enforceability may be limited
by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(i)
No Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the other Transaction Documents
to which such Buyer is a party and the consummation by such Buyer of the transactions contemplated hereby and thereby will not
(i) result in a violation of the organizational documents of such Buyer or (ii) conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which such Buyer is a party, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Buyer,
except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually
or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations
hereunder.

 

3.
REPRESENTATIONS AND WARRANTIES OF SONNET.

 

Sonnet
represents and warrants to each of the Buyers that, as of the date hereof and as of the Closing Date:

 

(a)
Organization and Qualification. Each of Sonnet and its “Sonnet Subsidiaries” (which for purposes of this Agreement
means any entity in which Sonnet, directly or indirectly, owns any of the capital stock or holds an equity or similar interest)
are entities duly organized and validly existing and in good standing under the laws of the jurisdiction in which they are formed,
and have the requisite power and authorization to own their properties and to carry on their business as now being conducted and
as presently proposed to be conducted. Each of Sonnet and each of the Sonnet Subsidiaries is duly qualified as a foreign entity
to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business
conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing
would not reasonably be expected to have a Sonnet Material Adverse Effect. As used in this Agreement, “Sonnet Material Adverse
Effect” means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations,
condition (financial or otherwise) or prospects of Sonnet and the Sonnet Subsidiaries, individually or taken as a whole, or on
the transactions contemplated hereby or on the other Sonnet Transaction Documents (as defined below) or by the agreements and
instruments to be entered into in connection herewith or therewith, or on the authority or ability of Sonnet to perform any of
its obligations under any of the Sonnet Transaction Documents (as defined below). Sonnet has no Sonnet Subsidiaries except as
set forth in Schedule 3(a). The outstanding shares of capital stock of each of the Sonnet Subsidiaries have been duly authorized
and validly issued, are fully paid and non-assessable and are owned by Sonnet or another Sonnet Subsidiary free and clear of all
liens, encumbrances and equities and claims; and no options, warrants or other rights to purchase, agreements or other obligations
to issue or other rights to convert any obligations into shares of capital stock or ownership interests in the Sonnet Subsidiaries
are outstanding.

 

    	10

    	 

    

 

(b)
Authorization; Enforcement; Validity. Sonnet has the requisite corporate power and authority to enter into and perform
its obligations under this Agreement, the Securities Escrow Agreement, the Lock-Up Agreements (as defined in Section 8(xi)), the
Leak-Out Agreements (as defined in Section 8(xx)) and each of the other agreements entered into by Sonnet in connection with the
transactions contemplated by this Agreement (collectively, the “Sonnet Transaction Documents”) and to issue
the Common Shares in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the other
Sonnet Transaction Documents by Sonnet and the consummation by Sonnet of the transactions contemplated hereby and thereby, including,
without limitation, the issuance of the Common Shares, have been duly authorized by Sonnet’s Board of Directors and (other
than the filing of a Form D with the SEC and any other filings as may be required by any state securities agencies), no further
filing, consent or authorization is required by Sonnet, its Board of Directors or its stockholders. This Agreement and the other
Sonnet Transaction Documents have been duly executed and delivered by Sonnet, and constitute the legal, valid and binding obligations
of Sonnet, enforceable against Sonnet in accordance with their respective terms, except as such enforceability may be limited
by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(c)
Issuance of Common Shares. The issuance of the Common Shares is duly authorized and, upon issuance in accordance with the
terms of the Sonnet Transaction Documents, the Common Shares shall be validly issued and free from all preemptive or similar rights
(except for those which have been validly waived prior to the date hereof), taxes, liens and charges and other encumbrances with
respect to the issue thereof and the Common Shares shall be fully paid and nonassessable with the holders being entitled to all
rights accorded to a holder of Sonnet Common Stock. Assuming the accuracy of each of the representations and warranties set forth
in Section 3 of this Agreement, the offer and issuance by Sonnet of the Common Shares is exempt from registration under the 1933
Act.

 

(d)
No Conflicts. Except as disclosed in Schedule 3(d), the execution, delivery and performance of the Sonnet Transaction
Documents by Sonnet and any of the Sonnet Subsidiaries and the consummation by Sonnet of the transactions contemplated hereby
and thereby (including, without limitation, the issuance of the Common Shares) will not (i) result in a violation of the Sonnet
Certificate of Incorporation (as defined below) or Sonnet Bylaws (as defined below) or other organizational documents of Sonnet
or any of the Sonnet Subsidiaries, any capital stock of Sonnet or any of the Sonnet Subsidiaries or the articles of association
or bylaws of Sonnet or any of the Sonnet Subsidiaries or (ii) conflict with, or constitute a default (or an event which with notice
or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which Sonnet or any of the Sonnet Subsidiaries is a
party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and
state securities laws, rules and regulations) applicable to Sonnet or any of the Sonnet Subsidiaries or by which any property
or asset of Sonnet or any of the Sonnet Subsidiaries is bound or affected, except, in the case of clauses (ii) and (iii) above,
as would not have or reasonably be expected to result in a Sonnet Material Adverse Effect.

 

    	11

    	 

    

 

(e)
Consents. Except as disclosed in Schedule 3(e), Sonnet is not required to obtain any consent from, authorization
or order of, or make any filing or registration with (other than the filing of a Form D with the SEC and any other filings as
may be required by any state securities agencies), any court, governmental agency or any regulatory or self-regulatory agency
or any other Person in order for it to execute, deliver or perform any of its obligations under or contemplated by the Sonnet
Transaction Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings
and registrations which Sonnet is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior
to the Closing Date (or in the case of filings detailed above, will be made timely after the Closing Date).

 

(f)
Acknowledgment Regarding Buyer’s Purchase of Securities. Sonnet acknowledges and agrees that each Buyer is acting
solely in the capacity of an arm’s length purchaser with respect to the Sonnet Transaction Documents and the transactions
contemplated hereby and thereby and that, prior to the purchase of Securities hereunder, no Buyer is (i) an officer or director
of Sonnet or any of the Sonnet Subsidiaries, (ii) an “affiliate” of Sonnet or any of the Sonnet Subsidiaries (as defined
in Rule 144) or (iii) to the knowledge of Sonnet, a “beneficial owner” of more than 10% of the Sonnet Common Stock
(as defined for purposes of Rule 13d-3 of the 1934 Act). Sonnet further acknowledges that no Buyer is acting as a financial advisor
or fiduciary of Sonnet or any of the Sonnet Subsidiaries (or in any similar capacity) with respect to the Sonnet Transaction Documents
and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives or agents
in connection with the Sonnet Transaction Documents and the transactions contemplated hereby and thereby is merely incidental
to such Buyer’s purchase of the Securities. Sonnet further represents to each Buyer that Sonnet’s decision to enter
into the Sonnet Transaction Documents has been based solely on the independent evaluation by Sonnet and its representatives.

 

(g)
No General Solicitation; Placement Agent’s Fees. Neither Sonnet, nor any of the Sonnet Subsidiaries or their affiliates,
nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the
meaning of Regulation D) in connection with the offer or sale of the Securities. Sonnet shall be responsible for the payment of
any placement agent’s fees, financial advisory fees, or brokers’ commissions (other than for Persons engaged by any
Buyer or its investment advisor) relating to or arising out of the transactions contemplated hereby, including, without limitation,
placement agent fees payable to Chardan Capital Markets LLC (the “Placement Agent”) in connection with the
sale of the Securities. Sonnet shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without
limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any such claim. Sonnet acknowledges that
it has engaged the Placement Agent in connection with the sale of the Securities. Other than the Placement Agent, neither Sonnet
nor any of the Sonnet Subsidiaries has not engaged any placement agent or other agent in connection with the offer or sale of
the Securities.

 

    	12

    	 

    

 

(h)
No Integrated Offering. None of Sonnet, the Sonnet Subsidiaries, their affiliates, nor any Person acting on their behalf
has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would require registration of the issuance of any of the Securities under the 1933 Act, whether through integration with
prior offerings or otherwise, or cause this offering of the Securities to require approval of stockholders of Sonnet for purposes
of the 1933 Act or any applicable stockholder approval provisions, including, without limitation, under the rules and regulations
of any exchange or automated quotation system on which any of the securities of Chanticleer are listed or designated for quotation.
None of Sonnet, the Sonnet Subsidiaries, their affiliates nor any Person acting on their behalf will take any action or steps
that would require registration of the issuance of any of the Securities under the 1933 Act or cause the offering of any of the
Securities to be integrated with other offerings for purposes of any such applicable stockholder approval provisions.

 

(i)
Application of Takeover Protections; Rights Agreement. Sonnet and its board of directors have taken all necessary action,
if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill
(including, without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under the
Sonnet Certificate of Incorporation, Sonnet Bylaws or other organizational documents or the laws of the jurisdiction of its formation
which is or could become applicable to any Buyer as a result of the transactions contemplated by this Agreement, including, without
limitation, Sonnet’s issuance of the Common Shares and any Buyer’s ownership of the Securities. Sonnet and its Board
of Directors have taken all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar arrangement
relating to accumulations of beneficial ownership of Sonnet Common Stock or a change in control of Sonnet or any of the Sonnet
Subsidiaries.

 

(j)
S-4; Financial Statements. As of the dates of the filing of the Form S-4, including any amendments thereto, the sections
of the Form S-4 titled “Risk Factors – Risks Relating to Sonnet’s Business and Stock Ownership in Sonnet,”
“Sonnet Business,” “Sonnet Management’s Discussion and Analysis of Financial Condition and Results of
Operations,” “Certain Relationships and Related-Party Transactions – Sonnet” and “Principal Stockholders
of Sonnet,” at the time the Form S-4 or such amendment thereto was filed with the SEC, did not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. As of each filing date of the Form S-4
or any amendment thereto, the financial statements of Sonnet included in the Form S-4 complied as to form in all material respects
with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial
statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), consistently
applied during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto,
or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements)
and fairly present in all material respects the financial position of Sonnet and the Sonnet Subsidiaries as of the dates thereof
and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to
normal year-end audit adjustments which will not be material, either individually or in the aggregate). No other information provided
by or on behalf of Sonnet to any of the Buyers which is not included in the Form S-4 (including, without limitation, information
referred to in Section 2(d) of this Agreement or in the disclosure schedules to this Agreement) contains any untrue statement
of a material fact or omits to state any material fact necessary in order to make the statements therein, in the light of the
circumstance under which they are or were made, not misleading.

 

    	13

    	 

    

 

(k)
Absence of Certain Changes. Except as disclosed in Schedule 3(k)(i), since September 30, 2019, there has been no
material adverse change and no material adverse development in the business, assets, liabilities, properties, operations, condition
(financial or otherwise), results of operations or prospects of Sonnet or the Sonnet Subsidiaries. Except as disclosed in Schedule
3(k)(ii), since September 30, 2019, neither Sonnet nor any of the Sonnet Subsidiaries have (i) declared or paid any dividends,
(ii) sold any assets, individually or in the aggregate, in excess of $100,000 outside of the ordinary course of business or (iii)
had capital expenditures, individually or in the aggregate, in excess of $100,000. Neither Sonnet nor any of the Sonnet Subsidiaries
has taken any steps to seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership,
liquidation or winding up, nor does Sonnet or any of the Sonnet Subsidiaries have any knowledge or reason to believe that any
of its creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably
lead a creditor to do so. Sonnet and the Sonnet Subsidiaries, individually and on a consolidated basis, are not as of the date
hereof, and, after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined
below). For purposes of this Agreement, “Insolvent” means, with respect to any Person, (i) the present fair
saleable value of such Person’s assets is less than the amount required to pay such Person’s total Indebtedness (as
defined below), (ii) such Person is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts
and liabilities become absolute and matured, (iii) such Person intends to incur or believes that it will incur debts that would
be beyond its ability to pay as such debts mature or (iv) such Person has unreasonably small capital with which to conduct the
business in which it is engaged as such business is now conducted and is proposed to be conducted.

 

(l)
No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has
occurred or exists, or is contemplated to occur with respect to Sonnet, the Sonnet Subsidiaries or their respective business,
properties, prospects, operations or financial condition, that would be required to be disclosed by Sonnet under applicable securities
laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by Sonnet of Sonnet Common Stock
and which has not been publicly announced.

 

    	14

    	 

    

 

(m)
Conduct of Business; Regulatory Permits. Neither Sonnet nor any of the Sonnet Subsidiaries is in violation of any term
of or in default under the Sonnet Certificate of Incorporation, any certificate of designations, preferences or rights of any
outstanding series of preferred stock of Sonnet or any of the Sonnet Subsidiaries, the Sonnet Bylaws or their organizational charter
or memorandum of association or certificate of incorporation or articles of association or bylaws, respectively. Neither Sonnet
nor any of the Sonnet Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation
applicable to Sonnet or any of the Sonnet Subsidiaries, and neither Sonnet nor any of the Sonnet Subsidiaries will conduct its
business in violation of any of the foregoing, except in all cases for possible violations which would not, individually or in
the aggregate, reasonably be expected to have a Sonnet Material Adverse Effect. Sonnet and the Sonnet Subsidiaries possess all
certificates, authorizations and permits issued by the appropriate foreign, federal or state regulatory authorities necessary
to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits would
not have, individually or in the aggregate, a Sonnet Material Adverse Effect, and neither Sonnet nor any such Sonnet Subsidiary
has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.
Without limiting the generality of the foregoing, except as set forth in Schedule 3(m), Sonnet has no knowledge of any
facts or circumstances that would reasonably lead to delisting or suspension of the Chanticleer Common Stock by the Nasdaq Capital
Market (the “Principal Market”) in the foreseeable future.

 

(n)
Foreign Corrupt Practices. Neither Sonnet nor any of the Sonnet Subsidiaries, nor any director, officer, agent, employee
or other Person acting on behalf of Sonnet or any of the Sonnet Subsidiaries has, in the course of its actions for, or on behalf
of, Sonnet or any of the Sonnet Subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or
other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic
government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful
payment to any foreign or domestic government official or employee.

 

(o)
[Reserved]

 

(p)
Transactions With Affiliates. Except as set forth in Schedule 3(p), none of the officers, directors or employees
of Sonnet or any of the Sonnet Subsidiaries is presently a party to any transaction with Sonnet or any of the Sonnet Subsidiaries
(other than for ordinary course services as employees, officers or directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any such officer, director or employee or, to the knowledge of the Sonnet or any of the Sonnet Subsidiaries,
any corporation, partnership, trust or other Person in which any such officer, director, or employee has a substantial interest
or is an employee, officer, director, trustee or partner.

 

    	15

    	 

    

 

(q)
Equity Capitalization. As of the date hereof, the authorized capital stock of Sonnet consists of (i) 100,000,000 shares
of Sonnet Common Stock, of which as of the date hereof, 53,603,250 shares are issued and outstanding, 7,111,947 shares are reserved
for issuance to Relief Therapeutics Holding SA (“Relief Holding”) for the acquisition of Relief Therapeutics SA (“Relief”)
pursuant to the Share Exchange Agreement dated August 9, 2019 between Sonnet and Relief Holding (the “Share Exchange Agreement”)
(which shares will be issued to Relief Holding upon the consummation of the Share Exchange Agreement, which will occur immediately
prior to the closing of the Merger) and 854,000 shares are reserved for issuance pursuant to securities exercisable or exchangeable
for, or convertible into Sonnet Common Stock, and (ii) 10,000,000 shares of preferred stock, of which as of the date hereof, no
shares were issued and outstanding. No Sonnet Common Stock is held in treasury. All of such outstanding shares are duly authorized
and have been, or upon issuance will be, validly issued and are fully paid and nonassessable. (i) Except as disclosed in Schedule
3(q)(i), hereto, none of Sonnet’s or any Sonnet Subsidiary’s capital stock is subject to preemptive rights or
any other similar rights or any liens or encumbrances suffered or permitted by Sonnet or any Sonnet Subsidiary’s; (ii) except
as disclosed in Schedule 3(q)(ii), there are no outstanding options, warrants, scrip, rights to subscribe to, calls or
commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable
for, any capital stock of Sonnet or any of the Sonnet Subsidiaries, or contracts, commitments, understandings or arrangements
by which Sonnet is or may become bound to issue additional capital stock of Sonnet or any of the Sonnet Subsidiaries or options,
warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights
convertible into, or exercisable or exchangeable for, any capital stock of Sonnet or any of the Sonnet Subsidiaries; (iii) except
as disclosed in Schedule 3(q)(iii), there are no outstanding debt securities, notes, credit agreements, credit facilities
or other agreements, documents or instruments evidencing Indebtedness of Sonnet or any of the Sonnet Subsidiaries or by which
Sonnet or any of the Sonnet Subsidiaries is or may become bound; (iv) except as disclosed in Schedule 3(q)(iv), there are
no financing statements securing obligations in any amounts filed in connection with Sonnet or any of the Sonnet Subsidiaries;
(v), except as disclosed in Schedule 3(q)(v), there are no agreements or arrangements under which Sonnet or any of the
Sonnet Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act; (vi) except as disclosed
in Schedule 3(q)(vi), there are no outstanding securities or instruments of Sonnet or any of the Sonnet Subsidiaries which
contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which
Sonnet or any of the Sonnet Subsidiaries is or may become bound to redeem a security of Sonnet or any of the Sonnet Subsidiaries;
(vii) except as disclosed in Schedule 3(q)(vii), there are no securities or instruments containing anti-dilution or similar
provisions that will be triggered by the issuance of the Securities; (viii) except as disclosed in Schedule 3(q)(viii),
neither Sonnet nor any of its Sonnet Subsidiaries has any stock appreciation rights or “phantom stock” plans or agreements
or any similar plan or agreement; and (ix) except as disclosed in Schedule 3(q)(ix), Sonnet or any of the Sonnet Subsidiaries
have no liabilities or obligations, other than those incurred in the ordinary course of Sonnet’s or any of the Sonnet Subsidiary’s
respective businesses and which, individually or in the aggregate, do not or could not have a Sonnet Material Adverse Effect.
True, correct and complete copies of Sonnet’s certificate of incorporation, as amended and as in effect on the date hereof
(the “Sonnet Certificate of Incorporation”), and Sonnet’s bylaws, as amended and as in effect on the
date hereof (the “Sonnet Bylaws”), and the terms of all securities convertible into, or exercisable or exchangeable
for, Sonnet Common Stock and the material rights of the holders thereof in respect thereto shall be provided to the Buyers on
the Closing Date.

 

    	16

    	 

    

 

(r)
Indebtedness and Other Contracts. Neither Sonnet nor any of the Sonnet Subsidiaries, (i) except as disclosed in Schedule
3(r)(i), has any outstanding Indebtedness (as defined below), (ii) except as disclosed in Schedule 3(r)(ii), is a party
to any contract, agreement or instrument, the violation of which, or default under which, by the other party(ies) to such contract,
agreement or instrument would reasonably be expected to result in a Sonnet Material Adverse Effect, (iii) except as disclosed
in Schedule 3(r)(iii), is in violation of any term of, or in default under, any contract, agreement or instrument relating
to any Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in a Sonnet
Material Adverse Effect, or (iv) except as disclosed in Schedule 3(r)(iv), is a party to any contract, agreement or instrument
relating to any Indebtedness, the performance of which, in the judgment of Sonnet’s officers, has or is expected to have
a Sonnet Material Adverse Effect. Schedule 3(r) provides a detailed description of the material terms of such outstanding
Indebtedness. For purposes of this Agreement: (x) “Indebtedness” of any Person means, without duplication (A)
all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property
or services (including, without limitation, “capital leases” in accordance with GAAP, consistently applied during
the periods involved) (other than trade payables entered into in the ordinary course of business consistent with past practice),
(C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D)
all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection
with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or
other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with
the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event
of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement
which, in connection with GAAP, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all
indebtedness referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness has an existing
right, contingent or otherwise, to be secured by) any mortgage, claim, lien, tax, right of first refusal, pledge, charge, security
interest or other encumbrance upon or in any property or assets (including accounts and contract rights) owned by any Person,
even though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness,
and (H) all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in clauses (A)
through (G) above; and (y) “Contingent Obligation” means, as to any Person, any direct or indirect liability,
contingent or otherwise, of that Person with respect to any indebtedness, capital lease, dividend or other obligation of another
Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance
to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will
be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto.

 

(s)
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the knowledge of Sonnet, threatened against or affecting
Sonnet or any of the Sonnet Subsidiaries, the Sonnet Common Stock or any of the Sonnet Subsidiary’s capital stock or any
of Sonnet’s or any of the Sonnet Subsidiary’s officers or directors, whether of a civil or criminal nature or otherwise,
in their capacities as such, except as set forth in Schedule 3(s). The matters set forth in Schedule 3(s) would
not reasonably be expected to have a Sonnet Material Adverse Effect.

 

(t)
Insurance. Sonnet and each of the Sonnet Subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as management of Sonnet believes to be prudent and customary in the businesses in which
Sonnet and the Sonnet Subsidiaries are engaged. Neither Sonnet nor any of the Sonnet Subsidiaries has been refused any insurance
coverage sought or applied for and neither Sonnet nor any of the Sonnet Subsidiaries has any reason to believe that it will be
unable to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business at a cost that would not have a Sonnet Material Adverse Effect.

 

    	17

    	 

    

 

(u)
Employee Relations. Neither Sonnet nor any of the Sonnet Subsidiaries is a party to any collective bargaining agreement
or employs any member of a union. Sonnet and the Sonnet Subsidiaries believe that their relations with their respective employees
are good. No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee of Sonnet or any
of the Sonnet Subsidiaries has notified Sonnet or any such Sonnet Subsidiary that such officer intends to leave Sonnet or any
such Sonnet Subsidiary or otherwise terminate such officer’s employment with Sonnet or any such Sonnet Subsidiary. No executive
officer or other key employee of Sonnet or any of the Sonnet Subsidiaries is, or is now expected to be, in violation of any material
term of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement,
or any other contract or agreement or any restrictive covenant, and the continued employment of each such executive officer or
other key employee (as the case may be) does not subject Sonnet or any of the Sonnet Subsidiaries to any liability with respect
to any of the foregoing matters. Sonnet and the Sonnet Subsidiaries are in compliance with all federal, state, local and foreign
laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and
wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected
to result in a Sonnet Material Adverse Effect.

 

(v)
Title. Sonnet and the Sonnet Subsidiaries have good and marketable title in fee simple to all real property and good and
marketable title to all personal property owned by them which is material to the business of Sonnet and the Sonnet Subsidiaries,
in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property
and do not interfere with the use made and proposed to be made of such property by Sonnet and any of the Sonnet Subsidiaries.
Any real property and facilities held under lease by Sonnet and any of the Sonnet Subsidiaries are held by them under valid, subsisting
and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made
of such property and buildings by Sonnet and the Sonnet Subsidiaries.

 

(w)
Intellectual Property Rights. Sonnet and the Sonnet Subsidiaries own or possess adequate rights or licenses to use all
trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, original
works of authorship, inventions, licenses, approvals, governmental authorizations, trade secrets and other intellectual property
rights and all applications and registrations therefor (“Intellectual Property Rights”) necessary to conduct
their respective businesses as now conducted. Each of the patents owned by Sonnet or any of the Sonnet Subsidiaries is listed
on Schedule 3(w)(i). Except as set forth in Schedule 3(w)(ii), none of Sonnet’s or any of the Sonnet’s
Subsidiaries’ Intellectual Property Rights have expired, terminated or been abandoned, or are expected to expire, terminate
or be abandoned, within three years from the date of this Agreement. Sonnet has no knowledge of any infringement by Sonnet or
the Sonnet Subsidiaries of Intellectual Property Rights of others. There is no claim, action or proceeding being made or brought,
or to the knowledge of Sonnet or any of the Sonnet Subsidiaries, being threatened, against Sonnet or any of the Sonnet Subsidiaries
regarding their Intellectual Property Rights. Neither Sonnet nor any of the Sonnet Subsidiaries is aware of any facts or circumstances
which might give rise to any of the foregoing infringements or claims, actions or proceedings. Sonnet and the Sonnet Subsidiaries
have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property
Rights.

 

    	18

    	 

    

 

(x)
Environmental Laws. Sonnet and the Sonnet Subsidiaries (A) are in compliance with all Environmental Laws (as defined below),
(B) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their
respective businesses and (C) are in compliance with all terms and conditions of any such permit, license or approval where, in
each of the foregoing clauses (A), (B) and (C), the failure to so comply could be reasonably expected to have, individually or
in the aggregate, a Sonnet Material Adverse Effect. The term “Environmental Laws” means all federal, state,
local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient
air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions,
discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes
(collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans
or regulations issued, entered, promulgated or approved thereunder.

 

(y)
Subsidiary Rights. Sonnet or one of the Sonnet Subsidiaries has the unrestricted right to vote, and (subject to limitations
imposed by applicable law) to receive dividends and distributions on, all capital securities of the Sonnet Subsidiaries as owned
by Sonnet or such Sonnet Subsidiary.

 

(z)
Tax Status. Sonnet and each of the Sonnet Subsidiaries (i) has timely made or filed all foreign, federal and state income
and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely paid
all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations, except those being contested in good faith and (iii) has set aside on its books provisions reasonably
adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers
of Sonnet know of no basis for any such claim.

 

(aa)
Internal Accounting. Sonnet and each of the Sonnet Subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP, consistently
applied during the periods involved and applicable law, and to maintain asset and liability accountability, (iii) access to assets
or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization and (iv)
the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals
and appropriate action is taken with respect to any difference. Except as set forth in Schedule 3(aa), during the twelve
months prior to the date hereof neither Sonnet nor any of the Sonnet Subsidiaries has received any notice or correspondence from
any accountant relating to any material weakness in any part of the system of internal accounting controls of Sonnet or any of
the Sonnet Subsidiaries.

 

    	19

    	 

    

 

(bb)
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between Sonnet and an unconsolidated
or other off balance sheet entity that would be reasonably likely to have a Sonnet Material Adverse Effect.

 

(cc)
Investment Company Status. Neither Sonnet nor any of the Sonnet Subsidiaries is, and upon consummation of the sale of the
Securities, and for so long as any Buyer holds any Securities, will not be, an “investment company,” an affiliate
of an “investment company,” a company controlled by an “investment company” or an “affiliated person”
of, or “promoter” or “principal underwriter” for, an “investment company” as such terms are
defined in the Investment Company Act of 1940, as amended.

 

(dd)
Acknowledgement Regarding Buyers’ Trading Activity. Sonnet acknowledges and agrees that, except as set forth in the
Leak-Out Agreements, (i) none of the Buyers has been asked to agree, nor has any Buyer agreed, to desist from purchasing or selling,
long and/or short, securities of Sonnet or Chanticleer, or “derivative” securities based on securities issued by Sonnet
or Chanticleer or to hold the Securities for any specified term; (ii) any Buyer, and counter-parties in “derivative”
transactions to which any such Buyer is a party, directly or indirectly, presently may have a “short” position in
the Sonnet Common Stock or Chanticleer Common Stock and (iii) each Buyer shall not be deemed to have any affiliation with or control
over any arm’s length counter-party in any “derivative” transaction. Sonnet further understands and acknowledges
that (a) one or more Buyers may engage in hedging and/or trading activities at various times during the period that the Securities
are outstanding, including, without limitation, during the periods that the value of the Warrant Shares are being determined and
(b) such hedging and/or trading activities, if any, can reduce the value of the existing stockholders’ equity interest in
Sonnet and/or Chanticleer both at and after the time the hedging and/or trading activities are being conducted. Sonnet acknowledges
that such aforementioned hedging and/or trading activities do not constitute a breach of this Agreement, the Warrants or any of
the documents executed in connection herewith.

 

(ee)
Manipulation of Price. Sonnet has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result, or that could reasonably be expected to cause or result, in the stabilization or manipulation
of the price of any security of Sonnet or Chanticleer to facilitate the sale or resale of any of the Securities, (ii) other than
the Placement Agent, sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or
(iii) other than the Placement Agent, paid or agreed to pay to any person any compensation for soliciting another to purchase
any other securities of Sonnet or Chanticleer.

 

    	20

    	 

    

 

(ff)
FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is
manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by Sonnet or any of its Sonnet Subsidiaries (each
such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled,
tested, distributed, sold and/or marketed by Sonnet in compliance with all applicable requirements under FDCA and similar laws,
rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval,
good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising,
record keeping and filing of reports, except where the failure to be in compliance would not have a Sonnet Material Adverse Effect.
There is no pending, completed or, to Sonnet’s knowledge, threatened, action (including any lawsuit, arbitration, or legal
or administrative or regulatory proceeding, charge, complaint, or investigation) against Sonnet or any of its Sonnet Subsidiaries,
and none of Sonnet or any of its Sonnet Subsidiaries has received any notice, warning letter or other communication from the FDA
or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses
of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any
Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders
the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by Sonnet or any of its Sonnet Subsidiaries, (iv) enjoins production at any facility of Sonnet
or any of its Sonnet Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with Sonnet or
any of its Sonnet Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by Sonnet or any of
its Sonnet Subsidiaries, and which, either individually or in the aggregate, would have a Sonnet Material Adverse Effect. The
properties, business and operations of Sonnet have been and are being conducted in all material respects in accordance with all
applicable laws, rules and regulations of the FDA. Except as set forth on Schedule 3(ff) or as Disclosed in the SEC Documents,
Sonnet has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of
any product proposed to be developed, produced or marketed by Sonnet nor has the FDA expressed any concern as to approving or
clearing for marketing any product being developed or proposed to be developed by Sonnet.

 

(gg)
U.S. Real Property Holding Corporation. Neither Sonnet nor any of the Sonnet Subsidiaries is, or has ever been, and so
long as any of the Securities are held by any of the Buyers, shall become, a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and Sonnet and each Sonnet Subsidiary shall so certify
upon any Buyer’s request.

 

(hh)
Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required
to be paid in connection with the issuance, sale and transfer of the Securities to be sold to each Buyer hereunder will be, or
will have been, fully paid or provided for by Sonnet, and all laws imposing such taxes will be or will have been complied with.

 

(ii)
Bank Holding Company Act. Neither Sonnet nor any of the Sonnet Subsidiaries or affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve
System (the “Federal Reserve”). Neither Sonnet nor any of the Sonnet Subsidiaries or their affiliates owns
or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or
twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by
the Federal Reserve. Neither Sonnet nor any of the Sonnet Subsidiaries or affiliates exercises a controlling influence over the
management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

    	21

    	 

    

 

(jj)
Shell Company Status. Sonnet is not, and has never been, an issuer identified in, or subject to, Rule 144(i)(1) of the
1933 Act.

 

(kk)
Compliance with Anti-Money Laundering Laws. The operations of Sonnet and the Sonnet
Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting
requirements and all other applicable U.S. and non-U.S. anti-money laundering laws, rules
and regulations, including, but not limited to, those of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
the United States Bank Secrecy Act, as amended by the USA PATRIOT Act of 2001, and the United States Money Laundering Control
Act of 1986 (18 U.S.C. §§1956 and 1957), as amended, as well as the implementing
rules and regulations promulgated thereunder, and the applicable money laundering statutes of all applicable jurisdictions, the
rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency or self-regulatory body (collectively, the “Anti-Money Laundering Laws”), and no
action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving Sonnet
or any of the Sonnet Subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of Sonnet, threatened.

 

(ll)
No Conflicts with Sanctions Laws. Neither Sonnet nor
any of the Sonnet Subsidiaries, nor any director, officer, employee, agent, affiliate or other person associated with or acting
on behalf of Sonnet or any of the Sonnet Subsidiaries or any of their affiliates
is, or is directly or indirectly owned or controlled by, a Person that is currently the subject or the target of any sanctions
administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S.
Department of the Treasury (“OFAC”) or the U.S. Departments of State or Commerce and including, without limitation,
the designation as a “Specially Designated National” or on the “Sectoral Sanctions Identifications List”,
collectively “Blocked Persons”), the United Nations Security Council, the European Union, Her Majesty’s
Treasury or any other relevant sanctions authority (collectively, “Sanctions Laws”); neither Sonnet,
nor any of the Sonnet Subsidiaries, any director, officer, employee, agent, affiliate or other person associated with or acting
on behalf of Sonnet, any of the Sonnet Subsidiaries or their affiliates, is located,
organized or resident in a country or territory that is the subject or target of a comprehensive embargo or Sanctions Laws prohibiting
trade with the country or territory, including, without limitation, Crimea, Cuba, Iran, North Korea, Sudan and Syria (each, a
“Sanctioned Country”); Sonnet maintains in effect and enforces policies and procedures designed to ensure
compliance by Sonnet and the Sonnet Subsidiaries with applicable Sanctions Laws;
neither Sonnet, nor any of the Sonnet Subsidiaries,
any director, officer, employee, agent, affiliate or other person associated with or acting on behalf of Sonnet or
any of the Sonnet Subsidiaries or their affiliates, acting in any capacity in connection with the operations of Sonnet
or the Sonnet Subsidiaries, conducts any business with or for the benefit of any
Blocked Person or engages in making or receiving any contribution of funds, goods or services to, from or for the benefit of any
Blocked Person, or deals in, or otherwise engages in any transaction relating to, any property or interests in property blocked
or subject to blocking pursuant to any applicable Sanctions Laws; no action of Sonnet
or the Sonnet Subsidiaries in connection with (i) the execution, delivery and performance
of this Agreement and the other Sonnet Transaction Documents, (ii) the issuance and sale of the Securities, or (iii) the direct
or indirect use of proceeds from the Securities or the consummation of any other transaction contemplated hereby or by the other
Sonnet Transaction Documents or the fulfillment of the terms hereof or thereof, will result in the proceeds of the transactions
contemplated hereby and by the other Sonnet Transaction Documents being used, or loaned, contributed or otherwise made available,
directly or indirectly, to any Sonnet Subsidiary, joint venture partner or other person or entity, for the purpose of (i) unlawfully
funding or facilitating any activities of or business with any person that, at the time of such funding or facilitation, is the
subject or target of Sanctions Laws, (ii) unlawfully funding or facilitating any activities of or business in any Sanctioned Country
or (iii) in any other manner that will result in a violation by any Person (including any Person participating in the transaction,
whether as underwriter, advisor, investor or otherwise) of Sanctions Laws. For the past five (5) years, Sonnet and the
Sonnet Subsidiaries have not knowingly engaged in and is not now knowingly engaged in any
dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of
Sanctions Laws or with any Sanctioned Country.

 

    	22

    	 

    

 

(mm)
Anti-Bribery. Neither Sonnet nor any of the Sonnet Subsidiaries has made any
contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law
which violation is required to be disclosed. Neither Sonnet,
nor any of the Sonnet Subsidiaries, any of their affiliates, nor any director, officer,
agent, employee or other person associated with or acting on behalf of Sonnet, the
Sonnet Subsidiaries or any of their affiliates, has (i) used any funds for any unlawful
contribution, gift, entertainment or other unlawful expense relating to political activity, (ii) made any direct or indirect unlawful
payment to any foreign or domestic government official or employee, to any employee or agent of a private entity with which Sonnet
or the Sonnet Subsidiaries does or seeks to do business or to foreign or domestic political
parties or campaigns, (iii) violated or is in violation of any provision of any applicable law or regulation implementing the
OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions or any applicable provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the U.K. Bribery Act 2010, or any
other similar law of any other jurisdiction in which Sonnet or the Sonnet Subsidiaries operates its business, including, in each
case, the rules and regulations thereunder (the “Anti-Bribery Laws”), (iv) taken, is currently taking or will
take any action in furtherance of an offer, payment, gift or anything else of value, directly or indirectly, to any person while
knowing that all or some portion of the money or value will be offered, given or promised to anyone to improperly influence official
action, to obtain or retain business or otherwise to secure any improper advantage or (v) otherwise made any offer, bribe, rebate,
payoff, influence payment, unlawful kickback or other unlawful payment; Sonnet and
the Sonnet Subsidiaries have instituted and have maintained, and will continue to
maintain, policies and procedures reasonably designed to promote and achieve compliance with the laws referred to in (iii) above
and with this representation and warranty; none of Sonnet, nor the Sonnet
Subsidiaries or any of their affiliates will directly or indirectly use the proceeds of
the convertible securities or lend, contribute or otherwise make available such proceeds to any subsidiary, affiliate, joint venture
partner or other person or entity for the purpose of financing or facilitating any activity that would violate the laws and regulations
referred to in (iii) above; there are, and have been, no allegations, investigations or inquiries with regard to a potential violation
of any Anti-Bribery Laws by Sonnet, the Sonnet Subsidiaries
or their affiliates, or any of their respective current or former directors, officers, employees, stockholders, representatives
or agents, or other persons acting or purporting to act on their behalf.

 

    	23

    	 

    

 

(nn)
No Additional Agreements. Neither Sonnet nor any of the Sonnet Subsidiaries have any agreement or understanding with any
Buyer with respect to the transactions contemplated by the Sonnet Transaction Documents
other than as specified in the Sonnet Transaction Documents.

 

(oo)
Disclosure. Except for discussions specifically regarding the offer and sale of the Securities, Sonnet confirms that neither
it nor any other Person acting on its behalf has provided any of the Buyers or their agents or counsel with any information that
constitutes or could reasonably be expected to constitute material, non-public information concerning Sonnet, any of any of the
Sonnet Subsidiaries, Chanticleer or any of the Chanticleer Subsidiaries, other than the existence of the transactions contemplated
by this Agreement and the other Transaction Documents. Sonnet understands and confirms that each of the Buyers will rely on the
foregoing representations in effecting transactions in securities of Sonnet and Chanticleer. All disclosure provided to the Buyers
regarding Sonnet or any of the Sonnet Subsidiaries, their business and the transactions contemplated hereby, including the schedules
to this Agreement, furnished by or on behalf of Sonnet is true and correct and does not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. All of the written information furnished after the date hereof by or on behalf of
Sonnet to you pursuant to or in connection with this Agreement and the other Sonnet Transaction
Documents, taken as a whole, will be true and correct in all material respects as of the date on which such information is so
provided and will not contain any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements made therein, in the light of the circumstances under which they are made, not misleading. Each press release
issued by Sonnet or any of the Sonnet Subsidiaries during the twelve (12) months preceding the date of this Agreement did not
at the time of release contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. No event or circumstance has occurred or information exists with respect to Sonnet or any of the Sonnet Subsidiaries
or its or their business, properties, liabilities, prospects, operations (including results thereof) or conditions (financial
or otherwise), which, under applicable law, rule or regulation, requires public disclosure at or before the date hereof or announcement
by Sonnet but which has not been so publicly disclosed. Sonnet acknowledges and agrees that no Buyer makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 2.

 

(pp)
Stock Option Plans. Each stock option granted by Sonnet was granted (i) in accordance with the terms of the applicable
Sonnet stock option plan and (ii) with an exercise price at least equal to the fair market value of the Sonnet Common Stock on
the date such stock option would be considered granted under GAAP, consistently applied during the periods involved and applicable
law. No stock option granted under Sonnet’s stock option plan has been backdated. Sonnet has not knowingly granted, and
there is no and has been no Sonnet policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate
the grant of stock options with, the release or other public announcement of material information regarding Sonnet or the Sonnet
Subsidiaries or their financial results or prospects.

 

(qq)
No Disagreements with Accountants and Lawyers. There are no material disagreements of any kind presently existing, or reasonably
anticipated by Sonnet to arise, between Sonnet and the accountants and lawyers formerly or presently employed by Sonnet and Sonnet
is current with respect to any fees owed to its accountants and lawyers which could affect Sonnet’s ability to perform any
of its obligations under any of the Sonnet Transaction Documents.

 

    	24

    	 

    

 

(rr)
No Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under
the 1933 Act (“Regulation D Securities”), none of Sonnet, any of its predecessors, any affiliated issuer, any
director, executive officer, other officer of Sonnet participating in the offering hereunder, any beneficial owner of 20% or more
of Sonnet’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term
is defined in Rule 405 under the 1933 Act) connected with Sonnet in any capacity at the time of sale (each, an “Sonnet
Covered Person” and, together, “Sonnet Covered Persons”) is subject to any of the “Bad Actor”
disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification Event”),
except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). Sonnet has exercised reasonable care to determine whether
any Issuer Covered Person is subject to a Disqualification Event. Sonnet has complied, to the extent applicable, with its disclosure
obligations under Rule 506(e), and has furnished to the Buyers a copy of any disclosures provided thereunder.

 

(ss)
Other Covered Persons. Sonnet is not aware of any Person (other than the Placement Agent) that has been or will be paid
(directly or indirectly) remuneration for solicitation of Buyers or potential purchasers in connection with the sale of any Regulation
D Securities.

 

(tt)
Notice of Disqualification Events. Sonnet will notify the Buyers and the Placement Agent in writing, prior to the Closing
Date of (i) any Disqualification Event relating to any Sonnet Covered Person and (ii) any event that would, with the passage of
time, become a Disqualification Event relating to any Sonnet Covered Person.

 

(uu)
Dilutive Effect. Sonnet understands
and acknowledges that the number of Additional Common Shares issuable pursuant to Section 1(c)(ii) and the number of Warrant Shares
issuable pursuant to the terms of the Warrants will increase in certain circumstances. Sonnet further acknowledges that its obligation
to issue Additional Common Shares pursuant to this Agreement and the obligation of Chanticleer to issue Warrant Shares pursuant
to the terms of the Warrants in accordance with this Agreement and with the Warrants are absolute and unconditional regardless
of the dilutive effect that such issuance may have on the ownership interests of other stockholders of Sonnet or Chanticleer.

 

    	25

    	 

    

 

4.
REPRESENTATIONS AND WARRANTIES OF CHANTICLEER.

 

Chanticleer
represents and warrants to each of the Buyers that, as of the date hereof and as of the Closing Date:

 

(a)
Organization and Qualification. Each of Chanticleer and each of its “Chanticleer Subsidiaries” (which
for purposes of this Agreement means any entity in which Chanticleer, directly or indirectly, owns any of the capital stock or
holds an equity or similar interest) (the Chanticleer Subsidiaries, together with the Sonnet Subsidiaries, the “Subsidiaries”)
are entities duly organized and validly existing and in good standing under the laws of the jurisdiction in which they are formed,
and have the requisite power and authorization to own their properties and to carry on their business as now being conducted and
as presently proposed to be conducted. Each of Chanticleer and each of the Chanticleer Subsidiaries is duly qualified as a foreign
entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business
conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing
would not reasonably be expected to have a Chanticleer Material Adverse Effect. As used in this Agreement, “Chanticleer
Material Adverse Effect” means any material adverse effect on the business, properties, assets, liabilities, operations,
results of operations, condition (financial or otherwise) or prospects of Chanticleer
and the Chanticleer Subsidiaries, individually or taken as a whole, or on the transactions
contemplated hereby or on the other Chanticleer Transaction Documents or by the agreements
and instruments to be entered into in connection herewith or therewith, or on the authority or ability of Chanticleer to perform
any of its obligations under any of the Chanticleer Transaction Documents (as defined
below). Chanticleer has no Chanticleer Subsidiaries except as set forth in Schedule 4(a). The outstanding shares of capital
stock of each of the Chanticleer Subsidiaries have been duly authorized and validly issued, are fully paid and non-assessable
and are owned by Chanticleer or another Chanticleer Subsidiary free and clear of all liens, encumbrances and equities and claims;
and no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to convert any
obligations into shares of capital stock or ownership interests in the Chanticleer Subsidiaries are outstanding.

 

(b)
Authorization; Enforcement; Validity. Chanticleer has the requisite corporate power and authority to enter into and perform
its obligations under this Agreement, the Warrants, the Registration Rights Agreement, the Securities Escrow Agreement, the Irrevocable
Transfer Agent Instructions (as defined in Section 6(b)), the Lock-Up Agreements, the Leak-Out Agreements and each of the other
agreements entered into by Chanticleer in connection with the transactions contemplated by this Agreement (collectively, the “Chanticleer
Transaction Documents” and, together with the Sonnet Transaction Documents, the “Transaction
Documents”) and to issue the Warrants and the Warrant Shares in accordance with the terms hereof and thereof. The execution
and delivery of this Agreement and the other Chanticleer Transaction Documents by
Chanticleer and the consummation by Chanticleer
of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Warrants and the
reservation for issuance and the issuance of the Warrant Shares issuable upon exercise of the Warrants have been duly authorized
by Chanticleer’s Board of Directors and (other than the filing with the SEC
of one or more Registration Statements (as defined in the Registration Rights Agreement) in accordance with the requirements of
the Registration Rights Agreement, a Form D with the SEC and any other filings as may be required by any state securities agencies)
no further filing, consent or authorization is required by Chanticleer, its Board
of Directors or its stockholders (other than, as of the date hereof, stockholder consent related to items in the Form S-4). This
Agreement and the other Chanticleer Transaction Documents have been duly executed
and delivered by Chanticleer, and constitute the legal, valid and binding obligations
of Chanticleer, enforceable against Chanticleer
in accordance with their respective terms, except as such enforceability may be limited by general principles of equity
or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally,
the enforcement of applicable creditors’ rights and remedies.

 

    	26

    	 

    

 

(c)
Issuance of Securities. The issuance of the Warrants are duly authorized and, upon issuance in accordance with the terms
of the Chanticleer Transaction Documents, the Warrants shall be validly issued and
free from all preemptive or similar rights (except for those which have been validly waived prior to the date hereof), taxes,
liens and charges and other encumbrances with respect to the issue thereof. As of the Closing Date, a number of shares of Chanticleer
Common Stock shall have been duly authorized and reserved for issuance which equals the sum of (i) until the Reservation
Date (as defined in the Warrants), such calculation shall assume that the Series A Warrants and the Series B Warrants are then
exercisable in full into a number of shares of Common Stock equal to the sum of (x) the number of Series A Warrant Shares issued
and issuable pursuant to the Series A Warrants determined in accordance with Section 2(d) of the Series A Warrants assuming a
Reset Price (as defined in the Series A Warrants) equal to the Reset Floor Price (as defined in the Warrants) without giving effect
to any limitation on exercise set forth therein, (y) the number of Series B Warrant Shares issued and issuable pursuant to the
Series B Warrants assuming that he Maximum Eligibility Number (as defined in the Series B Warrant) is determined based on a Reset
Price (as defined in the Series B Warrants) equal to the Reset Floor Price without giving effect to any limitation on exercise
set forth therein, and (ii) thereafter, 100% of the maximum number of shares of Common Stock as shall from time to time be necessary
to effect the exercise of all of the Warrants then outstanding, without giving effect to any limitation on exercise included herein
(the foregoing clauses (i) and (ii), as applicable, the “Required Reserve Amount”) (as adjusted for stock splits,
stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other similar events
occurring after the date hereof). Upon exercise of the Warrants in accordance with the Warrants, the Warrant Shares when issued
will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights, taxes, liens, charges and
other encumbrances with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Chanticleer
Common Stock. Assuming the accuracy of each of the representations and warranties set forth in Section 2 of this Agreement, the
offer and issuance by Chanticleer of the Warrants and the Warrant Shares is exempt from registration under the 1933 Act.

 

(d)
No Conflicts. Except as disclosed in Schedule 4(d), the execution, delivery and performance of the Chanticleer Transaction
Documents by Chanticleer and the consummation by Chanticleer of the transactions contemplated hereby and thereby (including, without
limitation, the issuance of the Warrants and reservation for issuance and issuance of the Warrant Shares) will not (i) result
in a violation of the Chanticleer Certificate of Incorporation (as defined below) or Chanticleer Bylaws (as defined below) or
other organizational documents of Chanticleer or any of the Chanticleer Subsidiaries, any capital stock of Chanticleer or any
of the Chanticleer Subsidiaries or the articles of association or bylaws of Chanticleer or any of the Chanticleer Subsidiaries
or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which Chanticleer or any of the Chanticleer Subsidiaries is a party, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations
and the rules and regulations of the Principal Market and including all applicable foreign, federal, state laws, rules and regulations)
applicable to Chanticleer or any of the Chanticleer Subsidiaries or by which any property or asset of Chanticleer or any of the
Chanticleer Subsidiaries is bound or affected; except, in the case of clauses (ii) and (iii) above, as would not have or reasonably
be expected to result in a Chanticleer Material Adverse Effect.

 

    	27

    	 

    

 

(e)
Consents. Except as disclosed in Schedule 4(e), other than from Sonnet pursuant to that certain Agreement and Plan
of Merger and Reorganization, dated as of October 10, 2019, among Chanticleer, Bio Sub, Inc., a Delaware corporation and a wholly
owned subsidiary of Chanticleer and Sonnet (the “Merger Agreement”) and approval of The Nasdaq Stock Market
LLC to list additional shares on the Principal Market (in each case, as of the date hereof), Chanticleer is not required to obtain
any consent from, authorization or order of, or make any filing or registration with (other than the filing with the SEC of one
or more Registration Statements in accordance with the requirements of the Registration Rights Agreement, a Form D with the SEC
and any other filings as may be required by any state securities agencies), any court, governmental agency or any regulatory or
self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its obligations under or contemplated
by the Chanticleer Transaction Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations,
orders, filings and registrations which Chanticleer is required to obtain pursuant to the preceding sentence have been obtained
or effected on or prior to the Closing Date (or in the case of filings detailed above, will be made timely after the Closing Date),
and Chanticleer is unaware of any facts or circumstances which might prevent Chanticleer from obtaining or effecting any of the
registration, application or filings contemplated by the Chanticleer Transaction Documents. Except as disclosed in Schedule
4(e) or as disclosed in the SEC Documents (as defined below), Chanticleer is not in violation of the listing requirements
of the Principal Market and has no knowledge of any facts or circumstances which would reasonably lead to delisting or suspension
of the Chanticleer Common Stock in the foreseeable future. The issuance by Chanticleer of the Warrants and Warrant Shares shall
not have the effect of delisting or suspending the Chanticleer Common Stock from the Principal Market.

 

(f)
Acknowledgment Regarding Buyer’s Purchase of Securities. Chanticleer acknowledges and agrees that each Buyer is acting
solely in the capacity of an arm’s length purchaser with respect to the Chanticleer Transaction Documents and the transactions
contemplated hereby and thereby and that no Buyer is (i) an officer or director of Chanticleer or any of the Chanticleer Subsidiaries,
(ii) an “affiliate” of Chanticleer or any of the Chanticleer Subsidiaries (as defined in Rule 144) or (iii) to the
knowledge of Chanticleer, a “beneficial owner” of more than 10% of the Chanticleer Common Stock (as defined for purposes
of Rule 13d-3 of the 1934 Act). Chanticleer further acknowledges that no Buyer is acting as a financial advisor or fiduciary of
Chanticleer or any of the Chanticleer Subsidiaries (or in any similar capacity) with respect to the Chanticleer Transaction Documents
and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its representatives or agents
in connection with the Chanticleer Transaction Documents and the transactions contemplated hereby and thereby is merely incidental
to such Buyer’s purchase of the Securities. Chanticleer further represents to each Buyer that Chanticleer’s decision
to enter into the Chanticleer Transaction Documents has been based solely on the independent evaluation by Chanticleer and its
representatives.

 

(g)
No General Solicitation. Neither Chanticleer, nor any of the Chanticleer Subsidiaries or their affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with the offer or sale of the Securities.

 

    	28

    	 

    

 

(h)
No Integrated Offering. None of Chanticleer, the Chanticleer Subsidiaries their affiliates, nor any Person acting on their
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would require registration of the issuance of any of the Securities under the 1933 Act, whether through integration
with prior offerings or otherwise, or cause this offering of the Securities to require approval of stockholders of Chanticleer
for purposes of the 1933 Act or any applicable stockholder approval provisions, including, without limitation, under the rules
and regulations of any exchange or automated quotation system on which any of the securities of Chanticleer are listed or designated
for quotation. None of Chanticleer, the Chanticleer Subsidiaries, their affiliates nor any Person acting on their behalf will
take any action or steps that would require registration of the issuance of any of the Securities under the 1933 Act or cause
the offering of any of the Securities to be integrated with other offerings for purposes of any such applicable stockholder approval
provisions.

 

(i)
Application of Takeover Protections; Rights Agreement. Chanticleer and its board of directors have taken all necessary
action, if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison
pill (including, without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under
the Chanticleer certificate of incorporation, as amended and as in effect on the date hereof (the “Chanticleer Certificate
of Incorporation”), and the Chanticleer bylaws, as amended and as in effect on the date hereof (the “Chanticleer
Bylaws”) or other organizational documents or the laws of the jurisdiction of its formation which is or could become
applicable to any Buyer as a result of the transactions contemplated by this Agreement, including, without limitation, Chanticleer’s
issuance of the Securities and any Buyer’s ownership of the Securities. Chanticleer and its Board of Directors have taken
all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar arrangement relating to accumulations
of beneficial ownership of Chanticleer Common Stock or a change in control of Chanticleer or any of the Chanticleer Subsidiaries.

 

(j)
SEC Documents; Financial Statements. Except as disclosed in Schedule 4(j), during the two (2) years prior to the
date hereof, Chanticleer has timely filed all reports, schedules, forms, statements and other documents required to be filed by
it with the SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof or
prior to the Closing Date, and all exhibits included therein and financial statements, notes and schedules thereto and documents
incorporated by reference therein being hereinafter referred to as the “SEC Documents”). Chanticleer has delivered
to the Buyers or their respective representatives true, correct and complete copies of the SEC Documents not available on the
EDGAR system. As of their respective filing dates, the SEC Documents complied in all material respects with the requirements of
the 1934 Act applicable to Chanticleer and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents,
and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading. As of the dates of the filing of the Form S-4, including any
amendments thereto, the Form S-4, other than the sections of the Form S-4 titled “Risk Factors – Risks Relating to
Sonnet’s Business and Stock Ownership in Sonnet,” “Sonnet Business,” “Sonnet Management’s
Discussion and Analysis of Financial Condition and Results of Operations,” “Certain Relationships and Related-Party
Transactions – Sonnet” and “Principal Stockholders of Sonnet,” at the time the Form S-4 or such amendment
thereto was filed with the SEC, did not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading. As of their respective filing dates, the financial statements of Chanticleer included in the SEC Documents
complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of
the SEC with respect thereto. As of each filing date of the Form S-4 or any amendment thereto, the financial statements of Chanticleer
included in the Form S-4 complied as to form in all material respects with applicable accounting requirements and the published
rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in accordance with GAAP, consistently
applied during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto,
or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements)
and fairly present in all material respects the financial position of Chanticleer and the Chanticleer Subsidiaries as of the dates
thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements,
to normal year-end audit adjustments which will not be material, either individually or in the aggregate). No other information
provided by or on behalf of Chanticleer to any of the Buyers which is not included in the SEC Documents (including, without limitation,
information referred to in Section 2(d) of this Agreement or in the disclosure schedules to this Agreement) contains any untrue
statement of a material fact or omits to state any material fact necessary in order to make the statements therein, in the light
of the circumstance under which they are or were made, not misleading.

 

    	29

    	 

    

 

(k)
No Undisclosed Events, Liabilities, Developments or Circumstances. No event, liability, development or circumstance has
occurred or exists, or is contemplated to occur with respect to Chanticleer, the Chanticleer Subsidiaries or their respective
business, properties, prospects, operations or financial condition, that would be required to be disclosed by Chanticleer under
applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by Chanticleer
of its Chanticleer Common Stock and which has not been publicly announced.

 

(l)
Regulatory Permits. Chanticleer and each of the Chanticleer Subsidiaries possess all certificates, authorizations and permits
issued by the appropriate foreign, federal or state regulatory authorities necessary to conduct their respective businesses, except
where the failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a
Chanticleer Material Adverse Effect, and neither Chanticleer nor any such Chanticleer Subsidiary has received any notice of proceedings
relating to the revocation or modification of any such certificate, authorization or permit.

 

(m)
Foreign Corrupt Practices. Neither Chanticleer, nor any of the Chanticleer Subsidiaries, nor any director, officer, agent,
employee or other Person acting on behalf of Chanticleer or any of the Chanticleer Subsidiaries has, in the course of its actions
for, or on behalf of, Chanticleer or any of the Chanticleer Subsidiaries (i) used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment
to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment,
kickback or other unlawful payment to any foreign or domestic government official or employee.

 

    	30

    	 

    

 

(n)
Sarbanes-Oxley Act; Internal Accounting Controls. Chanticleer is in compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and
regulations promulgated by the SEC thereunder that are effective as of the date hereof. Chanticleer and each of the Chanticleer
Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions
are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP, consistently applied during the periods involved and applicable
law, and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only
in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets and liabilities
is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any
difference. Chanticleer maintains disclosure controls and procedures (as such term is defined in Rule 13a-15 under the 1934 Act)
that are effective in ensuring that information required to be disclosed by Chanticleer in the reports that it files or submits
under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of
the SEC, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by
Chanticleer in the reports that it files or submits under the 1934 Act is accumulated and communicated to Chanticleer’s
management, including its principal executive officer or officers and its principal financial officer or officers, as appropriate,
to allow timely decisions regarding required disclosure. Except as set forth in Schedule 4(n), during the twelve months
prior to the date hereof neither Chanticleer nor any of the Chanticleer Subsidiaries has received any notice or correspondence
from any accountant relating to any material weakness in any part of the system of internal accounting controls of Chanticleer
or any of the Chanticleer Subsidiaries.

 

(o)
Transactions With Affiliates and Employees. Except as set forth in Schedule 4(o), none of the officers, directors
or employees of Chanticleer or any of the Chanticleer Subsidiaries is presently a party to any transaction with Chanticleer or
any of the Chanticleer Subsidiaries (other than for ordinary course services as employees, officers or directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from any such officer, director or employee or, to the knowledge of
Chanticleer or any of the Chanticleer Subsidiaries, any corporation, partnership, trust or other Person in which any such officer,
director, or employee has a substantial interest or is an employee, officer, director, trustee or partner.

 

    	31

    	 

    

 

(p)
Equity Capitalization. As of the date hereof, the authorized capital stock of Chanticleer consists of (i) 45,000,000 shares
of Chanticleer Common Stock, of which as of the date hereof, 10,450,699 are issued and outstanding, 42,800 shares are reserved
for issuance pursuant to Chanticleer’s stock option and purchase plans, of which 32,800 shares are subject to outstanding
Chanticleer options granted under the Chanticleer stock plans and 10,000 shares are subject to outstanding Chanticleer restricted
stock units, and 3,202,413 shares are reserved for issuance pursuant to securities (other than the aforementioned options and
Warrants) exercisable or exchangeable for, or convertible into, Chanticleer Common Stock and (ii) 5,000,000 shares of preferred
stock, no par value per share, of which 62,876 shares have been designated Series 1 Preferred Stock and have been issued and are
outstanding as of the date hereof. No Chanticleer Common Stock are held in treasury. All of such outstanding shares are duly authorized
and have been, or upon issuance will be, validly issued and are fully paid and nonassessable. 237,596 shares of Chanticleer’s
issued and outstanding Chanticleer Common Stock on the date hereof are as of the date hereof owned by Persons who are “affiliates”
(as defined in Rule 405 of the 1933 Act) of Chanticleer or any of the Chanticleer Subsidiaries. (i) Except as disclosed in Schedule
4(p)(i), hereto, none of Chanticleer’s or any Chanticleer Subsidiary’s capital stock is subject to preemptive
rights or any other similar rights or any liens or encumbrances suffered or permitted by Chanticleer or any Chanticleer Subsidiary;
(ii) except as disclosed in Schedule 4(p)(ii), there are no outstanding options, warrants, scrip, rights to subscribe to,
calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable
for, any capital stock of Chanticleer or any of the Chanticleer Subsidiaries, or contracts, commitments, understandings or arrangements
by which Chanticleer or any of the Chanticleer Subsidiaries is or may become bound to issue additional capital stock of Chanticleer
or any of the Chanticleer Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock of Chanticleer
or any of the Chanticleer Subsidiaries; (iii) except as disclosed in Schedule 4(p)(iii), there are no outstanding debt
securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing Indebtedness
of Chanticleer or any of the Chanticleer Subsidiaries or by which Chanticleer or any of the Chanticleer Subsidiaries is or may
become bound; (iv) except as disclosed in Schedule 4(p)(iv), there are no financing statements securing obligations in
any amounts filed in connection with Chanticleer or any of the Chanticleer Subsidiaries; (v), except as disclosed in Schedule
4(p)(v), there are no agreements or arrangements (other than pursuant to the Registration Rights Agreement) under which Chanticleer
or any of the Chanticleer Subsidiaries is obligated to register the sale of any of their securities under the 1933 Act; (vi) except
as disclosed in Schedule 4(p)(vi), there are no outstanding securities or instruments of Chanticleer or any of the Chanticleer
Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements
by which Chanticleer or any of the Chanticleer Subsidiaries is or may become bound to redeem a security of Chanticleer or any
of the Chanticleer Subsidiaries; (vii) except as disclosed in Schedule 4(p)(vii), there are no securities or instruments
containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; (viii) except as disclosed
in Schedule 4(p)(viii), neither Chanticleer nor any Chanticleer Subsidiary has any stock appreciation rights or “phantom
stock” plans or agreements or any similar plan or agreement; and (ix) neither Chanticleer nor any of the Chanticleer Subsidiaries
have any liabilities or obligations required to be disclosed in the SEC Documents which are not so disclosed in the SEC Documents,
other than those incurred in the ordinary course of Chanticleer’s or the Chanticleer Subsidiaries’ respective businesses
and which, individually or in the aggregate, do not or could not have a Chanticleer Material Adverse Effect. True, correct and
complete copies of the Chanticleer Certificate of Incorporation and Chanticleer Bylaws, and the terms of all securities convertible
into, or exercisable or exchangeable for, Chanticleer Common Stock and the material rights of the holders thereof in respect thereto
have heretofore been filed as part of the SEC Documents.

 

    	32

    	 

    

 

(q)
Compliance. Neither Chanticleer nor any Chanticleer Subsidiary: (i) is in default under or in violation of (and no event
has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by Chanticleer or
any Chanticleer Subsidiary under), nor has Chanticleer or any Chanticleer Subsidiary received notice of a claim that it is in
default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which
it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii)
is in violation of any judgment, decree, or order of any court, arbitrator or other governmental authority or (iii) is or has
been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all
foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result in a Chanticleer
Material Adverse Effect.

 

(r)
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by the Principal Market,
any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of Chanticleer,
threatened against or affecting Chanticleer or any of the Chanticleer Subsidiaries, the Chanticleer Common Stock or any of the
Chanticleer Subsidiary’s capital stock or any of Chanticleer’s or any of the Chanticleer Subsidiaries’ officers
or directors, whether of a civil or criminal nature or otherwise, in their capacities as such, except as set forth in Schedule
4(r). The matters set forth in Schedule 4(r) would not reasonably be expected to have a Chanticleer Material Adverse
Effect.

 

(s)
Insurance. Chanticleer and any of the Chanticleer Subsidiaries are insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as management of Chanticleer believes to be prudent and customary in the businesses
in which Chanticleer and the Chanticleer Subsidiaries are engaged. Neither Chanticleer nor any such Chanticleer Subsidiary has
been refused any insurance coverage sought or applied for and neither Chanticleer nor any such Chanticleer Subsidiary has any
reason to believe that it will be unable to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Chanticleer
Material Adverse Effect.

 

(t)
Employee Relations. Neither Chanticleer nor any of the Chanticleer Subsidiaries is a party to any collective bargaining
agreement or employs any member of a union. Chanticleer and the Chanticleer Subsidiaries believe that their relations with their
respective employees are good. No executive officer (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee
of Chanticleer or any of the Chanticleer Subsidiaries has notified Chanticleer or any such Chanticleer Subsidiary that such officer
intends to leave Chanticleer or any such Chanticleer Subsidiary or otherwise terminate such officer’s employment with Chanticleer
or any such Chanticleer Subsidiary. No executive officer or other key employee of Chanticleer or any of the Chanticleer Subsidiaries
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued
employment of each such executive officer or other key employee (as the case may be) does not subject Chanticleer or any of the
Chanticleer Subsidiaries to any liability with respect to any of the foregoing matters. Chanticleer and the Chanticleer Subsidiaries
are in compliance with all federal, state, local and foreign laws and regulations respecting labor, employment and employment
practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance would
not, either individually or in the aggregate, reasonably be expected to result in a Chanticleer Material Adverse Effect.

 

    	33

    	 

    

 

(u)
Title. Chanticleer and the Chanticleer Subsidiaries have good and marketable title in fee simple to all real property and
good and marketable title to all personal property owned by them which is material to the business of Chanticleer and the Chanticleer
Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value
of such property and do not interfere with the use made and proposed to be made of such property by Chanticleer and any of the
Chanticleer Subsidiaries. Any real property and facilities held under lease by Chanticleer or any of the Chanticleer Subsidiaries
are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere
with the use made and proposed to be made of such property and buildings by Chanticleer or any of the Chanticleer Subsidiaries.

 

(v)
Intellectual Property Rights. Chanticleer and the Chanticleer Subsidiaries own or possess adequate Intellectual Property
Rights necessary to conduct their respective businesses as now conducted and as presently proposed to be conducted. Each of patents
owned by Chanticleer or any of the Chanticleer Subsidiaries is listed on Schedule 4(v)(i). Except as set forth in Schedule
4(v)(ii), none of the Chanticleer’s or any of the Chanticleer Subsidiaries’ Intellectual Property Rights have
expired, terminated or been abandoned, or are expected to expire, terminate or be abandoned, within three years from the date
of this Agreement. Chanticleer has no knowledge of any infringement by Chanticleer or any of the Chanticleer Subsidiaries of Intellectual
Property Rights of others. There is no claim, action or proceeding being made or brought, or to the knowledge of Chanticleer or
the Chanticleer Subsidiaries, being threatened, against Chanticleer or any of the Chanticleer Subsidiaries regarding their Intellectual
Property Rights. Neither Chanticleer nor any of the Chanticleer Subsidiaries is aware of any facts or circumstances which might
give rise to any of the foregoing infringements or claims, actions or proceedings. Chanticleer and the Chanticleer Subsidiaries
have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property
Rights.

 

(w)
Environmental Laws. Chanticleer and the Chanticleer Subsidiaries (i) are in compliance with all Environmental Laws, (ii)
have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses and (ii) are in compliance with all terms and conditions of any such permit, license or approval where, in each of
the foregoing clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the
aggregate, a Chanticleer Material Adverse Effect.

 

(x)
Tax Status. Chanticleer and each of the Chanticleer Subsidiaries (i) has timely made or filed all foreign, federal and
state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
timely paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations
apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the
officers of the Chanticleer and the Chanticleer Subsidiaries know of no basis for any such claim.

 

    	34

    	 

    

 

(y)
Investment Company Status. Neither Chanticleer nor any of the Chanticleer Subsidiaries is, and upon consummation of the
sale of the Securities, and for so long as any Buyer holds any Securities, will not be, an “investment company,” an
affiliate of an “investment company,” a company controlled by an “investment company” or an “affiliated
person” of, or “promoter” or “principal underwriter” for, an “investment company” as
such terms are defined in the Investment Company Act of 1940, as amended.

 

(z)
Registration Rights. Except as set forth on Schedule 4(z), other than each of the Buyers, no Person has any right
to cause Chanticleer or any Chanticleer Subsidiary to effect the registration under the 1933 Act of any securities of Chanticleer
or any Chanticleer Subsidiary.

 

(aa)
Solvency. Based on the consolidated financial condition of Chanticleer as of the Closing Date, after giving effect to the
receipt by Sonnet of the proceeds from the sale of the Securities hereunder: (i) the fair saleable value of Chanticleer’s
assets exceeds the amount that will be required to be paid on or in respect of Chanticleer’s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) Chanticleer’s assets do not constitute unreasonably small
capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by Chanticleer, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of Chanticleer, together with the proceeds Chanticleer would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. Chanticleer does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). Chanticleer has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. Schedule 4(aa) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of Chanticleer
or any Chanticleer Subsidiary, or for which Chanticleer or any Chanticleer Subsidiary has commitments. For the purposes of this
Section 4, “Indebtedness” means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other
than trade account payables and accrued expenses incurred in the ordinary course of business), (y) all guaranties, endorsements
and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in Chanticleer’s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000
due under leases required to be capitalized in accordance with GAAP. Neither Chanticleer nor any Chanticleer Subsidiary is in
default with respect to any Indebtedness.

 

    	35

    	 

    

 

(bb)
Acknowledgment Regarding Buyer’s Trading Activity. Chanticleer acknowledges and agrees that, except as set forth
in the Leak-Out Agreements,, (i) none of the Buyers has been asked to agree, nor has any Buyer agreed, to desist from purchasing
or selling, long and/or short, securities of Chanticleer, or “derivative” securities based on securities issued by
Chanticleer or to hold the Securities for any specified term; (ii) any Buyer, and counter-parties in “derivative”
transactions to which any such Buyer is a party, directly or indirectly, presently may have a “short” position in
the Chanticleer Common Stock and (iii) each Buyer shall not be deemed to have any affiliation with or control over any arm’s
length counter-party in any “derivative” transaction. Chanticleer further understands and acknowledges that (a) one
or more Buyers may engage in hedging and/or trading activities at various times during the period that the Securities are outstanding,
including, without limitation, during the periods that the value of the Warrant Shares are being determined and (b) such hedging
and/or trading activities, if any, can reduce the value of the existing stockholders’ equity interest in Chanticleer both
at and after the time the hedging and/or trading activities are being conducted. Chanticleer acknowledges that such aforementioned
hedging and/or trading activities do not constitute a breach of this Agreement, the Warrants or any of the documents executed
in connection herewith.

 

(cc)
Manipulation of Price. Chanticleer has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or
indirectly, any action designed to cause or to result, or that could reasonably be expected to cause or result, in the stabilization
or manipulation of the price of any security of Chanticleer to facilitate the sale or resale of any of the Securities, (ii) other
than the Placement Agent, sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities,
or (iii) other than the Placement Agent, paid or agreed to pay to any person any compensation for soliciting another to purchase
any other securities of Chanticleer.

 

(dd)
FDA. As to each Pharmaceutical Product subject to the jurisdiction of the FDA under the FDCA (“FDCA”)
that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by Chanticleer or any of its Chanticleer,
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by Chanticleer
in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational
use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical
practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be
in compliance would not have a Chanticleer Material Adverse Effect. There is no pending, completed or, to Chanticleer’s
knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge,
complaint, or investigation) against Chanticleer or any of its Chanticleer Subsidiaries, and none of Chanticleer or any of its
Chanticleer Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental
entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of,
the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii)
withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising
or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation
by Chanticleer or any of its Chanticleer Subsidiaries, (iv) enjoins production at any facility of Chanticleer or any of its Chanticleer
Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with Chanticleer or any of its Chanticleer
Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by Chanticleer or any of its Chanticleer
Subsidiaries, and which, either individually or in the aggregate, would have a Chanticleer Material Adverse Effect. The properties,
business and operations of Chanticleer have been and are being conducted in all material respects in accordance with all applicable
laws, rules and regulations of the FDA. Except as set forth on Schedule 4(dd) or as Disclosed in the SEC Documents, Chanticleer
has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product
proposed to be developed, produced or marketed by Chanticleer nor has the FDA expressed any concern as to approving or clearing
for marketing any product being developed or proposed to be developed by Chanticleer.

 

    	36

    	 

    

 

(ee)
U.S. Real Property Holding Corporation. Neither Chanticleer nor any of the Chanticleer Subsidiaries is, or has ever been,
and so long as any of the Securities are held by any of the Buyers, shall become, a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and Chanticleer and each Chanticleer Subsidiary shall
so certify upon any Buyer’s request.

 

(ff)
Eligibility for Registration. Chanticleer is eligible to register the Warrant Shares for resale by the Buyers using Form
S-3 promulgated under the 1933 Act.

 

(gg)
Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required
to be paid in connection with the issuance, sale and transfer of the Securities to be sold to each Buyer hereunder will be, or
will have been, fully paid or provided for by Chanticleer, and all laws imposing such taxes will be or will have been complied
with.

 

(hh)
Bank Holding Company Act. Neither Chanticleer nor any of the Chanticleer Subsidiaries or affiliates is subject to BHCA
and to regulation by the Board of Governors of the Federal Reserve. Neither Chanticleer nor any of the Chanticleer Subsidiaries
or affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting
securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve. Neither Chanticleer nor any of the Chanticleer Subsidiaries or affiliates exercises a controlling
influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal
Reserve.

 

(ii)
Shell Company Status. Chanticleer is not, and has never been, an issuer identified in, or subject to, Rule 144(i)(1) of
the 1933 Act.

 

(jj)
Compliance with Anti-Money Laundering Laws. The operations of Chanticleer
and the Chanticleer Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements and all other
applicable Anti-Money Laundering Laws, and no action, suit or proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving Chanticleer or any of the Chanticleer Subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the knowledge of Chanticleer, threatened.

 

    	37

    	 

    

 

(kk)
No Conflicts with Sanctions Laws. Neither Chanticleer nor any of the Chanticleer
Subsidiaries, nor any director, officer, employee, agent, affiliate or other person associated
with or acting on behalf of Chanticleer or any of the Chanticleer Subsidiaries or
any of their affiliates is, or is directly or indirectly owned or controlled by, a Person that is currently the subject or the
target of any sanctions administered or enforced by the U.S. government (including, without limitation, the Sanctions Laws; neither
Chanticleer, nor any of Chanticleer Subsidiaries, any director, officer, employee, agent, affiliate or other person associated
with or acting on behalf of Chanticleer or any of the Chanticleer Subsidiaries or
their affiliates, is located, organized or resident in a country or territory that is the subject or target of a comprehensive
embargo or Sanctions Laws prohibiting trade with the country or territory, including, without limitation, a Sanctioned Country);
Chanticleer maintains in effect and enforces policies and procedures designed to ensure compliance by Chanticleer and the
Chanticleer Subsidiaries with applicable Sanctions Laws; neither Chanticleer, nor any of
the Chanticleer Subsidiaries, any director, officer, employee, agent, affiliate or other person associated with or acting on behalf
of Chanticleer or any of the Chanticleer Subsidiaries or their affiliates, acting
in any capacity in connection with the operations of Chanticleer or the Chanticleer Subsidiaries, conducts any business
with or for the benefit of any Blocked Person or engages in making or receiving any contribution of funds, goods or services to,
from or for the benefit of any Blocked Person, or deals in, or otherwise engages in any transaction relating to, any property
or interests in property blocked or subject to blocking pursuant to any applicable Sanctions Laws; no
action of Chanticleer or any of the Chanticleer Subsidiaries in connection with (i)
the execution, delivery and performance of this Agreement and the other Chanticleer Transaction Documents, (ii) the issuance and
sale of the Securities, or (iii) the direct or indirect use of proceeds from the Securities or the consummation of any other transaction
contemplated hereby or by the other Chanticleer Transaction Documents or the fulfillment of the terms hereof or thereof, will
result in the proceeds of the transactions contemplated hereby and by the other Chanticleer Transaction Documents being used,
or loaned, contributed or otherwise made available, directly or indirectly, to any Chanticleer Subsidiary, joint venture partner
or other person or entity, for the purpose of (i) unlawfully funding or facilitating any activities of or business with any person
that, at the time of such funding or facilitation, is the subject or target of Sanctions Laws, (ii) unlawfully funding or facilitating
any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any Person
(including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions Laws.
For the past five (5) years, Chanticleer and the Chanticleer Subsidiaries have not
knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the
dealing or transaction is or was the subject or the target of Sanctions Laws or with any Sanctioned Country.

 

(ll)
Anti-Bribery. Neither Chanticleer nor any of the Chanticleer Subsidiaries has made any contribution or other payment to
any official of, or candidate for, any federal, state or foreign office in violation of any law which violation is required to
be disclosed. Neither Chanticleer, nor any of the Chanticleer Subsidiaries or any of their affiliates, nor any director, officer,
agent, employee or other person associated with or acting on behalf of Chanticleer, the Chanticleer Subsidiaries or any of their
affiliates, has (i) used any funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political
activity, (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee, to any
employee or agent of a private entity with which Chanticleer or the Chanticleer Subsidiaries does or seeks to do business or to
foreign or domestic political parties or campaigns, (iii) violated or is in violation of any provision of any applicable law or
regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions
or any applicable provision of the FCPA, the U.K. Bribery Act 2010, or the Anti-Bribery Laws, (iv) taken, is currently taking
or will take any action in furtherance of an offer, payment, gift or anything else of value, directly or indirectly, to any person
while knowing that all or some portion of the money or value will be offered, given or promised to anyone to improperly influence
official action, to obtain or retain business or otherwise to secure any improper advantage or (v) otherwise made any offer, bribe,
rebate, payoff, influence payment, unlawful kickback or other unlawful payment; Chanticleer and the Chanticleer Subsidiaries have
instituted and have maintained, and will continue to maintain, policies and procedures reasonably designed to promote and achieve
compliance with the laws referred to in (iii) above and with this representation and warranty; none of Chanticleer, nor the Chanticleer
Subsidiaries or any of their affiliates will directly or indirectly use the proceeds of the convertible securities or lend, contribute
or otherwise make available such proceeds to any subsidiary, affiliate, joint venture partner or other person or entity for the
purpose of financing or facilitating any activity that would violate the laws and regulations referred to in (iii) above; there
are, and have been, no allegations, investigations or inquiries with regard to a potential violation of any Anti-Bribery Laws
by Chanticleer, the Chanticleer Subsidiaries or their affiliates, or any of their respective current or former directors, officers,
employees, stockholders, representatives or agents, or other persons acting or purporting to act on their behalf.

 

    	38

    	 

    

 

(mm)
No Additional Agreements. Neither Chanticleer nor any of the Chanticleer Subsidiaries have any agreement or understanding
with any Buyer with respect to the transactions contemplated by the Chanticleer Transaction Documents other than as specified
in the Chanticleer Transaction Documents.

 

(nn)
Disclosure. Except for discussions specifically regarding the offer and sale of the Securities, Chanticleer confirms that
neither it nor any other Person acting on its behalf has provided any of the Buyers or their agents or counsel with any information
that constitutes or could reasonably be expected to constitute material, non-public information concerning Sonnet, the Sonnet
Subsidiaries, Chanticleer or any of the Chanticleer Subsidiaries, other than the existence of the transactions contemplated by
this Agreement and the other Chanticleer Transaction Documents. Chanticleer understands and confirms that each of the Buyers will
rely on the foregoing representations in effecting transactions in securities of Chanticleer. All disclosure provided to the Buyers
regarding Chanticleer and the Chanticleer Subsidiaries, their businesses and the transactions contemplated hereby, including the
schedules to this Agreement, furnished by or on behalf of Chanticleer or any of the Chanticleer Subsidiaries is true and correct
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading. All of the written information
furnished after the date hereof by or on behalf of Chanticleer or any of the Chanticleer Subsidiaries to you pursuant to or in
connection with this Agreement and the other Chanticleer Transaction Documents, taken as a whole, will be true and correct in
all material respects as of the date on which such information is so provided and will not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they are made, not misleading. Each press release issued by Chanticleer or any of the Chanticleer Subsidiaries during
the twelve (12) months preceding the date of this Agreement did not at the time of release contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. No event or circumstance has occurred or information exists
with respect to Chanticleer or any of the Chanticleer Subsidiaries or its or their business, properties, liabilities, prospects,
operations (including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation,
requires public disclosure at or before the date hereof or announcement by Chanticleer but which has not been so publicly disclosed.
Chanticleer acknowledges and agrees that no Buyer makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 2.

 

    	39

    	 

    

 

(oo)
Stock Option Plans. Each stock option granted by Chanticleer was granted (i) in accordance with the terms of the applicable
Chanticleer stock option plan and (ii) with an exercise price at least equal to the fair market value of the Chanticleer Common
Stock on the date such stock option would be considered granted under GAAP, consistently applied during the periods involved and
applicable law. No stock option granted under Chanticleer’s stock option plan has been backdated. Chanticleer has not knowingly
granted, and there is no and has been no Chanticleer policy or practice to knowingly grant, stock options prior to, or otherwise
knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding
Chanticleer or the Chanticleer Subsidiaries or their financial results or prospects.

 

(pp)
No Disqualification Events. With respect to Regulation D Securities to be offered and sold hereunder, none of Chanticleer,
any of its predecessors, any affiliated issuer, any director, executive officer, other officer of Chanticleer participating in
the offering hereunder, any beneficial owner of 20% or more of Chanticleer’s outstanding voting equity securities, calculated
on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the 1933 Act) connected with Chanticleer
in any capacity at the time of sale (each, an “Chanticleer Covered Person” and, together, “Chanticleer
Covered Persons”) is subject to a Disqualification Event, except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3). Chanticleer has exercised reasonable care to determine whether any Chanticleer Covered Person is subject to a Disqualification
Event. Chanticleer has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished
to the Buyers a copy of any disclosures provided thereunder.

 

(qq)
Other Covered Persons. Chanticleer is not aware of any Person (other than the Placement Agent) that has been or will be
paid (directly or indirectly) remuneration for solicitation of Buyers or potential purchasers in connection with the sale of any
Regulation D Securities.

 

(rr)
Notice of Disqualification Events. Chanticleer will notify the Buyers and the Placement Agent in writing, prior to the
Closing Date of (i) any Disqualification Event relating to any Chanticleer Covered Person and (ii) any event that would, with
the passage of time, reasonably be expected to become a Disqualification Event relating to any Chanticleer Covered Person.

 

(ss)
Business Operations; Assets. As of immediately prior to the Closing Date, other than the ownership of Sonnet and its related
operations assets, contracts, agreements, liabilities and commitments, Chanticleer shall have no material operations, hold any
material assets, be a party to any material contracts, agreements, or instruments of any kind, or have any other material rights,
obligations, liabilities, or commitments of any type whatsoever.

 

    	40

    	 

    

 

(tt)
Lock-Up Parties. The Persons identified on Schedule 4(tt) set forth all Persons that will be subject to Section
16 of the 1934 Act immediately following the consummation of the Merger.

 

5.
COVENANTS.

 

(a)
Commercially Reasonable Efforts. Each party shall use its commercially reasonable efforts timely to satisfy each of the
covenants and the conditions to be satisfied by it as provided in Sections 7 and 8 of this Agreement.

 

(b)
Form D and Blue Sky. Each of Sonnet and Chanticleer agrees to file a Form D with respect to the Common Shares and Warrants,
respectively, as required under Regulation D and to provide a copy thereof to each Buyer promptly after such filing. Each of Sonnet
and Chanticleer shall, on or before the Closing Date, take such action as it shall reasonably determine is necessary in order
to obtain an exemption for or to qualify the Securities for sale to the Buyers at the Closing and the Warrant Closing pursuant
to this Agreement under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain
an exemption from such qualification), and shall provide evidence of any such action so taken to the Buyers on or prior to the
Closing Date. Each of Sonnet and Chanticleer shall make all filings and reports relating to the offer and sale of the Securities
required under applicable securities or “Blue Sky” laws of the states of the United States following the Closing Date.

 

(c)
Reporting Status. Until the date on which the Investors (as defined in the Registration Rights Agreement) shall have sold
all of the Warrant Shares and none of the Warrants are outstanding (the “Reporting Period”), Chanticleer shall
use its commercially reasonable efforts to timely file all reports required to be filed with the SEC pursuant to the 1934 Act,
and Chanticleer shall not terminate its status as an issuer required to file reports under the 1934 Act unless the 1934 Act or
the rules and regulations thereunder would no longer require or otherwise permit such termination, and Chanticleer shall take
all actions reasonably necessary to maintain its eligibility to register the Warrant Shares for resale by the Investors on Form
S-3 or, if it is ineligible to use Form S-3, on Form S-1.

 

(d)
Exchange of Shares.

 

(i)
Promptly following the issuance of the Common Shares on the Closing Date the Common Shares shall be exchanged for shares of Chanticleer
Common Stock (the “Exchange Shares”) on the terms described in the Merger Agreement. Such Exchange Shares shall
be delivered to each Buyer by crediting to such Buyer’s or its designee’s balance account within (i) with respect
to the Exchange Shares being issued in exchange of the Initial Common Shares, two (2) Trading Days following the Closing Date
and (ii) with respect to the Exchange Shares being issued in exchange of any Additional Common Shares, on the applicable Additional
Exchange Shares Delivery Date. Notwithstanding anything to the contrary contained herein, in no event will any Exchange Shares
be delivered with any restrictive legends or any restrictions or limitations on resale by the Buyers, except to the extent any
Buyer is then an affiliate of Chanticleer. If Chanticleer and/or the Transfer Agent requires any legal opinions with respect to
the delivery of any Exchange Shares without restrictive legends or the removal of any such restrictive legends, Chanticleer agrees
to cause at its expense its legal counsel to issue any such legal opinions.

 

    	41

    	 

    

 

(ii)
So long as such Buyer has paid its Purchase Price hereunder and has complied with the requirements set forth in Section 2.2 of
the Merger Agreement, as applicable, if Chanticleer shall fail for any reason or for no reason to credit such Buyer’s or
its designee’s balance account with DTC within two (2) Trading Days following the Closing Date (the “Merger Delivery
Date”) the applicable Exchange Shares with respect to the Initial Common Shares to which such Buyer is entitled hereunder
(a “Merger Delivery Failure”), then, in addition to all other remedies available to such Buyer, Chanticleer
shall pay in cash to such Buyer on each day after such Merger Delivery Date that Chanticleer shall fail to credit such Buyer’s
or its designee’s balance account with DTC for the number of shares of Chanticleer Common Stock to which such Buyer is entitled
pursuant to the exchange of the Initial Common Shares for Chanticleer Common Stock pursuant to the Merger, an amount equal to
2.0% of the product of (A) the number of Exchange Shares with respect to the Initial Common Shares not delivered to such Buyer
on or prior to the Merger Delivery Date and to which the Buyer is entitled, and (B) any trading price of the Chanticleer Common
Stock selected by the Buyer in writing as in effect at any time during the period beginning on the Merger Delivery Date and ending
on the date Chanticleer makes the applicable cash payment, and if on or after such Trading Day such Buyer (or any Person in respect
of, or on behalf, of such Buyer) purchases (in an open market transaction or otherwise) shares of Chanticleer Common Stock related
to the applicable Merger Delivery Failure, then, in addition to all other remedies available to such Buyer, Chanticleer shall,
within two (2) Trading Days after such Buyer’s request and in such Buyer’s discretion, either (i) pay cash to such
Buyer in an amount equal to such Buyer’s total purchase price (including brokerage commissions and other out-of-pocket expenses,
if any) for the shares of Chanticleer Common Stock so purchased (the “Merger Buy-In Price”), at which point
Chanticleer’s obligation to credit such Buyer’s or its designee’s balance account with DTC for such shares of
Chanticleer Common Stock shall terminate, or (ii) promptly honor its obligation to credit such Buyer’s or its designee’s
balance account with DTC and pay cash to such Buyer in an amount equal to the excess (if any) of the Merger Buy-In Price over
the product of (A) such number of shares of Chanticleer Common Stock, multiplied by (B) any trading price of the Chanticleer Common
Stock selected by such Buyer in writing as in effect at any time during the period beginning on the Merger Delivery Date and ending
on the date of such delivery and payment under this Section 5(d)(ii). Nothing shall limit any Buyer’s right to pursue any
other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance
and/or injunctive relief with respect to Chanticleer’s failure to timely electronically deliver shares of Chanticleer Common
Stock as required pursuant to the terms hereof.

 

    	42

    	 

    

 

(e)
Use of Proceeds. Sonnet shall use the proceeds from the sale of the Securities for working capital and general corporate
purposes.

 

(f)
Financial Information. Chanticleer agrees to send the following to each Investor (as defined in the Registration Rights
Agreement) during the Reporting Period (i) unless the following are filed with the SEC through EDGAR and are available to the
public through the EDGAR system, within one (1) Business Day after the filing thereof with the SEC, a copy of its Annual Reports
on Form 10-K, any Quarterly Reports on Form 10-Q, any Current Reports on Form 8-K (or any analogous reports under the 1934 Act)
and any registration statements (other than on Form S-8) or amendments filed pursuant to the 1933 Act, (ii) unless the following
have been widely disseminated by wire service or in one or more newspapers of general circulation, on the same day as the release
thereof, facsimile or e-mailed copies of all press releases issued by Chanticleer, and (iii) unless the following are filed with
the SEC through EDGAR and are available to the public through the EDGAR system, copies of any notices and other information made
available or given to the stockholders of Chanticleer generally, contemporaneously with the making available or giving thereof
to the stockholders.

 

(g)
Listing. During the Reporting Period, Chanticleer shall promptly secure the listing of all of the Exchange Shares and Registrable
Securities on the Principal Market and shall use its reasonable best efforts to maintain such listing of all Exchange Shares and
Registrable Securities from time to time issuable under the terms of the Transaction Documents. Chanticleer shall maintain the
authorization for quotation of the Chanticleer Common Stock on the Principal Market or any other Eligible Market (as defined in
the Warrants). During the Reporting Period, neither Chanticleer nor any of the Chanticleer Subsidiaries shall take any action
which would be reasonably expected to result in the delisting or suspension of the Chanticleer Common Stock on the Principal Market.
Chanticleer shall pay all fees and expenses in connection with satisfying its obligations under this Section 5(g).

 

(h)
Fees. Sonnet shall, upon the request of the Lead Investor (a Buyer) or its designee(s), deposit with counsel for the Lead
Investor up to $50,000 (in addition to any other amounts paid to any Buyer or its counsel prior to the date of this Agreement),
which amount may be withheld by such Buyer from its Purchase Price at the Closing to the extent not previously deposited by Sonnet.
Sonnet shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or broker’s commissions
(other than for Persons engaged by any Buyer) relating to or arising out of the transactions contemplated hereby, including, without
limitation, any fees or commissions payable to the Placement Agent and the Escrow Agent. Except as otherwise set forth in the
Transaction Documents, each party to this Agreement shall bear its own expenses in connection with the sale of the Securities
to the Buyers.

 

(i)
Pledge of Securities. Each of Sonnet and Chanticleer acknowledges and agrees that the Securities (excluding Securities
held in escrow pursuant to the Securities Escrow Agreement) may be pledged by an Investor, at the Investor’s sole cost and
expense, in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities.
The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Investor
effecting a pledge of Securities shall be required to provide Chanticleer with any notice thereof or otherwise make any delivery
to Chanticleer pursuant to this Agreement or any other Transaction Document, including, without limitation, Section 2(f) hereof;
provided that an Investor and its pledgee shall be required to comply with the provisions of Section 2(f) hereof in order
to effect a sale, transfer or assignment of Securities to such pledgee. Chanticleer hereby agrees to execute and deliver such
documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the Securities to such pledgee
by an Investor, at the Investor’s sole cost and expense.

 

    	43

    	 

    

 

(j)
Disclosure of Transactions and Other Material Information. On or before the Disclosure Time (as defined below), Chanticleer
shall file a Current Report on Form 8-K or Form S-4 describing the terms of the transactions contemplated by the Transaction Documents
in the form required by the 1934 Act and attaching the material Transaction Documents (including, without limitation, this Agreement
(and all schedules and exhibits to this Agreement), the form of the Warrant, the Registration Rights Agreement, the Securities
Escrow Agreement, the Form of Lock-Up Agreement and the form of Leak-Out Agreement as exhibits to such filing (including all attachments),
the “8-K Filing”). From and after the filing of the 8-K Filing, no Buyer shall be in possession of any material,
non-public information received from Sonnet, Chanticleer, any of their respective Subsidiaries or any of their respective officers,
directors, employees, affiliates or agents, that is not disclosed in the 8-K Filing. In addition, effective upon the filing of
the 8-K Filing, each of Sonnet and Chanticleer acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between Sonnet, Chanticleer, any of their respective Subsidiaries or any of their
respective officers, directors, affiliates, employees or agents, on the one hand, and any of the Buyers or any of their affiliates,
on the other hand, shall terminate and be of no further force or effect. Each of Sonnet and Chanticleer shall not, and shall cause
each of their respective Subsidiaries and its and each of their respective officers, directors, employees, affiliates and agents,
not to, provide any Buyer with any material, non-public information regarding Sonnet, Chanticleer or any of their respective Subsidiaries
from and after the date hereof without the express prior written consent of such Buyer. If a Buyer has, or believes it has, received
any such material, non-public information regarding Sonnet, Chanticleer or any of their respective Subsidiaries from Sonnet, Chanticleer,
any of their respective Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, it may provide
Chanticleer with written notice thereof. Chanticleer shall, within two (2) Trading Days of receipt of such notice, make public
disclosure of such material, non-public information. In the event of a breach of the foregoing covenant by Sonnet, Chanticleer,
any of their respective Subsidiaries, or any of their respective officers, directors, employees, affiliates and agents, in addition
to any other remedy provided herein or in the Transaction Documents, a Buyer shall have the right to make a public disclosure,
in the form of a press release, public advertisement or otherwise, of such material, non-public information without the prior
approval by Sonnet, Chanticleer, their respective Subsidiaries, or any of their respective officers, directors, employees, affiliates
or agents. No Buyer shall have any liability to Sonnet, Chanticleer, their respective Subsidiaries, or any of its or their respective
officers, directors, employees, affiliates or agents for any such disclosure. To the extent that Sonnet or Chanticleer delivers
any material, non-public information to a Buyer without such Buyer’s consent, each of Sonnet and Chanticleer hereby covenants
and agrees that such Buyer shall not have any duty of confidentiality to Sonnet, Chanticleer, any of their respective Subsidiaries
or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to Sonnet, Chanticleer,
any of their respective Subsidiaries or any of their respective officers, directors, employees, affiliates or agents not to trade
on the basis of, such material, non-public information. Subject to the foregoing, none of Sonnet, Chanticleer, their respective
Subsidiaries nor any Buyer shall issue any press releases or any other public statements with respect to the transactions contemplated
hereby; provided, however, that each of Sonnet and Chanticleer shall be entitled, without the prior approval of
any Buyer, to make any press release or other public disclosure with respect to such transactions (i) in substantial conformity
with the 8-K Filing and contemporaneously therewith and (ii) as is required by applicable law and regulations (provided,
that in the case of clause (i) the Lead Investor shall be consulted by Sonnet or Chanticleer in connection with any such 8-K Filing
or other public disclosure prior to its release). Except for the Form S-4 and the Registration Statement required to be filed
pursuant to the Registration Rights Agreement, without the prior written consent of any applicable Buyer, none of Sonnet, Chanticleer
or any of their respective Subsidiaries or affiliates shall disclose the name of such Buyer in any filing, announcement, release
or otherwise. Upon receipt or delivery by Chanticleer of any notice in accordance with the terms of this Agreement or any other
Transaction Document, unless Chanticleer has in good faith determined that the matters relating to such notice do not constitute
material, nonpublic information relating to Chanticleer or the Chanticleer Subsidiaries, Chanticleer shall contemporaneously with
any such receipt or delivery publicly disclose such material, nonpublic information on a Current Report on Form 8-K or otherwise.
In the event that Chanticleer believes that a notice contains material, nonpublic information relating to Chanticleer or the Chanticleer
Subsidiaries, Chanticleer so shall indicate to the Buyers contemporaneously with delivery of such notice, and in the absence of
any such indication, the Buyers shall be allowed to presume that all matters relating to such notice do not constitute material,
nonpublic information relating to Chanticleer or the Chanticleer Subsidiaries. As used herein, “Disclosure Time”
means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight
(New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof,
unless otherwise instructed in writing as to an earlier time by the Lead Investor, or (ii) if this Agreement is signed between
midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time)
on the date hereof, unless otherwise instructed in writing as to an earlier time by the Lead Investor.

 

(k)
Corporate Existence. So long as any Buyer beneficially owns any Securities, Chanticleer shall maintain its corporate existence
and shall not be party to any Fundamental Transaction (as defined in the Warrants) unless Chanticleer is in compliance with the
applicable provisions governing Fundamental Transactions set forth in the Warrants.

 

    	44

    	 

    

 

(l)
Reservation of Shares. Until the Reservation Date, Chanticleer shall take all action necessary to have authorized, and
reserved for the purpose of issuance, no less than the number of shares of Chanticleer Common Stock equal to the Required Reserve
Amount. From and after such Reservation Date, Chanticleer shall take all action necessary to have authorized, and reserved for
the purpose of issuance, no less than the number of shares of Chanticleer Common Stock necessary to effect the exercise of all
of the Warrants then outstanding, without regard to any limitation on exercise included therein. If at any time the number of
shares of Chanticleer Common Stock authorized and reserved for issuance is not sufficient to meet the requirements set forth in
this Section 5(l), Chanticleer will promptly take all corporate action necessary to authorize and reserve a sufficient number
of shares, including, without limitation, calling a special meeting of stockholders to authorize additional shares to meet Chanticleer’s
obligations under this Section 5(l), in the case of an insufficient number of authorized shares, obtain stockholder approval of
an increase in such authorized number of shares, and voting the management shares of Chanticleer in favor of an increase in the
authorized shares of Chanticleer Common Stock to ensure that the number of authorized shares is sufficient to meet the requirements
set forth in this Section 5(l).

 

(m)
Conduct of Business. The business of Sonnet, Chanticleer and their respective Subsidiaries shall not be conducted in violation
of any law, ordinance or regulation of any governmental entity, including, without limitation, FCPA and other applicable Anti-Bribery
Laws, OFAC regulations and other applicable Sanctions Laws, and Anti-Money Laundering Laws.

 

(i)
None of Sonnet, Chanticleer, nor any of their Subsidiaries or affiliates, directors, officers, employees, representatives or agents
shall:

 

(a)
conduct any business or engage in any transaction or dealing with or for the benefit of any Blocked Person, including the making
or receiving of any contribution of funds, goods or services to, from or for the benefit of any Blocked Person;

 

(b)
deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked or subject to blocking
pursuant to the applicable Sanctions Laws;

 

(c)
use any of the proceeds of the transactions contemplated by this Agreement to finance, promote or otherwise support in any manner
any illegal activity, including, without limitation, any Anti-Money Laundering Laws, Sanctions Laws, or Anti-Bribery Laws; or

 

(d)
violate, attempt to violate, or engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of
evading or avoiding, any of the Anti-Money Laundering Laws, Sanctions Laws, or Anti-Bribery Laws.

 

(ii)
Each of Sonnet and Chanticleer shall maintain in effect and enforce policies and procedures designed to ensure compliance by it
and its Subsidiaries and their directors, officers, employees, agents representatives and affiliates with the Sanctions Laws and
Anti-Bribery Laws.

 

(iii)
During the Reporting Period, each of Sonnet and Chanticleer will promptly notify the Buyers
in writing if any of it, or any of its Subsidiaries or affiliates, directors, officers, employees, representatives or agents,
shall become a Blocked Person, or become directly or indirectly owned or controlled by a
Blocked Person.

 

(iv)
During the Reporting Period, each of Sonnet and Chanticleer shall provide such information
and documentation as the Buyers or any of their affiliates may require to satisfy compliance with the Anti-Money Laundering Laws,
Sanctions Laws, or Anti-Bribery Laws.

 

(v)
The covenants set forth above shall be ongoing during the Reporting Period. During the Reporting
Period, each of Sonnet and Chanticleer shall promptly notify the Buyers in writing should it become aware (a) of any changes
to these covenants, or (b) if it cannot comply with the covenants set forth herein. During
the Reporting Period, each of Sonnet and Chanticleer shall also promptly notify the Buyers in writing should they become
aware of an investigation, litigation or regulatory action relating to an alleged or potential violation of the Anti-Money Laundering
Laws, Sanctions Laws, and Anti-Bribery Laws.

 

    	45

    	 

    

 

(n)
Additional Issuances of Securities.

 

(i)
For purposes of this Agreement, the following definitions shall apply.

 

(1)
“Convertible Securities” means any stock or securities (other than Options) convertible into or exercisable
or exchangeable for Sonnet Common Stock or Chanticleer Common Stock.

 

(2)
“Options” means any rights, warrants or options to subscribe for or purchase Sonnet Common Stock, Chanticleer
Common Stock or Convertible Securities, including without limitation, any Warrants.

 

(3)
“Common Stock Equivalents” means, collectively, Options and Convertible Securities.

 

(ii)
From the date hereof until the date that is ninety (90) calendar days after the earliest of (x) such time as all of the Registrable
Securities may be sold without restriction or limitation pursuant to Rule 144 and without the requirement to be in compliance
with Rule 144(c)(1), (y) the one (1) year anniversary of the Closing Date, and (z) the date that the Initial Registration Statement
(as defined in the Registration Rights Agreement) has been declared effective by the SEC; provided, that this clause (z)
shall only apply if there are no Cutback Shares (as defined in the Registration Rights Agreement) arising from the Initial Registration
Statement (the “Trigger Date”), Chanticleer shall not, directly or indirectly, file any registration statement
or any amendment or supplement thereto other than (A) the Form S-4 and (B) registration statements after the effective date of
the Merger with respect to the issuance or resale of any Excluded Securities (as defined in the Series A Warrants) ((A) and (B),
including any amendments or supplements thereto provided that the registration statements referenced in clauses (A) and (B) shall
not register pursuant to any amendment or supplement thereto a greater number of shares of Chanticleer Common Stock as being contemplated
on the date hereof (as such number of shares of Chanticleer Common Stock may be adjusted for any stock dividend, stock split,
stock combination, reclassification or similar transaction occurring after the date hereof), collectively, “Exempt Registration
Statements”), or cause any registration statement other than the Exempt Registration Statements to be declared effective
by the SEC, or grant any registration rights to any Person that can be exercised prior to such time as set forth above, other
than pursuant to the Registration Rights Agreement. From the date hereof until the Trigger Date, neither Sonnet nor Chanticleer
shall, (1) directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer,
sale, grant or any option to purchase or other disposition of) any of its or its Subsidiaries’ debt, equity or equity equivalent
securities, including without limitation any debt, preferred stock or other instrument or security that is, at any time during
its life and under any circumstances, convertible into or exchangeable or exercisable for Sonnet Common Stock, Chanticleer Common
Stock or Common Stock Equivalents, including, without limitation, any rights, warrants or options to subscribe for or purchase
Sonnet Common Stock or Chanticleer Common Stock or directly or indirectly convertible into or exchangeable or exercisable for
Sonnet Common Stock or Chanticleer Common Stock at a price which varies or may vary with the market price of the Sonnet Common
Stock or Chanticleer Common Stock, including by way of one or more reset(s) to any fixed price (any such offer, sale, grant, disposition
or announcement being referred to as a “Subsequent Placement”), (2) enter into, or effect a transaction under,
any agreement, including, but not limited to, an equity line of credit or “at-the-market” offering, whereby Sonnet
or Chanticleer may issue securities at a future determined price or (3) be party to any solicitations, negotiations or discussions
with regard to the foregoing.

 

    	46

    	 

    

 

(iii)
The restrictions contained in Section 5(n)(ii) shall not apply to any issuance or proposed issuance of any Excluded Securities.

 

(o)
Public Information. At any time during the period commencing from the six (6) month anniversary of the Closing Date and
ending at such time that all of the Registrable Securities, if a registration statement is not available for the resale of all
of the Registrable Securities, may be sold without restriction or limitation pursuant to Rule 144 and without the requirement
to be in compliance with Rule 144(c)(1), if Chanticleer shall (i) fail for any reason to satisfy the requirements of Rule 144(c)(1),
including, without limitation, the failure to satisfy the current public information requirements under Rule 144(c) or (ii) if
Chanticleer has ever been an issuer described in Rule 144(i)(1)(i) or becomes such an issuer in the future, and Chanticleer shall
fail to satisfy any condition set forth in Rule 144(i)(2) (each, a “Public Information Failure”) then, as partial
relief for the damages to any holder of Securities by reason of any such delay in or reduction of its ability to sell the Securities
(which remedy shall not be exclusive of any other remedies available at law or in equity), Chanticleer shall pay to each such
holder an amount in cash equal to two percent (2.0%) of the aggregate Purchase Price of such holder’s Securities on the
day of a Public Information Failure and on every thirtieth day (prorated for periods totaling less than thirty days) thereafter
until the earlier of (i) the date such Public Information Failure is cured and (ii) such time that such Public Information Failure
no longer prevents a holder of Securities from selling such Securities pursuant to Rule 144 without any restrictions or limitations.
The payments to which a holder shall be entitled pursuant to this Section 5(o) are referred to herein as “Public Information
Failure Payments.” Public Information Failure Payments shall be paid on the earlier of (I) the last day of the calendar
month during which such Public Information Failure Payments are incurred and (II) the third Business Day after the event or failure
giving rise to the Public Information Failure Payments is cured. In the event Chanticleer fails to make Public Information Failure
Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of one and one-half percent
(1.5%) per month (prorated for partial months) until paid in full.

 

(p)
Notice of Disqualification Events. Each of Sonnet and Chanticleer will notify the Buyers in writing, prior to the Closing
Date of (i) any Disqualification Event relating to any Sonnet Covered Person or Chanticleer Covered Person, respectively, and
(ii) any event that would, with the passage of time, reasonably be expected to become a Disqualification Event relating to any
Sonnet Covered Person or Chanticleer Covered Person, respectively.

 

(q)
FAST Compliance. While any Warrants are outstanding, Chanticleer shall maintain a transfer agent that participates in the
DTC Fast Automated Securities Transfer Program.

 

(r)
Lock-Up. Chanticleer shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except
to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms.
If any officer or director that is a party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, Chanticleer shall
promptly use its commercially reasonable efforts to seek specific performance of the terms of such Lock-Up Agreement.

 

    	47

    	 

    

 

(s)
Leak-Out. Chanticleer shall not amend, modify, waive or terminate any provision of any of the Leak-Out Agreements and shall
enforce the provisions of each Leak-Out Agreement in accordance with its terms. If any officer or director that is a party to
a Leak-Out Agreement breaches any provision of a Leak-Out Agreement, Chanticleer shall promptly use its commercially reasonable
efforts to seek specific performance of the terms of such Leak-Out Agreement.

 

(t)
Variable Securities. Until the date that is three (3) years following the Closing Date, Sonnet, Chanticleer, each Sonnet
Subsidiary and each Chanticleer Subsidiary shall be prohibited from effecting or entering into an agreement to effect any Subsequent
Placement involving a Variable Rate Transaction other than with respect to the Common Stock
Purchase Agreement dated August 6, 2019 between the Company GEM Global Yield Fund LLC SCS, as amended, provided that such Common
Stock Purchase Agreement is not amended, modified or changed on or after the date hereof. “Variable Rate Transaction”
means a transaction in which Sonnet, Chanticleer, any Sonnet Subsidiary or any Chanticleer Subsidiary (i) issues or sells any
Convertible Securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with
the trading prices of or quotations for the shares of Sonnet Common Stock or Chanticleer Common Stock at any time after the initial
issuance of such Convertible Securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at
some future date after the initial issuance of such Convertible Securities or upon the occurrence of specified or contingent events
directly or indirectly related to the business of Sonnet or Chanticleer or the market for the Sonnet Common Stock or Chanticleer
Common Stock, other than pursuant to a customary “weighted average” anti-dilution provision or (ii) enters into any
agreement (including, without limitation, an equity line of credit or an “at-the-market” offering) whereby Sonnet,
Chanticleer, any Sonnet Subsidiary or any Chanticleer Subsidiary may sell securities at a future determined price (other than
standard and customary “preemptive” or “participation” rights). Each Buyer shall be entitled to obtain
injunctive relief against Sonnet, Chanticleer, the Sonnet Subsidiaries and the Chanticleer Subsidiaries to preclude any such issuance,
which remedy shall be in addition to any right to collect damages for an actual breach of this Section 5(s).

 

(u)
[Reserved]

 

(v)
Merger Agreement. Neither Sonnet nor Chanticleer shall amend or waive any of the terms of the Merger Agreement without
the prior written consent of the Required Holders (as defined in Section 10(e)).

 

(w)
Options and Convertible Securities. Notwithstanding anything to the contrary contained in any Transaction Documents, neither
Sonnet nor Chanticleer shall amend any Options or Convertible Securities after their respective issuance (whether such Options
or Convertible Securities were issued on or prior to the date hereof or will be issued at any time after the date hereof, including,
without limitation, pursuant to this Agreement), unless each holder of Series A Warrants as of the applicable date of determination
consents to such amendment in writing prior to the effective date of such amendment.

 

    	48

    	 

    

 

(x)
Closing Documents. On or prior to fourteen (14) calendar days after the Closing Date, Chanticleer agrees to deliver, or
cause to be delivered, to each Buyer and Schulte Roth & Zabel LLP a complete closing set (which may be solely in electronic
format) of the executed Transaction Documents, Securities and any other documents required to be delivered to any party pursuant
to Section 8 hereof or otherwise.

 

6.
REGISTER; TRANSFER AGENT INSTRUCTIONS.

 

(a)
Register. Chanticleer shall maintain at its principal executive offices (or such other office or agency of Chanticleer
as it may designate by notice to each holder of Securities), a register for the Warrants in which Chanticleer shall record the
name and address of the Person in whose name the Warrants have been issued (including the name and address of each transferee)
and the number of Warrant Shares issuable upon exercise of the Warrants held by such Person. Chanticleer shall keep the register
open and available at all times during business hours for inspection of any Buyer or its legal representatives.

 

(b)
Transfer Agent Instructions. Chanticleer shall issue irrevocable instructions to its Transfer Agent, and any subsequent
transfer agent, in the form attached hereto as Exhibit E, (the “Irrevocable Transfer Agent Instructions”)
to issue certificates or credit shares to the applicable balance accounts at DTC, registered in the name of each Buyer or its
respective nominee(s), for the Exchange Shares issued in exchange of the Additional Common Shares and the Warrant Shares upon
delivery of a Capacity Notice or upon exercise of the Warrant, as applicable, in such amounts as specified from time to time by
each Buyer to Chanticleer upon delivery of a Capacity Notice or upon exercise of the Warrants, as applicable. Chanticleer warrants
that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 6(b), and stop transfer
instructions to give effect to Section 2(f) hereof, will be given by Chanticleer to its Transfer Agent, and that the Securities
shall otherwise be freely transferable on the books and records of Chanticleer as and to the extent provided in this Agreement
and the other Transaction Documents. If a Buyer effects a sale, assignment or transfer of the Securities in accordance with Section
2(f), Chanticleer shall permit the transfer and shall promptly instruct its Transfer Agent to issue one or more certificates or
credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Buyer to effect
such sale, transfer or assignment. In the event that such sale, assignment or transfer involves the Warrant Shares sold, assigned
or transferred pursuant to an effective registration statement or pursuant to Rule 144, the Transfer Agent shall issue such Securities
to the Buyer, assignee or transferee, as the case may be, without any restrictive legend. Chanticleer acknowledges that a breach
by it of its obligations hereunder will cause irreparable harm to a Buyer. Accordingly, Chanticleer acknowledges that the remedy
at law for a breach of its obligations under this Section 6(b) will be inadequate and agrees, in the event of a breach or threatened
breach by Chanticleer of the provisions of this Section 6(b), that a Buyer shall be entitled, in addition to all other available
remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity
of showing economic loss and without any bond or other security being required.

 

    	49

    	 

    

 

7.
CONDITIONS TO SONNET’S OBLIGATION TO SELL AND CHANTICLEER’S OBLIGATION TO ISSUE.

 

The
obligation of Sonnet hereunder to issue and sell the Common Shares at the Closing and the obligation of Chanticleer hereunder
to issue the Warrants at the Warrant Closing is subject to the satisfaction, at or before the Closing Date, of each of the following
conditions, provided that these conditions are for each of Sonnet’s and Chanticleer’s sole benefit and may
be waived by Sonnet and/or Chanticleer at any time in its sole discretion by providing each Buyer with prior written notice thereof:

 

(i)
Such Buyer shall have executed each of the Transaction Documents to which it is a party and delivered the same to Sonnet.

 

(ii)
Such Buyer shall have delivered to Sonnet the Purchase Price (less, in the case of the Lead Investor, the amounts withheld pursuant
to Section 5(h)), for the Common Shares and the related Warrants being purchased by such Buyer at the Closing by wire transfer
of immediately available funds pursuant to the wire instructions provided by Sonnet; provided, however, that with
respect to Chardan, its Purchase Price shall be deemed paid by virtue of the services provided by Chardan to Sonnet and Chanticleer
as contemplated by that certain Omnibus Amendment to Letter Agreements dated as of February 7, 2020, and the Agreements
referenced therein.

 

(iii)
The representations and warranties of such Buyer shall be true and correct as of the date when made and as of the Closing Date
as though made at that time (except for representations and warranties that speak as of a specific date which shall be true and
correct as of such specified date), and such Buyer shall have performed, satisfied and complied in all material respects with
the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Buyer
at or prior to the Closing Date.

 

(iv)
All conditions precedent to the closing of the merger (the “Merger”) contained in the Merger Agreement shall
have been satisfied or waived.

 

8.
CONDITIONS TO EACH BUYER’S OBLIGATION TO PURCHASE.

 

The
obligation of each Buyer hereunder to purchase the Common Shares and the related Warrants at the Closing is subject to the satisfaction,
at or before the Closing Date, of each of the following conditions, provided that these conditions are for each Buyer’s
sole benefit and may be waived by such Buyer at any time in its sole discretion by providing Sonnet with prior written notice
thereof:

 

(i)
Sonnet shall have duly executed and delivered to such Buyer (A) each of the Sonnet Transaction Documents and (B) the Common Shares
(allocated in such amounts as such Buyer shall request), being purchased by such Buyer at the Closing pursuant to this Agreement.

 

(ii)
Chanticleer shall have duly executed and delivered to such Buyer each of the Chanticleer Transaction Documents.

 

    	50

    	 

    

 

(iii)
Such Buyer shall have received the opinion of Lowenstein Sandler LLP, Sonnet’s outside counsel, dated as of the Closing
Date, in the form attached hereto as Exhibit F-1.

 

(iv)
Such Buyer shall have received the opinion of Libertas Law Group, Inc., Chanticleer’s outside counsel, dated as of the Closing
Date, in the form attached hereto as Exhibit F-2.

 

(v)
Chanticleer shall have delivered to such Buyer a copy of the Irrevocable Transfer Agent Instructions in escrow to be released
upon the effectiveness of the Merger, which instructions shall have been delivered to and acknowledged in writing by the Transfer
Agent.

 

(vi)
Each of Sonnet and Chanticleer shall have delivered to such Buyer a certificate evidencing the formation and good standing of
Sonnet and Chanticleer in such entity’s jurisdiction of formation issued by the Secretary of State (or comparable office)
of such jurisdiction, as of a date within ten (10) calendar days prior to the Closing Date.

 

(vii)
Each of Sonnet and Chanticleer shall have delivered to such Buyer a certificate evidencing its qualification as a foreign corporation
and good standing issued by the Secretary of State (or comparable office) of the jurisdiction in which it has its headquarters,
as of a date within ten (10) calendar days prior to the Closing Date.

 

(viii)
Each of Sonnet and Chanticleer shall have delivered to such Buyer a certified copy of the Sonnet Certificate of Incorporation
and the Chanticleer Certificate of Incorporation, respectively, as certified by the Secretary of State (or comparable office)
of its jurisdiction of formation within ten (10) calendar days prior to the Closing Date.

 

(ix)
Each of Sonnet and Chanticleer shall have delivered to such Buyer a certificate, executed by its Secretary and dated as of the
Closing Date, as to (i) the resolutions consistent with Section 3(b) or Section 4(b), respectively, as adopted by its Board of
Directors in a form reasonably acceptable to such Buyer, (ii) the Sonnet Certificate of Incorporation or the Chanticleer Certificate
of Incorporation, respectively, and (iii) the Sonnet Bylaws and Chanticleer Bylaws, respectively, each as in effect at the Closing,
in the form attached hereto as Exhibit G.

 

(x)
The representations and warranties of each of Sonnet and Chanticleer shall be true and correct as of the date when made and as
of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date which
shall be true and correct as of such specified date) and each of Sonnet and Chanticleer shall have performed, satisfied and complied
in all respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied
or complied with by it at or prior to the Closing Date. Such Buyer shall have received certificates, executed by the Chief Executive
Officer of each of Sonnet and Chanticleer, dated as of the Closing Date, to the foregoing effect and as to such other matters
as may be reasonably requested by such Buyer in the form attached hereto as Exhibit H.

 

    	51

    	 

    

 

(xi)
Each of Sonnet and Chanticleer shall have delivered to each Buyer a lock-up agreement, in the form attached hereto as Exhibit
I (collectively, the “Lock-Up Agreements”), executed by any Person that will be subject to Section 16 of
the 1934 Act with respect to Chanticleer immediately following the consummation of the Merger.

 

(xii)
Chanticleer shall have delivered to such Buyer a letter from its Transfer Agent certifying the number of shares of Chanticleer
Common Stock outstanding as of a date within five (5) calendar days of the Closing Date.

 

(xiii)
The proposed Merger between Sonnet and Chanticleer shall have been consummated or shall occur immediately following the Closing
and the Chanticleer Common Stock (I) shall be designated for quotation or listed on the Principal Market and (II) shall not have
been suspended, as of the Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension
by the SEC or the Principal Market have been threatened, as of the Closing Date, either (A) in writing by the SEC or the Principal
Market or (B) by falling below the minimum listing maintenance requirements or initial listing requirements of the Principal Market.

 

(xiv)
Each of Sonnet and Chanticleer shall have obtained all stockholder, governmental, regulatory or other third party consents and
approvals, including, without limitation, approval of the Principal Market, necessary for the completion of the Merger and the
sale of the Securities, including, without limitation, in the case of Chanticleer, any and all stockholder approval required by
the Principal Market with respect to the issuances of the Warrants and the Warrant Shares in full upon exercise of the Warrants
without giving effect to any limitation on the exercise of the Warrants set forth therein.

 

(xv)
All conditions precedent to the closing of the Merger contained in the Merger Agreement shall have been satisfied or waived.

 

(xvi)
The Form S-4 shall have become effective in accordance with the provisions of the 1933 Act, and shall not be subject to any stop
order or proceeding (or threatened proceeding by the SEC) seeking a stop order with respect to the Form S-4 that has not been
withdrawn.

 

(xvii)
The Securities Escrow Agreement shall have been executed and delivered to such Buyer by the other parties thereto.

 

(xviii)
Sonnet shall have issued the Additional Common Shares in escrow in the name of the Escrow Agent in accordance with the terms of
the Securities Escrow Agreement.

 

(xix)
Such Buyer shall have received Sonnet’s wire instructions on Sonnet’s letterhead duly executed by an authorized executive
officer of Sonnet.

 

(xx)
Each Buyer shall have delivered to Sonnet a leak-out agreement, in the form attached hereto as Exhibit J, executed by each
Buyer.

 

    	52

    	 

    

 

(xxi)
Each of Sonnet and Chanticleer shall have delivered to such Buyer such other documents relating to the transactions contemplated
by this Agreement as such Buyer or its counsel may reasonably request.

 

9.
TERMINATION. In the event that the Closing shall not have occurred with respect to a Buyer on or before March 31, 2020
due to Sonnet’s, Chanticleer’s or such Buyer’s failure to satisfy the conditions set forth in Sections 7 and
8 above (and the nonbreaching party’s failure to waive such unsatisfied condition(s)), the Buyer, if such Buyer is the nonbreaching
party, or Sonnet, if Sonnet is the nonbreaching party, shall have the option to terminate this Agreement with respect to such
Buyer, if such Buyer is the breaching party, or with respect to Sonnet and Chanticleer, if Sonnet or Chanticleer are the breaching
party, at the close of business on such date by delivering a written notice to that effect to each other party to this Agreement
and without liability of any party to any other party; provided, however, that if this Agreement is terminated pursuant
to this Section 9, Sonnet shall remain obligated to reimburse the Lead Investor or its designee(s), as applicable, for the expenses
described in Section 5(h) above.

 

10.
MISCELLANEOUS.

 

(a)
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law
or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any
such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or
proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served
in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. In addition to, but not in limitation of, any
other rights of a Buyer hereunder, if (a) this Agreement is placed in the hands of an attorney for collection of any indemnification
or other obligation hereunder then outstanding or enforcement or any such obligation is collected or enforced through any legal
proceeding or a Buyer otherwise takes action to collect amounts due under this Agreement or to enforce the provisions of this
Agreement or (b) there occurs any bankruptcy, reorganization, receivership of Sonnet or Chanticleer or other proceedings affecting
Sonnet’s or Chanticleer’s creditors’ rights and involving a claim under this Agreement, then Sonnet or Chanticleer,
as applicable, shall pay the costs incurred by such Buyer for such collection, enforcement or action or in connection with such
bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys’ fees and disbursements.

 

    	53

    	 

    

 

(b)
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party; provided that a facsimile or .pdf signature shall be considered due execution and shall be binding upon the signatory thereto
with the same force and effect as if the signature were an original, not a facsimile or .pdf signature.

 

(c)
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.

 

(d)
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred
upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s).

 

(e)
Entire Agreement; Amendments. This Agreement and the other Transaction Documents supersede all other prior oral or written
agreements between Sonnet, Chanticleer, their affiliates and Persons acting on their behalf, on the one hand, and the Buyers,
their affiliates and Persons acting on their behalf, on the other hand, with respect to the matters discussed herein, and this
Agreement, the other Transaction Documents and the instruments referenced herein and therein contain the entire understanding
of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein,
none of Sonnet, Chanticleer nor any Buyer makes any representation, warranty, covenant or undertaking with respect to such matters.
No provision of this Agreement may be amended other than by an instrument in writing signed by Sonnet, Chanticleer and the Required
Holders, and any amendment to this Agreement made in conformity with the provisions of this Section 10(e) shall be binding on
all Buyers and holders of Securities, Sonnet and Chanticleer. No provisions hereto may be waived other than by an instrument in
writing signed by the party against whom enforcement is sought. No such amendment shall be effective to the extent that it applies
to less than all of the Buyers or holders of the applicable Securities then outstanding. No consideration shall be offered or
paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless
the same consideration (other than the reimbursement of legal fees) also is offered to all of the parties to the Transaction Documents,
holders of Common Shares or holders of the Warrants, as the case may be. Neither Sonnet nor Chanticleer has, directly or indirectly,
made any agreements with any Buyers relating to the terms or conditions of the transactions contemplated by the Transaction Documents
except as set forth in the Transaction Documents. Without limiting the foregoing, each of Sonnet and Chanticleer confirms that,
except as set forth in this Agreement, no Buyer has made any commitment or promise or has any other obligation to provide any
financing to Sonnet or Chanticleer or otherwise. As used herein, “Required Holders” means (I) prior to the
Closing Date, the Buyers entitled to purchase at the Closing a majority of the aggregate amount of Securities issued and issuable
hereunder and under the Warrants (without regard to any restriction or limitation on the exercise of the Warrants or the delivery
of the Exchange Shares issued in exchange of Additional Common Shares contained therein or herein) and shall include the Lead
Investor and (II) on or after the Closing Date, holders of at least a majority of the aggregate amount of Securities issued and
issuable hereunder and under the Warrants (without regard to any restriction or limitation on the exercise of the Warrants or
the delivery of the Exchange Shares issued in exchange of Additional Common Shares contained therein or herein) as of the applicable
time of determination and shall include the Lead Investor so long as the Lead Investor or any of its Affiliates holds any Securities.

 

    	54

    	 

    

 

(f)
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this
Agreement or any of the other Transaction Documents must be in writing and will be deemed to have been delivered: (i) upon receipt,
when delivered personally; (ii) upon delivery, when sent by facsimile (provided confirmation of transmission is mechanically
or electronically generated and kept on file by the sending party) or by electronic mail; (iii) upon delivery, when sent by electronic
mail (provided that the sending party does not receive an automated rejection notice); or (iv) one (1) Business Day after
deposit with an overnight courier service, in each case properly addressed to the party to receive the same. The addresses, facsimile
numbers and e-mail addresses for such communications shall be:

 

If
to Sonnet:

 

Sonnet
BioTherapeutics, Inc.

100
Overlook Center, Second Floor

Princeton,
NJ 08540

Telephone:
(609) 375-2227

Facsimile:
(609) 228-4330

Attention:
Dr. Pankaj Mohan

E-mail:
pankajmohan@sonnetbio.com

 

With
a copy (for informational purposes only) to:

 

Lowenstein
Sandler LLP

1251
Avenue of the Americas

New
York, NY 10020

Telephone:
(212) 262-6700

Facsimile:
(973) 597-2477

Attention:
Steven M. Skolnick, Esq.

E-mail:
sskolnick@lowenstein.com

 

    	55

    	 

    

 

If
to Chanticleer:

 

Chanticleer
Holdings, Inc.

7621
Little Avenue, Suite 414

Charlotte,
NC 28226

Telephone:
(704) 366-5122

Facsimile:
(704) 366-2463

Attention:
Michael D. Pruitt

E-mail:
mp@chanticleerholdings.com

 

With
a copy (for informational purposes only) to:

 

Libertas
Law Group, Inc.

225
Santa Monica Boulevard, 5th Floor

Santa
Monica, CA 90401

Telephone:
(949) 355-5405

Facsimile:
(310) 356-1922

Attention:
Ruba Qashu, Esq

E-mail:
ruba@libertaslaw.com

 

If
to the Escrow Agent:

 

The
Bank of New York Mellon

Corporate
Trust Administration

240
Greenwich Street

New
York, NY 10286

Attention:
Escrow Unit

 

If
to the Transfer Agent:

 

Securities
Transfer Corporation

2901
N Dallas Parkway, Suite 380

Plano,
TX 75093

Telephone:
(469) 633-0101

Attention:
Matthew Smith

E-mail:
smith@stctransfer.com

 

    	56

    	 

    

 

If
to a Buyer, to its address, facsimile number and e-mail address set forth on the Schedule of Buyers, with copies to such Buyer’s
representatives as set forth on the Schedule of Buyers,

 

With
a copy (for informational purposes only) to:

 

Schulte
Roth & Zabel LLP

919
Third Avenue

New
York, NY 10022

Telephone:
(212) 756-2000

Facsimile:
(212) 593-5955

Attention:
Eleazer N. Klein, Esq.

E-mail:
eleazer.klein@srz.com

 

or
to such other address, facsimile number and/or e-mail address and/or to the attention of such other Person as the recipient party
has specified by written notice given to each other party five (5) calendar days prior to the effectiveness of such change. Written
confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the sender’s facsimile machine or e-mail containing the time, date, recipient facsimile number
and an image of the first page of such transmission or (C) provided by an overnight courier service shall be rebuttable evidence
of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or
(iii) above, respectively.

 

(g)
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns, including any purchasers of the Common Shares or the Warrants. Neither Sonnet nor Chanticleer shall assign
this Agreement or any rights or obligations hereunder without the prior written consent of the Required Holders, including by
way of a Fundamental Transaction (unless Chanticleer is in compliance with the applicable provisions governing Fundamental Transactions
set forth in the Warrants and other than the Merger in accordance with the terms and conditions of the Merger Agreement). A Buyer
may assign some or all of its rights hereunder without the consent of Sonnet or Chanticleer, in which event such assignee shall
be deemed to be a Buyer hereunder with respect to such assigned rights.

 

(h)
Third Party Beneficiaries. The Placement Agent shall be a third party beneficiary of the representations and warranties
of the Buyers in Section 2, the representations and warranties of Sonnet in Section 3 and the representations and warranties of
Chanticleer in Section 4. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except that each Indemnitee
shall have the right to enforce the obligations of Sonnet and Chanticleer with respect to Section 10(k) and as otherwise set forth
in this Section 10(h).

 

(i)
Survival. Unless this Agreement is terminated under Section 9, the representations and warranties of Sonnet, Chanticleer
and the Buyers contained in Sections 2, 3 and 4, and the agreements and covenants set forth in Sections 5, 6 and 10 shall survive
the Closing. Each Buyer, and each of Sonnet and Chanticleer, shall be responsible only for its own representations, warranties,
agreements and covenants hereunder.

 

    	57

    	 

    

 

(j)
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

(k)
Indemnification. (i) In consideration of each Buyer’s execution and delivery of the Transaction Documents and acquiring
the Securities thereunder and in addition to all of Sonnet’s other obligations under the Transaction Documents, Sonnet shall
defend, protect, indemnify and hold harmless each Buyer and each other holder of the Securities and all of their stockholders,
partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents
or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this
Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether
any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’
fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising
out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by Sonnet in the Transaction
Documents or any other certificate, instrument or document of Sonnet contemplated hereby or thereby, (b) any breach of any covenant,
agreement or obligation of Sonnet contained in the Transaction Documents or any other certificate, instrument or document of Sonnet
contemplated hereby or thereby or (c) any cause of action, suit or claim brought or made against such Indemnitee by a third party
(including for these purposes a derivative action brought on behalf of Sonnet or Chanticleer) and arising out of or resulting
from (i) the execution, delivery, performance or enforcement of the Transaction Documents or any other certificate, instrument
or document contemplated hereby or thereby, (ii) any transaction financed or to be financed in whole or in part, directly or indirectly,
with the proceeds of the issuance of the Securities, (iii) any disclosure made by such Buyer pursuant to Section 5(j), or (iv)
the status of such Buyer or holder of the Securities as an investor in Sonnet pursuant to the transactions contemplated by the
Transaction Documents. To the extent that the foregoing undertaking by Sonnet may be unenforceable for any reason, Sonnet shall
make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities that is permissible under
applicable law. Except as otherwise set forth herein, the mechanics and procedures with respect to the rights and obligations
under this Section 10(k)(i) shall be the same as those set forth in Section 6 of the Registration Rights Agreement.

 

(ii)
In consideration of each Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities thereunder
and in addition to all of Chanticleer’s other obligations under the Transaction Documents, Chanticleer shall defend, protect,
indemnify and hold harmless the Indemnitees from and against any and all Indemnified Liabilities incurred by any Indemnitee as
a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by Chanticleer
in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (b) any breach of
any covenant, agreement or obligation of Chanticleer contained in the Transaction Documents or any other certificate, instrument
or document contemplated hereby or thereby or (c) any cause of action, suit or claim brought or made against such Indemnitee by
a third party (including for these purposes a derivative action brought on behalf of Sonnet or Chanticleer) and arising out of
or resulting from (i) the execution, delivery, performance or enforcement of the Transaction Documents or any other certificate,
instrument or document contemplated hereby or thereby, (ii) any transaction financed or to be financed in whole or in part, directly
or indirectly, with the proceeds of the issuance of the Securities, (iii) any disclosure made by such Buyer pursuant to Section
5(j), or (iv) the status of such Buyer or holder of the Securities as an investor in Chanticleer pursuant to the transactions
contemplated by the Transaction Documents. To the extent that the foregoing undertaking by Chanticleer may be unenforceable for
any reason, Chanticleer shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities
that is permissible under applicable law. Except as otherwise set forth herein, the mechanics and procedures with respect to the
rights and obligations under this Section 10(k)(ii) shall be the same as those set forth in Section 6 of the Registration Rights
Agreement.

 

    	58

    	 

    

 

(l)
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent, and no rules of strict construction will be applied against any party.

 

(m)
Remedies. Each Buyer and each holder of the Securities shall have all rights and remedies set forth in the Transaction
Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and
all of the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall
be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any
breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore, each of Sonnet and Chanticleer
recognizes that in the event that it fails to perform, observe, or discharge any or all of its obligations under the Transaction
Documents, any remedy at law may prove to be inadequate relief to the Buyers. Each of Sonnet and Chanticleer therefore agrees
that the Buyers shall be entitled to seek temporary and permanent injunctive relief in any such case without the necessity of
proving actual damages and without posting a bond or other security.

 

(n)
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) the Transaction Documents, whenever any Buyer exercises a right, election, demand or option under a Transaction
Document and either Sonnet or Chanticleer does not timely perform its related obligations within the periods therein provided,
then such Buyer may rescind or withdraw, in its sole discretion from time to time upon written notice to Sonnet or Chanticleer,
as applicable, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.

 

(o)
Payment Set Aside. To the extent that Sonnet or Chanticleer makes a payment or payments to the Buyers hereunder or pursuant
to any of the other Transaction Documents or the Buyers enforce or exercise their rights hereunder or thereunder, and such payment
or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent
or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to Sonnet
or Chanticleer, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign,
state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part
thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred.

 

(p)
Independent Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under any Transaction Document
are several and not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance
of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and each of Sonnet and
Chanticleer acknowledges that the Buyers do not so constitute, a partnership, an association, a joint venture or any other kind
of entity, or create a presumption that the Buyers are in any way acting in concert or as a group, and neither Sonnet nor Chanticleer
shall assert any such claim with respect to such obligations or the transactions contemplated by the Transaction Documents and
each of Sonnet and Chanticleer acknowledges that the Buyers are not acting in concert or as a group with respect to such obligations
or the transactions contemplated by the Transaction Documents. Each of Sonnet and Chanticleer acknowledges and each Buyer confirms
that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel
and advisors. Each Buyer shall be entitled to independently protect and enforce its rights, including, without limitation, the
rights arising out of this Agreement or out of any other Transaction Documents, and it shall not be necessary for any other Buyer
to be joined as an additional party in any proceeding for such purpose.

 

[Signature
Pages Follow]

 

    	59

    	 

    

 

IN
WITNESS WHEREOF, each Buyer, Sonnet and Chanticleer have caused their respective signature page to this Securities Purchase
Agreement to be duly executed as of the date first written above.

 

	 	SONNET
    BIOTHERAPEUTICS, INC.
	 	 
	 	By:	/s/
    Pankaj Mohan                         
	 	Name:	Pankaj
    Mohan
	 	Title:	Chief
    Executive Officer

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, each Buyer, Sonnet and Chanticleer have caused their respective signature page to this Securities Purchase
Agreement to be duly executed as of the date first written above.

 

	 	CHANTICLEER
    HOLDINGS, INC.
	 	 
	 	By:	/s/
    Michael D. Pruitt                 
	 	Name:	Michael
    D. Pruitt
	 	Title:	Chief
    Executive Officer

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

SCHEDULE
OF BUYERS

 

	(1)	 	(2)	 	(3)	 	(4)	 	(5)	 	(6)
	Buyer
	 	Address,
        Facsimile Number

        and E-mail
	 	Number
        of Initial Common Shares
	 	Number
        of Additional Common Shares
	 	Purchase
        Price
	 	Legal
        Representative’s Address, Facsimile Number and E-mail

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 

 

    	 

    	 

    

 

EXHIBITS

 

	Exhibit
    A	Form
    of Securities Escrow Agreement
	Exhibit
    B-1	Form
    of Series A Warrants
	Exhibit
    B-2	Form
    of Series B Warrants
	Exhibit
    C	Form
    of Registration Rights Agreement
	Exhibit
    D	Form
    of Capacity Notice
	Exhibit
    E	Form
    of Irrevocable Transfer Agent Instructions
	Exhibit
    F-1	Form
    of Opinion of Sonnet’s Counsel
	Exhibit
    F-2	Form
    of Opinion of Chanticleer’s Counsel
	Exhibit
    G	Form
    of Secretary’s Certificate
	Exhibit
    H	Form
    of Officer’s Certificate
	Exhibit
    I	Form
    of Lock-Up Agreement
	Exhibit
    J	Form
    of Leak-Out Agreement

 

SCHEDULES

 

Sonnet
Disclosure Schedules

 

	Schedule
    3(a)	Sonnet
    Subsidiaries
	Schedule
    3(d)	No
    Conflicts
	Schedule
    3(e)	Consents
	Schedule
    3(k)	Absence
    of Certain Changes
	Schedule
    3(m)	Conduct
    of Business; Regulatory Permits
	Schedule
    3(p)	Transactions
    with Affiliates
	Schedule
    3(q)	Equity
    Capitalization
	Schedule
    3(r)	Indebtedness
    and Other Contracts
	Schedule
    3(s)	Absence
    of Litigation
	Schedule
    3(w)	Intellectual
    Property Rights
	Schedule
    3(aa)	Internal
    Accounting
	Schedule
    3(ff)	FDA

 

Chanticleer
Disclosure Schedules

 

	Schedule
    4(a)	Chanticleer
    Subsidiaries
	Schedule
    4(d)	No
    Conflicts
	Schedule
    4(e)	Consents
	Schedule
    4(j)	SEC
    Documents; Financial Statements
	Schedule
    4(k)	Absence
    of Certain Changes
	Schedule
    4(n)	Sarbanes-Oxley
    Act; Internal Accounting Controls
	Schedule
    4(o)	Transactions
    with Affiliates and Employees
	Schedule
    4(p)	Equity
    Capitalization
	Schedule
    4(r)	Absence
    of Litigation
	Schedule
    4(v)	Intellectual
    Property Rights
	Schedule
    4(z)	Registration
    Rights
	Schedule
    4(aa)	Solvency
	Schedule
    4(dd)	FDA
	Schedule
    4(tt)	Lock-Up
    PartiesEX-10.1

 Exhibit 10.1 

Adopted Effective February 16, 2005 

Amended and Restated February 14, 2006 

Amended and Restated June 6, 2006 

Amended and Restated February 6, 2007 

Amended and Restated November 6, 2007 

Amended and Restated November 9, 2010 

Amended and Restated February 2, 2011 

Amended and Restated July 26, 2011 

Amended and Restated February 5, 2013 

Amended and Restated September 24, 2013 

Amended and Restated February 3, 2015 

Amended and Restated November 10, 2015 

Amended and Restated February 7, 2017 

Amended and Restated and Renamed February 4, 2020 

DOLBY LABORATORIES, INC. 

2020 STOCK PLAN 
 1.
Purposes of the Plan. The purposes of this Plan are: 
  

	 	•	 	 to attract and retain the best available personnel for positions of substantial responsibility,

  

	 	•	 	 to provide additional incentive to Employees, Directors and Consultants, and 

 

	 	•	 	 to promote the success of the Company’s business. 

The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock
Appreciation Rights, Deferred Stock Units, Performance Units, Performance Bonus Awards and Performance Shares. 
 2.
Definitions. As used herein, the following definitions will apply: 
 (a) “Administrator” means the Board or
any of its Committees as will be administering the Plan, in accordance with Section 4 of the Plan. 
 (b) “Applicable
Laws” means the requirements relating to the administration of equity-based awards or equity compensation programs under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on
which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan. 

 (c) “Award” means, individually or collectively, a grant under the Plan of
Options, SARs, Restricted Stock, Restricted Stock Units, Deferred Stock Units, Performance Units, Performance Bonus Awards or Performance Shares. 

(d) “Award Agreement” means the written or electronic agreement setting forth the terms and provisions applicable to each
Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan. 
 (e) “Award Transfer
Program” means any program instituted by the Administrator that would permit Participants the opportunity to transfer for value any outstanding Awards to a financial institution or other person or entity approved by the Administrator. A
transfer for “value” shall not be deemed to occur under this Plan where an Award is transferred by a Participant for bona fide estate planning purposes to a trust or other testamentary vehicle approved by the Administrator. 

(f) “Awarded Stock” means the Common Stock subject to an Award. 

(g) “Board” means the Board of Directors of the Company. 

(h) “Cause” means, with respect to the termination by the Company or a Related Entity of a Participant, that such termination
is for “Cause” as such term is expressly defined in a then-effective written agreement between the Participant and the Company or a Related Entity, or in the absence of such then-effective written agreement and definition, is based on, in
the determination of the Administrator, the Participant’s: (i) refusal or failure to act in accordance with any specific, lawful direction or order of the Company or a Related Entity; (ii) unfitness or unavailability for service or
unsatisfactory performance (other than as a result of Disability); (iii) performance of any act or failure to perform any act in bad faith and to the detriment of the Company or Related Entity; (iv) dishonesty, intentional misconduct or
material breach of any agreement with the Company or Related Entity; or (v) commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person. At least 30 days prior to the termination of the
Participant’s service pursuant to (i) or (ii) above, the Company or Related Entity shall provide the Participant with notice of the Company’s or Related Entity’s intent to terminate, the reason therefor, and an opportunity for
the Participant to cure such defects in his or her service to the Company’s or Related Entity’s satisfaction. During this 30 day (or longer) period, no Award issued to the Participant under the Plan may be exercised or purchased. 

(i) “Change in Control” means the occurrence of any of the following events: 

(i) For any Awards granted prior to November 6, 2007, any “person” (as such term is used in Sections 13(d) and 14(d) of the
Exchange Act) other than a Permitted Transferee (as defined in the Company’s Amended and Restated Certificate of Incorporation) becomes the “beneficial owner” (as defined in Rule 13d-3 of the
Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities; or 

  
 -2- 

 (ii) For any Awards granted on or after November 6, 2007, any “person” (as
such term is used in Sections 13(d) and 14(d) of the Exchange Act) other than a Permitted Transferee (as defined in the Company’s Amended and Restated Certificate of Incorporation) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company’s then outstanding voting
securities; or 
 (iii) The consummation of the sale or disposition by the Company of all or substantially all of the Company’s
assets; or 
 (iv) For any Awards granted prior to November 6, 2007, a change in the composition of the Board occurring within a two-year period, as a result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” means directors who either (A) are Directors as of the effective date of the
Plan, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Directors at the time of such election or nomination (but will not include an individual whose election or nomination is
in connection with an actual or threatened proxy contest relating to the election of directors to the Company); or 
 (v) For any Awards
granted on or after November 6, 2007, a change in the composition of the Board occurring within a one-year period, as a result of which fewer than a majority of the directors are Incumbent Directors.
“Incumbent Directors” means directors who either (A) are Directors as of the effective date of the Plan, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the
Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company); or 

(vi) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which
would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty
percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. 

(j) “Code” means the Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code or regulation
thereunder shall include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation. 

(k) “Committee” means a committee of Directors or other individuals satisfying Applicable Laws appointed by the Board in
accordance with Section 4 of the Plan. 
 (l) “Common Stock” means the Class A Common Stock of the Company, or in
the case of certain Stock Appreciation Rights or Performance Units, the cash equivalent thereof. 
 (m) “Company” means
Dolby Laboratories, Inc., a Delaware corporation, or any successor thereto. 
 (n) “Consultant” means any person, including
an advisor, engaged by the Company or a Related Entity to render services to such entity. 

  
 -3- 

 (o) “Deferred Stock Unit” means an Award that the Administrator permits to
be paid in installments or on a deferred basis pursuant to Sections 4 and 13 of the Plan. 
 (p) “Director” means a member
of the Board. 
 (q) “Disability” means total and permanent disability as defined in Section 22(e)(3) of the Code,
provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and
non-discriminatory standards adopted by the Administrator from time to time. 
 (r)
“Dividend Equivalent” means a credit, made at the discretion of the Administrator, to the account of a Participant in an amount equal to the cash dividends paid on one Share for each Share represented by an Award held by such
Participant. 
 (s) “Employee” means any person, including Officers and Directors, employed by the Company or a Related
Entity. Neither service as a Director nor payment of a director’s fee by the Company or Related Entity will be sufficient to constitute “employment” by the Company or Related Entity. 

(t) “Exchange Act” means the Securities Exchange Act of 1934, as amended. Reference to a specific section of the Exchange Act
or regulation thereunder shall include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or
regulation. 
 (u) “Exchange Program” means a program under which (i) outstanding Awards are surrendered or cancelled
in exchange for Awards of the same type (which may have lower exercise prices and different terms), Awards of a different type, and/or cash, and/or (ii) the exercise price of an outstanding Award is reduced. The Administrator will determine the
terms and conditions of any Exchange Program in its sole discretion; provided, however, that the Administrator may only institute an Exchange Program with the approval of the Company’s stockholders. 

(v) “Fair Market Value” means, as of any date, the value of Common Stock determined as follows: 

(i) If the Common Stock is listed on any established stock exchange or a national market system, including without limitation the New York
Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market or the Nasdaq Capital Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange
or system for the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; 

(ii) If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of
a Share of Common Stock will be the mean between the high bid and low asked prices for the Common Stock for the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or 

  
 -4- 

 (iii) In the absence of an established market for the Common Stock, the Fair Market Value
will be determined in good faith by the Administrator. 
 (iv) Notwithstanding the preceding, for federal, state, and local income tax
reporting purposes and for such other purposes as the Administrator deems appropriate, the Fair Market Value shall be determined by the Administrator in accordance with uniform and nondiscriminatory standards adopted by it from time to time. 

(w) “Good Reason” means the occurrence following a Change in Control of any of the following events or conditions unless
consented to by the Participant: 
 (i) For any Awards granted prior to November 6, 2007, a reduction in the Participant’s base
salary to a level below that in effect at any time within six (6) months preceding the consummation of a Change in Control or at any time thereafter; or 

(ii) For any Awards granted on or after November 6, 2007, a material reduction in the Participant’s base salary to a level below
that in effect immediately preceding the consummation of a Change in Control or at any time thereafter; or 
 (iii) Requiring the
Participant to be based at any place outside a 50-mile radius from the Participant’s job location or residence prior to the Change in Control except for reasonably required travel on business which is not
materially greater than such travel requirements prior to the Change in Control. 
 (x) “Incentive Stock Option” means an
Option that by its terms qualifies and otherwise is intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations promulgated thereunder. 

(y) “Inside Director” means a Director who is an Employee. 

(z) “Nonstatutory Stock Option” means an Option that by its terms does not qualify or is not intended to qualify as an
Incentive Stock Option. 
 (aa) “Officer” means a person who is an officer of the Company within the meaning of
Section 16 of the Exchange Act and the rules and regulations promulgated thereunder. 
 (bb) “Option” means a stock
option granted pursuant to the Plan. 
 (cc) “Outside Director” means a Director who is not an Employee. 

(dd) “Parent” means a “parent corporation,” whether now or hereafter existing, as defined in Section 424(e) of
the Code. 
 (ee) “Participant” means the holder of an outstanding Award. 

(ff) “Performance-Based Award” means any Award that is subject to the terms and conditions set forth in Section 12. 

  
 -5- 

 (gg) “Performance Bonus Award” means a cash award set forth in
Section 11. 
 (hh) “Performance Goals” means the goal(s) determined by the Administrator (in its discretion) to be
applicable to a Participant with respect to an Award. For example, but not by way of limitation, the Performance Goals applicable to an Award may provide for a targeted level or levels of achievement using one or more of the following measures:
(i) revenue, (ii) gross margin, (iii) operating margin, (iv) operating income, (v) pre-tax profit, (vi) earnings before interest, taxes and depreciation, (vii) net income,
(viii) cash flow, (ix) expenses, (x) the market price of the Share, (xi) earnings, (xii) return on stockholder equity, (xiii) return on capital, (xiv) product quality, (xv) economic value added, (xvi) number of
customers, (xvii) market share, (xviii) return on investments, (xix) profit after taxes, (xx) customer satisfaction, (xxi) business divestitures and acquisitions, (xxii) supplier awards from significant customers,
(xxiii) new product development, (xxiv) working capital, (xxv) objectively determinable individual objectives, (xxvi) time to market, (xxvii) return on net assets, and (xxviii) sales. The Performance Goals may differ
from Participant to Participant and from Award to Award. Any Performance Goal used may be measured (1) in absolute terms, (2) in combination with another Performance Goal or Goals (for example, but not by way of limitation, as a ratio or
matrix), (3) in relative terms (including, but not limited to, as compared to results for other periods of time, and/or against another company, companies or an index or indices), (4) on a per-share or per-capita basis, (5) against the performance of the Company as a whole or a specific business unit(s), business segment(s) or product(s) of the Company, and/or (6) on a
pre-tax or after-tax basis. The Administrator, in its discretion, will determine whether any significant element(s) or item(s) will be included in or excluded from the
calculation of any Performance Goal with respect to any Participants (for example, but not by way of limitation, the effect of mergers and acquisitions). As determined in the discretion of the Administrator, achievement of Performance Goals for a
particular Award may be calculated in accordance with the Company’s financial statements, prepared in accordance with generally accepted accounting principles, or as adjusted for certain costs, expenses, gains and losses to provide non-GAAP measures of operating results. 
 (ii) “Performance Share” means an Award
granted to a Service Provider pursuant to Section 10 of the Plan. 
 (jj) “Performance Unit” means an Award granted to
a Service Provider pursuant to Section 10 of the Plan. 
 (kk) “Period of Restriction” means the period during which
Restricted Stock Units and/or the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, continued service,
the achievement of Performance Goals, and/or the occurrence of other events as determined by the Administrator. 
 (ll)
“Plan” means this 2020 Stock Plan. The Plan was originally named the “2005 Stock Plan” when adopted effective February 16, 2005, and was renamed the “2020 Stock Plan” effective February 4, 2020. 

  
 -6- 

 (mm) “Related Entity” means any Parent, Subsidiary and any business,
corporation, partnership, limited liability company or other entity in which the Company, a Parent or a Subsidiary holds a substantial ownership interest, directly or indirectly. 

(nn) “Restricted Stock” means Shares issued pursuant to a Restricted Stock award under the Plan or issued pursuant to the
early exercise of an Option. 
 (oo) “Restricted Stock Unit” means a bookkeeping entry representing an amount equal to the
Fair Market Value of one Share, granted pursuant to Section 8. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company. 

(pp) “Rule 16b-3” means Rule 16b-3 of the
Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised with respect to the Plan. 

(qq) “Section 16(b)” means Section 16(b) of the Exchange Act. 

(rr) “Service Provider” means an Employee, Director or Consultant. 

(ss) “Share” means a share of the Common Stock, as adjusted in accordance with Section 17 of the Plan. 

(tt) “Stock Appreciation Right” or “SAR” means an Award, granted alone or in connection with an Option, that
pursuant to Section 9 of the Plan is designated as a SAR. 
 (uu) “Subsidiary” means a “subsidiary
corporation”, whether now or hereafter existing, as defined in Section 424(f) of the Code. 
 (vv) “Unvested
Awards” shall mean any Award that (i) was granted to an individual in connection with such individual’s position as a Service Provider and (ii) is still subject to vesting or lapsing of Company repurchase rights or similar
restrictions. 
 3. Stock Subject to the Plan. 

(a) Stock Subject to the Plan. Subject to the provisions of Section 17 of the Plan, the maximum aggregate number of Shares that
may be issued under the Plan is 55,000,000. Any Shares subject to an Award with a per Share exercise (or purchase) price equal to or greater than 100% of Fair Market Value on the date of grant shall be counted against the numerical limits of this
Section 3 as one (1) Share for every one (1) Share subject thereto. Except as provided in the previous sentence, any Shares subject to any other Award, including specifically any Restricted Stock, Restricted Stock Unit, Performance
Unit, Performance Shares, or any other Award with a per Share exercise (or purchase) price lower than 100% of Fair Market Value on the date of grant, shall be counted against the numerical limits of this Section 3 as follows: (i) for any
Awards granted prior to February 2, 2011, as two (2) Shares for every one (1) Share subject thereto and shall be counted as two (2) Shares for every one (1) Share returned to or deemed not issued from the Plan pursuant to
this Section 3; and (ii) for any Awards granted on or after February 2, 2011, as 1.6 Shares for every one (1) Share subject thereto and shall be counted as 1.6 Shares for every one (1) Share returned to or deemed not issued
from the Plan pursuant to this Section 3. The Shares may be authorized, but unissued, or reacquired Common Stock. 

  
 -7- 

 (b) Lapsed Awards and Share Accounting. If an Award expires or becomes unexercisable
without having been exercised in full, or, with respect to Restricted Stock, Restricted Stock Units, Deferred Stock Units, Performance Shares or Performance Units, is forfeited to or repurchased by the Company, the unpurchased Shares (or for Awards
other than Options and Stock Appreciation Rights, the forfeited or repurchased Shares) which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated). Upon exercise of a Stock Appreciation
Right settled in Shares, the gross number of Shares covered by the portion of the Award so exercised will cease to be available under the Plan. Shares that have actually been issued under the Plan under any Award will not be returned to the Plan and
will not become available for future distribution under the Plan; provided, however, that if unvested Shares of Restricted Stock, Restricted Stock Units, Deferred Stock Units, Performance Shares or Performance Units are repurchased by the Company or
are forfeited to the Company, such Shares will become available for future grant under the Plan. Shares used to pay the exercise or purchase price of an Award (including specifically an Option exercised through an approved net exercise feature as
provided in Section 7(d)(vi) and/or to satisfy the tax withholding obligations related to an Option or Stock Appreciation Right will not become available for future grant or sale under the Plan. Shares used to satisfy tax withholding
obligations related to any Award hereunder shall not become available for future grant or sale under the Plan. To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not reduce the number of Shares
available for issuance under the Plan. Notwithstanding anything in the Plan or any Award Agreement to the contrary, Shares actually issued pursuant to Awards transferred under any Award Transfer Program will not be again available for grant under
the Plan. Notwithstanding the foregoing provisions of this Section 3(b), subject to adjustment as provided in Section 17, the maximum number of Shares that may be issued upon the exercise of Incentive Stock Options will equal the aggregate
Share number stated in Section 3(a), plus, to the extent allowable under Section 422 of the Code and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under the Plan under this
Section 3(b). 
 4. Administration of the Plan. 

(a) Procedure. 
 (i)
Multiple Administrative Bodies. Different Committees with respect to different groups of Service Providers may administer the Plan. 

(ii) Section 162(m). To the extent that the Administrator determines it to be desirable or necessary to qualify previously-granted
Awards hereunder as “performance-based compensation” within the meaning of Section 162(m) of the Code, the Plan will be administered by a Committee of two or more “outside directors” within the meaning of Section 162(m)
of the Code. 
 (iii) Rule 16b-3. To the extent desirable to qualify transactions hereunder
as exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3. 

  
 -8- 

 (iv) Other Administration. Other than as provided above, the Plan will be
administered by (A) the Board or (B) a Committee, which committee will be constituted to satisfy Applicable Laws. 
 (v)
Delegation of Authority for Day-to-Day Administration. Except to the extent prohibited by Applicable Law, the Administrator may delegate to one or more
individuals the day-to-day administration of the Plan and any of the functions assigned to it in this Plan. Such delegation may be revoked at any time. 

(b) Powers of the Administrator. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties
delegated by the Board to such Committee, the Administrator will have the authority, in its discretion: 
 (i) to determine the Fair Market
Value; 
 (ii) to select the Service Providers to whom Awards may be granted hereunder; 

(iii) to determine the number of Shares to be covered by each Award granted hereunder; 

(iv) to approve forms of agreement for use under the Plan; 

(v) to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture or repurchase restrictions, and any
restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator, in its sole discretion, will determine; 

(vi) to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; 

(vii) to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws including qualifying for preferred tax treatment under applicable foreign tax laws; 

(viii) to modify or amend each Award (subject to Section 17(c) of the Plan), including the discretionary authority to extend the
post-termination exercisability period of Awards longer than is otherwise provided for in the Plan; provided, however that in no event may the term of an Option or SAR be extended such that its maximum term exceeds ten (10) years from the grant
date; provided, further that no Exchange Program can be implemented without prior stockholder approval; 
 (ix) to allow Participants to
satisfy withholding tax obligations as provided in Section 26; 

  
 -9- 

 (x) to authorize any person to execute on behalf of the Company any instrument required to
effect the grant of an Award previously granted by the Administrator; 
 (xi) to allow a Participant, in compliance with all Applicable
Laws, including, but not limited to, Section 409A of the Code, to defer the receipt of the payment of cash or the delivery of Shares that would otherwise be due to such Participant under an Award; 

(xii) to determine whether Awards will be settled in Shares, cash or in any combination thereof; 

(xiii) to determine whether Awards will be adjusted for Dividend Equivalents; provided, however that in no event will a Dividend Equivalent
be attached to an Option or SAR, nor will a Dividend Equivalent be paid out on any full-value Award prior to the vesting of such Award; 

(xiv) to establish a program, in compliance with all Applicable Laws, including specifically Section 409A of the Code, whereby Service
Providers designated by the Administrator can reduce compensation otherwise payable in cash in exchange for Awards under the Plan; 
 (xv)
to impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by a Participant or other subsequent transfers by the Participant of any Shares issued as a result of or under an Award,
including without limitation, (A) restrictions under an insider trading policy, and (B) restrictions as to the use of a specified brokerage firm for such resales or other transfers; 

(xvi) to determine the terms and conditions of, and with the approval of the Company’s stockholders to institute, any Exchange Program;

 (xvii) to require that the Participant’s rights, payments and benefits with respect to an Award (including amounts received upon
the settlement or exercise of an Award) shall be subject to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance conditions of an Award, as
may be specified in an Award Agreement at the time of the Award, or later if (A) Applicable Laws require the Company to adopt a policy requiring such reduction, cancellation, forfeiture or recoupment, or (B) pursuant to an amendment of an
outstanding Award; and 
 (xviii) to make all other determinations deemed necessary or advisable for administering the Plan. 

(c) Effect of Administrator’s Decision. The Administrator’s decisions, determinations and interpretations will be final and
binding on all Participants and any other holders of Awards. 
 5. Eligibility. Nonstatutory Stock Options, Restricted
Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units, Performance Bonus Awards, Performance Shares and Deferred Stock Units may be granted to Service Providers. Incentive Stock Options may be granted only to Employees as
required by the Code. 

  
 -10- 

 6. Limitations. 

(a) ISO $100,000 Rule. Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory
Stock Option. However, notwithstanding such designation, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year
(under all plans of the Company and a Related Entity) exceeds $100,000, such Options will be treated as Nonstatutory Stock Options. For purposes of this Section 6(a), Incentive Stock Options will be taken into account in the order in which they
were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted. 

(b) No Rights as a Service Provider. Neither the Plan nor any Award shall confer upon a Participant any right with respect to
continuing his or her relationship as a Service Provider, nor shall they interfere in any way with the right of the Participant or the right of the Company or a Related Entity to terminate such relationship at any time, with or without cause. 

(c) Limitations on Grants. The following limitations shall apply to Awards under the Plan: 

(i) No Service Provider shall be granted, in any fiscal year of the Company, (A) Options or SARs to purchase more than 2,000,000 Shares,
(B) Restricted Stock or Restricted Stock Units covering more than 2,000,000 Shares, (C) Performance Shares covering more than 2,000,000 Shares or (D) Performance Units or Performance Bonus Awards that could result in such Service
Provider receiving more than $5,000,000. 
 (ii) In connection with his or her initial service, a Service Provider may be granted Options
or SARS to purchase up to an additional 2,000,000 Shares, which shall not count against the limit set forth in subsection (i) above. 

(iii) If an Award is cancelled in the same fiscal year of the Company in which it was granted (other than in connection with a transaction
described in Section 17(c)), the cancelled Award will be counted against the limits set forth in subsections (i) and (ii) above. 

(d) Outside Director Award Limitations. 

(i) Cash-Settled Awards. No Outside Director may be granted, in any fiscal year of the Company, cash-settled Awards with a grant date
fair value (determined in accordance with U.S. generally accepted accounting principles) of more than $1,000,000, increased to $2,000,000 in connection with his or her initial service. 

(ii) Stock-Settled Awards. No Outside Director may be granted, in any fiscal year of the Company, stock-settled Awards with a grant
date fair value (determined in accordance with U.S. generally accepted accounting principles) of more than $1,000,000, increased to $2,000,000 in connection with his or her initial service. 

  
 -11- 

 7. Stock Options. 

(a) Term of Option. The term of each Option will be stated in the Award Agreement; provided, however, that the term will be no more
than ten (10) years from the date of grant thereof. In the case of an Incentive Stock Option, the term will be ten (10) years from the date of grant or such shorter term as may be provided in the Award Agreement. Moreover, in the case of
an Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any Parent
or Subsidiary, the term of the Incentive Stock Option will be five (5) years from the date of grant or such shorter term as may be provided in the Award Agreement. Incentive Stock Options may be granted only to an Employee of the Company or of
a Parent or Subsidiary. 
 (b) Option Exercise Price. The per Share exercise price for the Shares to be issued pursuant to exercise
of an Option will be no less than 100% of the Fair Market Value per Share on the date of grant. Notwithstanding the foregoing, in the case of an Incentive Stock Option granted to an Employee who, at the time the Incentive Stock Option is granted,
owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or of any Parent or Subsidiary, the per Share exercise price will be no less than 110% of the Fair Market Value per Share on the date of
grant. 
 (c) Waiting Period and Exercise Dates. At the time an Option is granted, the Administrator will fix the period within which
the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised. 
 (d) Form of
Consideration. The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of
consideration at the time of grant. Such consideration to the extent permitted by Applicable Laws may consist entirely of: 
 (i) cash; 

(ii) check; 
 (iii) promissory
note; 
 (iv) other Shares which meet the conditions established by the Administrator to avoid adverse accounting consequences (as
determined by the Administrator); 
 (v) consideration received by the Company under a cashless exercise program implemented by the Company
in connection with the Plan; 
 (vi) consideration received by the Company under a net exercise program (surrendering shares subject to the
Option to pay the applicable exercise price and/or associated tax withholding obligation) implemented by the Company (whether through a broker or otherwise) in connection with the Plan; 

  
 -12- 

 (vii) a reduction in the amount of any Company liability to the Participant; 

(viii) any combination of the foregoing methods of payment; or 

(ix) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws. 

(e) Exercise of Option. 

(i) Procedure for Exercise; Rights as a Stockholder. Any Option granted hereunder will be exercisable according to the terms of the
Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share. 

An Option will be deemed exercised when the Company receives: (x) written or electronic notice of exercise (in such form as the
Administrator may specify from time to time) from the person entitled to exercise the Option, and (y) full payment for the Shares with respect to which the Option is exercised (together with any applicable withholding taxes). Full payment may
consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the
Participant, in the name of the Participant and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive
dividends or any other rights as a stockholder will exist with respect to the Awarded Stock, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment
will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 17 of the Plan or the applicable Award Agreement. 

Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under
the Option, by the number of Shares as to which the Option is exercised. 
 (ii) Termination of Relationship as a Service Provider.
If a Participant ceases to be a Service Provider, other than upon the Participant’s death or Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent that the
Option is vested on the date of termination of service (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain
exercisable for three (3) months following the Participant’s termination of service. Unless otherwise provided by the Administrator, if on the date of termination of service the Participant is not vested as to his or her entire Option, the
Shares covered by the unvested portion of the Option will revert to the Plan. If after termination of service the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the
Shares covered by such Option will revert to the Plan. 

  
 -13- 

 (iii) Disability of Participant. If a Participant ceases to be a Service Provider as
a result of the Participant’s Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination of service (but in no event
later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following the Participant’s
termination of service. Unless otherwise provided by the Administrator, if on the date of termination of service the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to
the Plan. If after termination of service the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan. 

(iv) Death of Participant. If a Participant dies while a Service Provider, the Option may be exercised following the
Participant’s death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of the term of such Option
as set forth in the Award Agreement), by the Participant’s designated beneficiary, provided such beneficiary has been designated prior to Participant’s death in a form acceptable to the Administrator. If no such beneficiary has been
designated by the Participant, then such Option may be exercised by the personal representative of the Participant’s estate or by the person(s) to whom the Option is transferred pursuant to the Participant’s will or in accordance with the
laws of descent and distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12) months following Participant’s death. Unless otherwise provided by the Administrator, if at the
time of death Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so exercised within the time specified herein, the Option will
terminate, and the Shares covered by such Option will revert to the Plan. 
 8. Restricted Stock and Restricted Stock Units.

 (a) Restricted Stock. 

(i) Grant of Restricted Stock. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time,
may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine. 

(ii) Restricted Stock Agreement. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period
of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine. Unless the Administrator determines otherwise, Shares of Restricted Stock will be held by the Company as
escrow agent until the restrictions on such Shares have lapsed. 
 (iii) Transferability. Except as provided in this Section 8,
Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction. 

  
 -14- 

 (iv) Other Restrictions. The Administrator, in its sole discretion, may impose such
other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate, including granting such an Award of Restricted Stock subject to the requirements of Section 12. 

(v) Removal of Restrictions. Except as otherwise provided in this Section 8, Shares of Restricted Stock covered by each
Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction. The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be
removed. 
 (vi) Voting Rights. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted
hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise. 
 (vii)
Dividends and Other Distributions. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares unless otherwise
provided in the Award Agreement. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were
paid. 
 (viii) Return of Restricted Stock to Company. On the date set forth in the Award Agreement, the Restricted Stock for which
restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan. 
 (b) Restricted Stock
Units. 
 (i) Grant of Restricted Stock Units. Subject to the terms and provisions of the Plan, the Administrator, at any time
and from time to time, may grant Restricted Stock Units in such amounts as the Administrator, in its sole discretion, will determine. After the Administrator determines that it will grant Restricted Stock Units under the Plan, it will advise the
Participant in an Award Agreement of the terms, conditions, and restrictions related to the grant, including the number of Restricted Stock Units. 

(ii) Vesting Criteria and Other Terms. The Administrator will set vesting criteria in its discretion, which, depending on the extent
to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant. The Administrator may set vesting criteria based upon service with the Company, the achievement of Company-wide, business
unit, or individual goals (including, but not limited to, continued employment), Performance Goals or any other basis determined by the Administrator in its discretion. 

(iii) Earning Restricted Stock Units. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a
payout as determined by the Administrator. Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a
payout. 

  
 -15- 

 (iv) Form and Timing of Payment. Payment of earned Restricted Stock Units will be
made as soon as practicable after the date(s) determined by the Administrator and set forth in the Award Agreement. The Administrator, in its sole discretion, may settle earned Restricted Stock Units only in cash, Shares, or a combination of both.

 (v) Cancellation. On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the
Company. 
 9. Stock Appreciation Rights. 

(a) Grant of SARs. Subject to the terms and conditions of the Plan, a SAR may be granted to Service Providers at any time and from time
to time as will be determined by the Administrator, in its sole discretion. 
 (b) Number of Shares. The Administrator will have
complete discretion to determine the number of SARs granted to any Service Provider. 
 (c) Exercise Price and Other Terms. The
Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of SARs granted under the Plan. Notwithstanding the foregoing, the per Share exercise price for the Shares to be issued
pursuant to exercise of a SAR will be no less than 100% of the Fair Market Value per Share on the date of grant. 
 (d) Exercise of
SARs. SARs will be exercisable on such terms and conditions as the Administrator, in its sole discretion, will determine. 
 (e) SAR
Agreement. Each SAR grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the SAR, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will
determine. 
 (f) Expiration of SARs. An SAR granted under the Plan will expire upon the date determined by the Administrator, in its
sole discretion, and set forth in the Award Agreement. Notwithstanding the foregoing, the term of each SAR will be no more than ten (10) years from the date of grant thereof and the rules of Sections 7(e)(ii), 7(e)(iii) and 7(e)(iv) also will
apply to SARs. 
 (g) Payment of SAR Amount. Upon exercise of an SAR, a Participant will be entitled to receive payment from the
Company in an amount determined by multiplying: 
 (i) The difference between the Fair Market Value of a Share on the date of exercise over
the exercise price; times 
 (ii) The number of Shares with respect to which the SAR is exercised. 

At the discretion of the Administrator, the payment upon SAR exercise may be in cash, in Shares of equivalent value, or in some combination
thereof. 

  
 -16- 

 10. Performance Units and Performance Shares. 

(a) Grant of Performance Units/Shares. Subject to the terms and conditions of the Plan, Performance Units and Performance Shares may be
granted to Service Providers at any time and from time to time, as will be determined by the Administrator, in its sole discretion. The Administrator will have complete discretion in determining the number of Performance Units and Performance Shares
granted to each Participant. 
 (b) Value of Performance Units/Shares. Each Performance Unit will have an initial value that is
established by the Administrator on or before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant. 

(c) Performance Objectives and Other Terms. The Administrator will set performance objectives or other vesting provisions (including,
without limitation, continued status as a Service Provider) in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. The
time period during which the performance objectives must be met will be called the “Performance Period.” Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the Performance Period, and such
other terms and conditions as the Administrator, in its sole discretion, will determine. The Administrator may set Performance Goals based upon the achievement of Company-wide, divisional, or individual goals, applicable federal or state securities
laws, or any other basis determined by the Administrator in its discretion. 
 (d) Earning of Performance Units/Shares. After the
applicable Performance Period has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of
the extent to which the corresponding performance objectives have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives for such Performance Unit/Share.

 (e) Form and Timing of Payment of Performance Units/Shares. Payment of earned Performance Units/Shares will be made as soon after
the expiration of the applicable Performance Period at the time determined by the Administrator. The Administrator, in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market
Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof. 

(f) Cancellation of Performance Units/Shares. On the date set forth in the Award Agreement, all unearned or unvested Performance
Units/Shares will be forfeited to the Company, and again will be available for grant under the Plan. 
 11. Performance Bonus
Awards. Any Service Provider selected by the Committee may be granted one or more Performance-Based Awards in the form of a cash bonus payable upon the attainment of Performance Goals or other performance metrics, in each case that are
established by the Committee, in each case on a specified date or dates or over any period or periods determined by the Committee. 

  
 -17- 

 12. Terms and Conditions of Any Performance-Based Award. 

(a) Purpose. If the Committee, in its discretion, decides to grant a Performance-Based Award subject to Performance Goals, the
provisions of this Section 12 will apply; provided, however, that the Committee may in its discretion grant Awards that are based on Performance Goals or other specific criteria or goals that do not satisfy the requirements of this
Section 12. 
 (b) Procedures with Respect to Performance Based Awards. The Committee will, in writing, (a) designate one
or more Participants who are to receive one or more Performance Based Awards, (b) select the Performance Goals applicable to the Performance Period, (c) establish the Performance Goals, and amounts or methods of computation of such Awards,
as applicable, which may be earned for such Performance Period, and (d) specify the relationship between Performance Goals and the amounts or methods of computation of such Awards, as applicable, to be earned by each Participant for such
Performance Period. Following the completion of each Performance Period, the Committee will certify in writing whether the applicable Performance Goals have been achieved for such Performance Period. In determining the amounts earned by a
Participant, the Committee will have the right to increase, reduce or eliminate the amount payable at a given level of performance to take into account additional factors that the Committee may deem relevant to the assessment of individual or
corporate performance for the Performance Period. 
 (c) Payment of Performance Based Awards. Unless otherwise provided in the
applicable Award Agreement, a Participant must be employed by the Company or a Related Entity on the day a Performance-Based Award for such Performance Period is paid to the Participant. 

13. Deferred Stock Units. Deferred Stock Units shall consist of a Restricted Stock, Performance Share or Performance Unit Award
that the Administrator, in its sole discretion permits to be paid out in installments or on a deferred basis, in accordance with rules and procedures established by the Administrator. Deferred Stock Units may be settled, in the discretion of the
Administrator, in cash, Shares or a combination thereof. 
 14. Outside Director Awards. Except as provided in
Section 14(e), grants of Awards to Outside Directors pursuant to this Section 14 will be automatic and will be made in accordance with the following provisions: 

(a) Type of Award. The Company shall grant Restricted Stock Units to Outside Directors automatically pursuant to this Section 14
for all Awards on or after November 10, 2015. All Restricted Stock Units granted pursuant to this Section 14 will be subject to the other terms and conditions of the Plan. 

(b) Initial Restricted Stock Unit Award. Each person who first becomes an Outside Director on or after November 10, 2015 will be
automatically granted an Award of Restricted Stock Units on the date upon which such person first becomes an Outside Director, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy (an
“Initial Restricted Stock Unit Award”); provided, however, that an Inside Director who ceases to be an Inside Director but who remains a Director will not receive an Initial Restricted Stock Unit Award. Each Initial Restricted Stock Unit
Award granted under this Section 14(b) to an Outside Director who was first appointed or elected to the Board effective as of the date of an annual meeting of stockholders shall cover that number of Shares as determined by dividing a dollar
amount as set by the Board or 

  
 -18- 

 
any authorized Committee from time to time by the average of the Fair Market Value of a Share for the thirty (30) trading days ending on (and including) the trading day immediately preceding
the date of grant, rounded down to the nearest whole Restricted Stock Unit. Each Initial Restricted Stock Unit Award granted under this Section 14(b) to an Outside Director who was first appointed or elected to the Board effective as of any
date other than the date of an annual meeting of stockholders shall be prorated such that the Initial Restricted Stock Unit Award shall cover that number of Shares determined by multiplying a dollar amount as set by the Board or any authorized
Committee from time to time by a fraction the numerator of which is equal to the number of fully completed months between the date such Outside Director was first appointed or elected to the Board and the expected date of the next annual meeting of
stockholders, and a denominator of which is equal to twelve (12), with the result divided by the average of the Fair Market Value of a Share for the thirty (30) trading days ending on (and including) the trading day immediately preceding the
date of grant, rounded down to the nearest whole Restricted Stock Unit. By way of example only, if an Outside Director is first appointed or elected to the Board as of July 1 (which is not the date of an annual meeting of stockholders), and the
next annual meeting of stockholders is expected to occur on December 15, the Outside Director will receive an Initial Restricted Stock Unit Award covering that number of Shares as determined by multiplying such dollar amount set by the Board
(or such authorized Committee) by 5/12 (the number of fully completed months between July 1 and December 15, and a denominator of twelve (12)), with the result divided by the average of the Fair Market Value of a Share for the thirty
(30) trading days ending on (and including) the trading day immediately preceding the date of grant, rounded down to the nearest whole Restricted Stock Unit. 

(c) Annual Restricted Stock Unit Award. Each Outside Director automatically will be granted an Award of Restricted Stock Units on the
date of each annual meeting of the stockholders of the Company beginning on the date of the 2016 annual meeting of stockholders (an “Annual Restricted Stock Unit Award”), provided he or she is then an Outside Director. Each Annual
Restricted Stock Unit Award shall cover that number of Shares as determined by dividing a dollar amount as set by the Board or any authorized Committee from time to time by the average of the Fair Market Value of a Share for the thirty
(30) trading days ending on (and including) the trading day immediately preceding the date of grant, rounded down to the nearest whole Restricted Stock Unit. 

(d) Terms. Except as provided in Section 14(e), the terms of each Restricted Stock Unit granted pursuant to this Section 14
will be as follows: 
 (i) Initial Restricted Stock Unit Award. Subject to Section 17 of the Plan, any Initial Restricted Stock
Unit Award will become one hundred percent (100%) vested and be settled pursuant to the issuance of Shares on the earlier of (1) the first anniversary of such Initial Stock Unit Award’s date of grant or (2) the date immediately
preceding the date of the next annual meeting of stockholders that occurs after such Initial Restricted Stock Unit Award’s date of grant, provided that the Participant continues to serve as a Director on such date. 

(ii) Annual Restricted Stock Unit Award. Subject to Section 17 of the Plan, each Annual Restricted Stock Unit Award will become
one hundred percent (100%) vested and be settled pursuant to the issuance of Shares on the earlier of (1) the first anniversary of such Annual Restricted Stock Unit Award’s date of grant or (2) the date immediately preceding the date
of the next annual meeting of stockholders that occurs after such Annual Restricted Stock Unit Award’s date of grant, provided that the Participant continues to serve as a Director on such date. 

  
 -19- 

 (e) Amendment. Notwithstanding the foregoing, the Board or any authorized Committee
in its discretion may change the number, type and terms of Awards granted under this Section 14. 
 15. Leaves of
Absence. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence and will resume on the date the Participant returns to work on a regular schedule as determined by
the Company. A Service Provider will not cease to be an Employee in the case of (i) any leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company and a Related Entity. For purposes
of Incentive Stock Options, no such leave may exceed ninety (90) days, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not
so guaranteed, then three months following the 91st day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated
for tax purposes as a Nonstatutory Stock Option. 
 16. Non-Transferability of Awards.
Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the
lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate. Notwithstanding anything to the contrary in
the Plan, in no event will the Administrator have the right to determine and implement the terms and conditions of any Award Transfer Program without stockholder approval. 

17. Adjustments; Dissolution or Liquidation; Merger or Change in Control. 

(a) Adjustments. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other
property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares
or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs such that an adjustment is determined by the Administrator (in its sole discretion) to be appropriate in order to prevent
dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, then the Administrator shall, in such manner as it may deem equitable, adjust the number and class of shares which may be delivered under the
Plan, the per person limits on grants contained in Section 6(c), and the number, class, and price of shares subject to outstanding Awards. Notwithstanding the preceding, the number of shares subject to any Award always shall be a whole number.

 (b) Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the Administrator will
notify each Participant as soon as practicable prior to the effective date of such proposed transaction. The Administrator in its discretion may provide for a Participant to have the right to exercise his or her Award, to the extent applicable,
until ten (10) days 

  
 -20- 

 
prior to such transaction as to all of the Awarded Stock covered thereby, including Shares as to which the Award would not otherwise be exercisable. In addition, the Administrator may provide
that any Company repurchase option or forfeiture rights applicable to any Award shall lapse in full, and that any Award’s vesting schedule shall accelerate in full, provided the proposed dissolution or liquidation takes place at the time and in
the manner contemplated. To the extent it has not been previously exercised or vested, an Award will terminate immediately prior to the consummation of such proposed action. 

(c) Merger or Change in Control. 

(i) Stock Options and SARS. In the event of a merger or Change in Control, an outstanding Option or SAR may be (i) assumed or
substituted with an equivalent option or SAR of the successor corporation or a Parent or Subsidiary of the successor corporation, (ii) replaced with a cash incentive program of the successor corporation or a Parent or Subsidiary of the
successor corporation, or (iii) terminated. Unless determined otherwise by the Administrator, in the event that the successor corporation does not assume, substitute or replace a Participant’s Option or SAR, the Participant shall,
immediately prior to the merger or Change in Control, fully vest in and have the right to exercise such Option or SAR that is not assumed, substituted or replaced as to all of the Awarded Stock, including Shares as to which it would not otherwise be
vested or exercisable. If an Option or SAR is not assumed, substituted or replaced in the event of a merger or Change in Control, the Administrator shall notify the Participant in writing or electronically that the Option or SAR shall be
exercisable, to the extent vested, for a period of up to fifteen (15) days from the date of such notice, and the Option or SAR shall terminate upon the expiration of such period. For the purposes of this paragraph, the Option or SAR shall be
considered assumed if, following the merger or Change in Control, the option or stock appreciation right confers the right to purchase or receive, for each Share of Awarded Stock subject to the Option or SAR immediately prior to the merger or Change
in Control, the consideration (whether stock, cash, or other securities or property) received in the merger or Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a
choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the merger or Change in Control is not solely common stock of the successor
corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of the Option or SAR, for each Share of Awarded Stock subject to the Option or SAR, to be
solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the merger or Change in Control. Notwithstanding anything herein to the contrary, an
Award that vests, is earned or paid-out upon the satisfaction of one or more Performance Goals will not be considered assumed if the Company or its successor modifies any of such Performance Goals without the
Participant’s consent; provided, however, a modification to such Performance Goals only to reflect the successor corporation’s post-merger or post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid
Award assumption. 
 With respect to Options and SARs granted to an Outside Director, the Participant shall, immediately prior to the merger
or Change in Control, fully vest in and have the right to exercise such Options and SARs as to all of the Awarded Stock, including Shares as to which it would not otherwise be vested or exercisable. With respect to Options and SARs granted to an
Employee, the Employee, 

  
 -21- 

 
upon a termination of the Employee by the Company or a Related Entity without Cause or a resignation of the Employee with Good Reason, shall receive one year of additional vesting for each full
year of service performed for the Company or a Related Entity; provided, that such termination or resignation occurs within the twelve (12) month period following a Change in Control. 

(ii) Restricted Stock, Restricted Stock Units, Performance Shares, Performance Units, Performance Bonus Awards and Deferred Stock
Units. In the event of a merger or Change in Control, an outstanding Restricted Stock, Restricted Stock Unit, Performance Share, Performance Unit, Performance Bonus Award or Deferred Stock Unit award may be (i) assumed or substituted with
an equivalent Restricted Stock, Restricted Stock Unit, Performance Share, Performance Unit, Performance Bonus Award or Deferred Stock Unit award of the successor corporation or a Parent or Subsidiary of the successor corporation, (ii) replaced
with a cash incentive program of the successor corporation or a Parent or Subsidiary of the successor corporation, or (iii) terminated. Unless determined otherwise by the Administrator, in the event that the successor corporation refuses to
assume, substitute or replace a Participant’s Restricted Stock, Restricted Stock Unit, Performance Share, Performance Unit, Performance Bonus Award or Deferred Stock Unit award, the Participant shall, immediately prior to the merger or Change
in Control, fully vest in such Restricted Stock, Restricted Stock Unit, Performance Share, Performance Unit, Performance Bonus Award or Deferred Stock Unit including as to Shares which would not otherwise be vested. For the purposes of this
paragraph, a Restricted Stock, Restricted Stock Unit, Performance Share, Performance Unit, Performance Bonus Award and Deferred Stock Unit award shall be considered assumed if, following the merger or Change in Control, the award confers the right
to purchase or receive, for each Share subject to the Award immediately prior to the merger or Change in Control, the consideration (whether stock, cash, or other securities or property) received in the merger or Change in Control by holders of
Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if
such consideration received in the merger or Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received,
for each Share and each unit/right to acquire a Share subject to the Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the
merger or Change in Control. Notwithstanding anything herein to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more Performance Goals will not be considered assumed if
the Company or its successor modifies any of such Performance Goals without the Participant’s consent; provided, however, a modification to such Performance Goals only to reflect the successor corporation’s post-merger or post-Change in
Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption. 
 With respect to Awards granted to an
Outside Director, the Participant shall, immediately prior to the merger or Change in Control, fully vest in such Awards, including Shares as to which it would not otherwise be vested. With respect to Awards granted to an Employee, the Employee,
upon a termination of the Employee by the Company or a Related Entity without Cause or a resignation of the Employee with Good Reason, shall receive one year of additional vesting for each full year of service performed for the Company or a Related
Entity; provided, that such termination or resignation occurs within the twelve (12) month period following a Change in Control. 

  
 -22- 

 18. Date of Grant. The date of grant of an Award will be, for all purposes,
the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant within a reasonable time after the date
of such grant. 
 19. Term of Plan. Subject to Section 25 of the Plan, this amended and restated Plan was adopted by the
Board on November 13, 2019 and will become effective on the date of the next annual meeting of stockholders (February 4, 2020). It will continue in effect thereafter unless and until terminated under Section 20 of the Plan. Notwithstanding
the preceding, no new Incentive Stock Options may be granted after November 12, 2029. 
 20. Amendment and Termination of the
Plan. 
 (a) Amendment and Termination. The Board may at any time amend, alter, suspend or terminate the Plan. 

(b) Stockholder Approval. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to
comply with Applicable Laws. 
 (c) Effect of Amendment or Termination. No amendment, alteration, suspension or termination of the
Plan will impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will not affect
the Administrator’s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination. 

21. Conditions Upon Issuance of Shares. 

(a) Legal Compliance. The granting of Awards and the issuance and delivery of Shares under the Plan shall be in compliance with any
Applicable Laws, rule and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. Shares will not be issued pursuant to the exercise or vesting of an Award unless the exercise or vesting
of such Award and the issuance and delivery of such Shares will comply with Applicable Laws, rules and regulations and will be further subject to the approval of counsel for the Company with respect to such compliance. 

(b) Investment Representations. As a condition to the exercise or receipt of an Award, the Company may require the person exercising or
receiving such Award to represent and warrant at the time of any such exercise or receipt that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for
the Company, such a representation is required. 
 22. Severability. Notwithstanding any contrary provision of the Plan or an
Award to the contrary, if any one or more of the provisions (or any part thereof) of this Plan or the Awards shall be held invalid, illegal or unenforceable in any respect, such provision shall be modified so as to make it valid, legal and
enforceable, and the validity, legality and enforceability of the remaining provisions (or any part thereof) of the Plan or Award, as applicable, shall not in any way be affected or impaired thereby. 

  
 -23- 

 23. Inability to Obtain Authority. The inability of the Company to obtain
authority from any regulatory body having jurisdiction or to complete or comply with the requirements of any registration or other qualification of the Shares under any state, federal or foreign law or under the rules and regulations of the
Securities and Exchange Commission, the stock exchange on which Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed by the Company’s
counsel to be necessary or advisable for the issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration,
qualification or rule compliance will not have been obtained. 
 24. Forfeiture Events. The Administrator may specify in an
Award Agreement that the Participant’s rights, payments, and benefits with respect to an Award shall be subject to reduction, cancellation, forfeiture, or recoupment upon the occurrence of certain specified events, in addition to any otherwise
applicable vesting or performance conditions of an Award. Such events may include, but shall not be limited to, fraud, breach of a fiduciary duty, restatement of financial statements as a result of fraud or willful errors or omissions, termination
of employment for cause, violation of material Company and/or Subsidiary policies, breach of non-competition, confidentiality, or other restrictive covenants that may apply to the Participant, or other conduct
by the Participant that is detrimental to the business or reputation of the Company and/or its Subsidiaries. The Administrator may also require the application of this Section 24 with respect to any Award previously granted to a Participant
even without any specified terms being included in any applicable Award Agreement to the extent required under Applicable Laws. 
 25.
Stockholder Approval. The Plan will be subject to approval by the stockholders of the Company within twelve (12) months after the date the Plan is adopted. Such stockholder approval will be obtained in the manner and to the degree
required under Applicable Laws. 
 26. Tax. 

(a) Withholding Requirements. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof) or such earlier
time as any tax withholding obligations are due, the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes
(including the Participant’s FICA obligation, social taxes, payment on account or other tax liability legally applicable to the Participant) required to be withheld with respect to such Award (or exercise thereof). 

(b) Withholding Arrangements. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to
time and such terms as set forth in any Award Agreement, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (a) paying cash, (b) withholding from cash due to the Participant
(whether from the sale of Shares or otherwise), (c) electing to have the Company withhold otherwise deliverable Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld, or (d) delivering to the Company
already-owned Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be
withheld. 

  
 -24- 

 (c) Compliance With Code Section 409A. Awards will be designed and
operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Section 409A of the Code such that the grant, payment, settlement or deferral will not be subject to the additional tax or
interest applicable under Section 409A, except as otherwise determined in the sole discretion of the Administrator. Each payment or benefit under this Plan and under each Award Agreement is intended to constitute a separate payment for purposes
of Section 1.409A-2(b)(2) of the Treasury Regulations. The Plan, each Award and each Award Agreement under the Plan is intended to be exempt from or otherwise meet the requirements of Section 409A
and will be construed and interpreted, including but not limited with respect to ambiguities and/or ambiguous terms, in accordance with such intent, except as otherwise specifically determined in the sole discretion of the Administrator. To the
extent that an Award or payment, or the settlement or deferral thereof, is subject to Section 409A the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Section 409A, such that the grant,
payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A. 
 27.
Governing Law and Venue. The Plan and all determinations made and actions taken pursuant hereto will be governed by, and construed in accordance with, the laws of the State of California, USA without regard to principles of conflict of
laws. For purposes of any action or dispute that arises directly or indirectly from the relationship of the parties evidenced by the Plan, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree
that such action or dispute shall be conducted only in the courts of San Francisco County, California, or the federal courts for the United States for the Northern District of California, and no other courts. 

  
 -25-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]